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Abstract
Abstract
Turner Syndrome (TS) results from the complete or partial absence of one X 
chromosome in females. Short stature and gonadal dysgenesis are characteristic, with 
increased risks of cardiovascular disease, diabetes and obesity. This thesis 
investigates the prevalence and pathogenesis of factors contributing to cardiovascular 
risk. Because women with TS differ from normals in terms of their X-chromosome 
defect and oestrogen deficiency, they were compared to similarly-aged normal 
women, and a second control group o f similarly-aged women with 46,XX oestrogen 
deficiency was also recruited.
A cross-sectional study investigated the spectrum of structural disease in the heart, 
aorta and conduit vessels using various imaging techniques. Intima media thickness 
(IMT), arterial stiffness and endothelial function were also assessed. Progression of 
aortic dilatation was investigated in a longitudinal echocardiography study.
Metabolic abnormalities in TS were investigated by measuring anthropometric 
parameters and serum markers of adiposity and comparing them in all three groups. 
Adipose tissue distribution was further investigated in a subgroup of women with TS 
and normal controls.
A longitudinal oestrogen dose-ranging study was performed in women with TS and 
46,XX primary amenorrhoea to assess oestrogen effects on various parameters 
pertaining to cardiovascular risk.
Women with TS had greater height-adjusted arterial diameters than controls, and 
greater IMT, the latter amenable to reduction by increasing doses of oestrogen. The 
rate of aortic dilatation was greater than in the normal population. Endothelial 
function did not differ significantly.
Women with TS have some features of the metabolic syndrome, but fasting insulin, 
glucose and leptin concentrations are surprisingly low, despite increased C-reactive
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protein and Interleukin-6 concentrations, greater central obesity and increased visceral 
fat than controls.
Age, bicuspid aortic valve, blood pressure and oestrogen status were the most 
important predictors of cardiovascular disease in TS. This knowledge should aid 
identification of therapeutic targets to improve care in this population.
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Chapter 1 
Introduction
General Background
Turner syndrome (TS), the most commonly occurring chromosomal abnormality in 
females, results from complete or partial absence of one X chromosome in a phenotypic 
female. It is usually accompanied by characteristic clinical features, of which the most 
consistent are short stature and primary amenorrhoea.
The Italian anatomist Morgagni first described TS in 1768. There were further 
descriptions by Funke in 1902 and Ullrich in 1930, but the syndrome is named after the 
American endocrinologist Henry Turner, who described seven women with typical 
features of the syndrome in 1938 (1). He drew attention to the presence of primary 
amenorrhoea in the syndrome, and also pioneered treatment with oestrogen (2).
Approximately 1:2500 live female births have TS with an estimated worldwide 
prevalence of 1.5 million women (3). Mortality rates in TS are three times higher than in 
the general population, with a reduction in life expectancy of up to 13 years (4). This is 
mainly accounted for by higher rates of cardiovascular disease, both structural and 
atherosclerotic (4-6).
Although the majority o f women with TS will have been diagnosed in childhood or 
adolescence, about 10% are not diagnosed until adulthood (see Chapter 2, Figure 2.1). 
This variability reflects the wide clinical spectrum of the syndrome, which ranges from 
the severe phenotype with short stature, primary amenorrhoea, lymphoedema and 
characteristic dysmorphic appearance, to the more mildly affected with minimal impact 
on stature or secondary amenorrhoea.
1.1. Clinical Manifestations of Turner Syndrome in Adults
1.1.1. Genetics
The Turner karyotype is characterised by absence of one X chromosome, monosomy X or
15
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45,X, the most common karyotype found in approximately 50% (7)) or presence of an 
abnormal X chromosome such as isochromosome X, a partial deletion or ring X. In 
addition, various mosaic forms exist, which include 45,X/ 46,XX and 45,X/46,XY 
mosaicism. Many adult units reassess karyotype in adults as low-grade mosaicism may 
have been missed in the past if too few cells were counted. To some extent, an accurate 
karyotype has a bearing on future morbidity. Women with monosomy X generally have 
the most severe phenotype, while isochromosome X is more frequently associated with 
autoimmunity (8,9) and inflammatory bowel disease (10). Ring X karyotype is also 
associated with a particularly severe phenotype, as well as psychological and learning 
difficulties. This appears to be related to failure of X inactivation which is more likely 
with a smaller X ring (11,12). Mosaicism generally results in a milder phenotype, with up 
to 40% of such women spontaneously entering puberty, although premature ovarian 
failure may ensue (13). Women with Y-chromosome mosaicism have an increased risk of 
gonadoblastoma, and a minority may be virilised.
In monosomy X (45,X), the X-chromosome is of maternal origin in 68-80% of women, 
and of paternal origin in 20-32%, indicating that paternal sex chromosome loss is the most 
common cause of this condition (14-16). Parental origin of the X-chromosome has been 
associated with cardiovascular disease, height, webbing of the neck and psychological 
profiles (16,17), suggesting that genetic imprinting of certain genes may affect function.
In a normal woman with 46,XX karyotype, one X chromosome in each cell is inactivated 
by the process o f lyonisation, which occurs at an early stage of development in the foetus. 
It has become clear, however, that this random process is not absolute, in that some genes, 
which also have homologues on the Y chromosome, are required in duplicate for normal 
development. Absence o f a second copy, or ‘haploinsufficiency’ of certain genes, of 
which the majority have been found to map to the short arm of the X chromosome, is 
considered to be largely responsible for the Turner phenotype (18).
The search for specific genes which account for the Turner phenotype has focused 
particularly on the two predominant features of the syndrome, short stature and ovarian 
dysgenesis. The SHOX gene (short stature homoeobox-containing gene), situated in 
pseudoautosomal regions on the X chromosome, encodes for a protein found mainly in 
bone fibroblasts, and is favoured as a gene responsible for short stature (19-22). There
16
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have been extensive searches in the ‘critical regions’ of both the long and short arms of 
the X chromosome for genes governing ovarian dysgenesis, but none have been 
conclusive (22,23). Conversely, it may be that any abnormality of the X-chromosome 
results in impaired cell division and hence oocyte atresia (24).
1.1.2. Ovarian Dysgenesis, Fertility and Oestrogen Replacement
In normal development, germ cell numbers fall progressively from their peak of 
approximately 7,000,000 at 5 months’ gestation so that only half remain at full gestation, 
and these continue to decline until menopause (25). In TS the process of accelerated 
oocyte apoptosis and increased ovarian stromal fibrosis begins after the third month of 
gestation. Ovarian failure ensues within the first few months or years of life with a 
consequent rise in serum gonadotrophin concentrations (26,27). The Middlesex Hospital 
series found the overall incidence o f spontaneous puberty to be 12% in the Adult Turner 
Clinic population, ranging from 8% in those with monosomy X, to 10% in those with 
isochromosome X and 47% in those with 45,X/ 46,XX mosaicism (26). A recent study 
has demonstrated follicles in eight o f nine adolescent girls investigated with ovarian 
biopsy (28). Fertility is poor, however, and unassisted pregnancy occurs in only 2-8% of 
women (13,29,30). O f these, approximately one third end in spontaneous abortion or 
perinatal death, and a further third have chromosomal abnormalities, particularly Down’s 
or Turner’s syndrome, and congenital malformations (29,31). Earlier studies are probably 
subject to publication bias, but a recent Danish study suggests that, with prospective 
monitoring, the outlook may be better than previously thought (30).
Long-term requirement for oestrogen replacement therapy is the norm in adults with TS. 
After induction of puberty, which some will attain spontaneously, this will take the form 
o f cyclical oestrogen with a progestogen. Oestrogen replacement has been shown to 
reduce the risks of osteoporosis (32), aspects of vascular risk (33-35), and may improve 
liver function (36,37). The relative benefits of different oestrogen preparations including 
transdermal oestrogen, continuous oral natural oestrogens such as conjugated oestrogen or 
oestradiol valerate, and oral contraceptive preparations (OCP) with regard to liver 
function in TS have yet to be clarified. The ethinyloestradiol-containing OCP has been 
associated with an increased risk o f liver disease (38), but in TS, ethinyloestradiol has 
been shown to be more efficient than oestradiol valerate in suppressing raised hepatic
17
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enzymes (37). Improvement o f cognitive function (39,40), and reduction in risk of 
colonic carcinoma (41,42) with oestrogen replacement therapy in TS remain to be 
confirmed. The use of oestrogen replacement in oestrogen deficient women is not thought 
to cause an increased risk o f breast cancer above that of the general population (5).
1.1.3. Osteoporosis
It has been postulated that there is a primary defect in bone formation, such as an 
abnormality o f chondroplasia, which may explain the short stature and apparently high 
incidence of osteoporosis in TS. This may be related to oestrogen deficiency or other 
endocrine/ paracrine derangement (43). Measurement of BMD is affected by stature, and 
it therefore remains to be clarified whether the low BMD found in women with TS 
reflects true osteoporosis or is, in fact, an artefact of short stature. Volumetric correction 
of BMD suggests that this may be normal or only slightly reduced, particularly in cortical 
bone (44-46). Fracture risk at characteristic fracture sites is certainly increased in TS by a 
factor of two to three (5,47,48), and especially the forearm has been implicated (49). It 
has been suggested that the increased fracture risk is due to inadequate bone strength 
relative to body weight (45) or to an increased risk of falls, and recently a selective 
deficiency o f forearm cortical bone has been demonstrated which is apparently 
independent of oestrogen exposure (50).
In adulthood, oestrogen deficiency is proposed as the most important factor affecting 
BMD, with oestrogen replacement resulting in improvement of BMD (32,51). Treatment 
with growth hormone and oestrogen during childhood and adolescence has been found to 
contribute to higher bone mass, combination of the two having a greater effect (52). 
Earlier start age of oestrogen (before age 12) and growth hormone treatment for over one 
year are beneficial (53). Those with spontaneous puberty have relatively preserved bone 
mass (26), and it may be that after correction for bone volume and oestrogen deficiency, 
there is, in fact, no evidence for osteoporosis in TS (51).
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1.1.4. Endocrine Dysfunction
The most common endocrine abnormalities in TS are thyroid disease, abnormalities of the 
growth hormone axis, diabetes, dyslipidaemia and oestrogen deficiency. The latter three 
will be examined more closely under the heading of cardiovascular risk (see below).
The incidence of autoimmune thyroid disease increases with age in TS. Approximately 
half of an adult TS population have positive thyroid autoantibodies, and 25-30% are 
hypothyroid, compared with 1.5% o f the general population (9,54,55). Graves’ disease 
does not show increased incidence despite its similar pathogenetic mechanism. 
Isochromosome X (46,Xi(Xq)) karyotype is particularly associated with autoimmune 
thyroid disease.
There is continuing debate about the abnormalities of the growth hormone (GH) axis in 
TS. It is thought that girls with TS are relatively resistant to GH, but may also be 
relatively deficient. One study showed that GH levels before the age of nine years in girls 
with TS are the same as in controls, but the levels are lower in those with TS aged 9-20 
years. IGF-1 levels, however, were found to be lower through the entire age range (56). 
A relationship between reduced GH levels and higher body weight has been reported, 
although this appeared to apply to both TS patients and controls, whilst there was no 
difference in IGF-1 levels in TS and controls (57,58). Gravholt et al. showed that 
although total IGF-1 levels in TS may be normal, free IGF-1 levels are reduced compared 
to controls (59). It has also been demonstrated that TS fibroblasts secrete less IGF-1 and 
IGF-2 in response to GH stimulation (60), and indeed that TS monocytes and T- 
lymphocytes are relatively resistant to the action of GH and IGF-1 (61). This relative 
resistance to GH is reflected by the reports from the Dutch experience with GH treatment 
in TS, which have suggested that their recent improvement in long-term and final height 
results may be due to higher GH doses and/or younger start age (62). There is no 
evidence to suggest that adults with TS are deficient or resistant to GH.
1.1.5. Renal Abnormalities
Renal disorders in TS are generally categorised as congenital and renovascular. With a 
nine-fold increased incidence o f congenital anomalies (5), the most common
19
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malformations are horseshoe kidney and collecting system abnormalities, both of which 
occur in approximately 7-8% of girls with TS. Of those patients with congenital renal 
pathology, 8% require surgical intervention (63). There is a weak association between 
renal malformations and monosomy X, but any karyotype may be affected (64). With 
regard to the sequelae o f renal abnormalities, there is an increased risk of pyelonephritis 
and pelvi-ureteric obstruction, which may result in chronic renal failure. Although 
horseshoe kidney is considered to confer greater susceptibility to renal malignancy in the 
normal population, no excess risk of neoplasia has been found in TS (65). Renovascular 
disease may contribute to the development of hypertension in TS as discussed below 
(Section 1.2.2.1.).
1.1.6. Gastrointestinal Disorders
A variety of gastrointestinal problems affect women with TS with greater frequency. 
These include inflammatory bowel disease, liver dysfunction, intestinal telangiectasia, 
colonic carcinoma (see Section 1.1.10) and possibly coeliac disease.
Inflammatory bowel disease (IBD) is estimated to be two to three times more common 
in TS than in the general population (5,66). In our series the prevalence was found to be 
2.6%, with the prevalence of Crohn’s disease being twice that o f ulcerative colitis, a 
reversal of the general population trend (7). Three fatal cases of IBD in TS have been 
reported, reflecting the frequent severity of the condition in TS. Complications are 
common and include colectomy in 40% o f reported cases, fistula formation and sepsis. 
Threshold for suspecting IBD should be low in TS patients with unexplained diarrhoea or 
gastrointestinal bleeding, and conversely a diagnosis of Turner Syndrome should be 
considered in adolescents with IBD and short stature.
The association with karyotype isochromosome Xq (found in 52% of reported cases of 
IBD in TS) (10) mirrors that of autoimmune thyroid disease in TS (see above). This lends 
weight to the theory that the cause of IBD may be immune dysfunction. There is still 
debate surrounding reports o f an increased prevalence of coeliac disease in TS, reports 
ranging from 4 to 10% (67,68), and 6.4% in the largest, most recent study (69).
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Intestinal telangiectasia, thought to be a developmental defect, may increase the risk of 
gastrointestinal bleeding in TS (70).
Hepatic dysfunction, initially manifest as derangement of liver enzymes, has been 
reported in up to 80% o f women with TS (54), although in the Middlesex Hospital series 
the figure was 44% (36). The findings included elevated transaminases, alkaline 
phosphatase and particularly gamma glutamyl transferase, but no demonstrable 
association with karyotype, body mass index, immune markers or history of HRT use 
(type and duration). Alcohol excess and infectious hepatitis are not thought to be 
aetiological factors (71). The risk of progression to cirrhosis, the prevalence of which is 
five times that in the general population (5), is unknown. Histology from liver biopsies 
varies from fatty infiltration to hepatic fibrosis and vascular abnormalities. Similarities to 
neonatal hepatic morphology have been proposed, suggesting that lifelong oestrogen 
deficiency may be a causative factor (72).
The relationship o f hepatic dysfunction to oestrogen administration remains controversial. 
The suggestion that the abnormalities found in TS may be due to oestrogen deficiency is 
based on the finding that oestrogen improves the disturbance (36,37); but others have 
documented a deterioration in liver function with oestrogen therapy (73). It is notable that 
in a recent series o f hepatic abnormalities in TS, almost one third of the patients had never 
been treated with oestrogen (74). The optimal type of oestrogen replacement is still in 
question. The combined oral contraceptive pill is thought to cause liver dysfunction in 
women with a normal karyotype whilst natural oestrogens such as oestradiol valerate are 
not. It has been suggested that transdermal oestrogens which avoid the hepatic first pass 
effect may be preferable (75). Others have found that the overall oestrogen dose may be 
the crucial factor, a higher dose being more effective in normalising liver enzymes (37).
1.1.7. Neurological Complications
Hearing loss, comprising conductive (CHL), sensorineural deafness (SNHL) or a mixed 
picture, is very common in TS. Over 90% of middle aged women are affected and 60% 
have clinically significant deficit (76).
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CHL is attributed to congenital craniofacial abnormalities which cause distortion of the 
eustachian tubes and defective ventilation, as well as impaired mucociliary transport (77). 
The resulting otitis media affects up to 68-78% of patients (7), and of these, 43% have 
been reported to have conductive hearing loss (78). SNHL is less well understood and its 
aetiology is not fully explained. It has been reported in 58% of girls, down to the age of 6 
years (78), and in 61% of women over 35 years of age (54) and is known to progress with 
age.
Oestrogen receptors have been demonstrated in the inner ear which may be of 
significance (79), and an association between hearing loss and the growth hormone axis 
has also been suggested. In a study of girls and women with TS, Barrenas et al. showed a 
weak inverse correlation between otitis media and serum insulin-like growth factor (IGF- 
1) concentration, the latter being positively correlated with stature (77), although another 
group has shown a greater incidence and severity of otitis media in TS patients receiving 
GH treatment than in a placebo group (80). It has recently been suggested that there may 
be an association between the thrifty phenotype hypothesis and SNHL, with low foetal 
concentrations of IGF-1 as the possible mechanism, programming future hearing 
problems in early life (81). An in vitro study in chick embryos has demonstrated that 
IGF-1 stimulates growth of the otic vesicle and cochleo-vestibular ganglion (82). Our 
own study found no association between either CHL or SNHL and history of previous 
oestrogen deficiency or growth hormone therapy (83).
An association between CHL and karyotypes monosomy X and isochromosome Xq has 
been reported, and a ‘dose-response’ relationship has been proposed between the degree 
o f Xp (short arm of the X-chromosome) mosaicism and hearing function (84). Our own 
study confirmed only the association with monosomy X (83). The influence of karyotype 
on SNHL in the literature is difficult to interpret. Some papers offer no statistical testing 
o f an apparent adverse effect of isochromosome X (85,86). While SNHL is more 
prevalent in monosomy X compared to mosaics, this might reflect the generally more 
severe phenotype in the former, rather than an effect specific to the short arm of X (Xp) 
(84). We found no association between SNHL and karyotype in our study (83).
Ophthalmological disorders are present in up to 63% of women with TS(87) and are 
thought to result from foetal lymphoedema. Strabismus is found in up to 37% of women,
2 2
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with amblyopia (41%), hypermetropia (41%), bilateral epicanthus (10-45%), ptosis (16- 
29%) and impairment o f colour vision (10%) also occurring with greater frequency than 
in the general population (88,89).
1.1.8. Respiratory Disease
Until fairly recently, the respiratory system was believed to be spared from any effects in 
TS. A recent study has shown, however, that the relative risk of mortality due to 
respiratory disease, especially pneumonia, is 7.9 in TS patients of all ages, although the 
effect is predominantly in adults (6). Another study demonstrated increased bronchial 
reactivity in TS which is ameliorated by oestrogen therapy (90), and there have been case 
reports o f ciliary aplasia causing bronchiectasis, ciliary dyskinesia and sleep apnoea 
syndrome (91-93).
1.1.9. Psychosocial Issues
Cognitive impairment in the form of generalised intellectual impairment is not a marked 
feature of TS except in those with karyotype ring X (11). Specific areas of intellectual 
functioning may be affected, however. Verbal skills are generally well preserved, but 
deficits may be apparent in non-verbal skills such as visuo-spatial processing, motor 
coordination, perceptual abilities, affect recognition, and attentional abilities (94,95). As 
a result, women with TS may have difficulty with arithmetic, constructional tasks, sense 
o f direction and learning to drive (96).
The relative contributions of an abnormal X-chromosome and oestrogen deficiency to 
differences in brain structure have not been clarified. An ‘X-chromosome dosage’ effect 
has been proposed, whereby the amount of X chromosome missing determines the 
severity o f cognitive impairment (97,98). This is supported by the finding of cognitive 
deficits in oestrogen-replete women with TS which were not apparent in women with 
premature ovarian failure or normal control women (99). It is interesting to note that 
functional and structural neuroimaging studies have detected abnormalities of neural 
development in TS females, including smaller size of the cerebellum and pons, thalamus 
and hippocampal, caudate and lenticular nuclei (100). Reductions in parieto-occipital 
areas, corpus callosum white matter tracts and the right temporal lobe have also been
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noted (101). These structural differences appear to be at least partly related to the degree 
o f monosomy X (97).
It has also been suggested that cognitive abilities and social functioning are influenced by 
an imprinted gene on the X-chromosome which escapes X-inactivation. Those with a 
paternally-derived X-chromosome were reported to have superior verbal and executive 
skills than those with a maternally-derived X-chromosome (16). Despite the genetic 
influences, oestrogen replacement has been demonstrated to improve nonverbal and 
visuo-motor skills (102), but growth hormone treatment has not (103).
The difficulties with non-verbal communication may partly account for the fact that 
women with TS characteristically find it more difficult to make friends and embark on 
sexual relationships. Poor self-image which derives from short stature and delayed sexual 
maturation is a contributory factor (104) and this may be improved by commencing 
oestrogen replacement therapy before the age of 12-14 years (105). Women with TS tend 
to leave the parental home and become sexually mature at a later age than their peers 
(106). Another trait seen in women with TS is that although over one third may have a 
university education, they are often employed in jobs for which they are overqualified. 
Childcare or healthcare professions appear to be a frequent choice (7,54).
1.1.10. Risk of Malignancy
The risk of gonadoblastoma increases ten-fold between the ages of 10 and 30 years (2% to 
27.5%) in those women with 45,X/ 46,XY mosaicism (107). 50% of these tumours have 
been reported to develop into dysgerminomas, and a further 10% into other malignant 
germ cell tumours in women with levels of Y-chromosome mosaicism detected by 
conventional cytogenetics (108), prompting recommendations of early prophylactic 
gonadectomy in these patients. It has recently been found that a further 5% of TS 
individuals have low levels of Y-chromosome material when tested by the more sensitive 
polymerase chain reaction technique, but the clinical significance of this is not clear 
(109).
Breast, ovarian and endometrial cancers are not thought to occur with greater frequency in 
TS than in the general population (5), although the use of unopposed oestrogens has been
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associated with reports of endometrial carcinoma (110). It is recommended that women 
with TS should be prescribed a combination of oestrogen and progesterone in 
physiological doses. The practice by some of using continuous combined preparations as 
a means o f avoiding endometrial shedding has been shown to be safe with regard to 
endometrial carcinoma only in an older age group with a greater degree of uterine 
atrophy, although the risk of ovarian carcinoma is increased in postmenopausal women 
(111). Safety evidence in younger women is currently not available.
The relative risk of colon cancer in women with TS has been reported to be between five 
and seven (5,112), although there is no excess of reports in the literature. Both 
inflammatory bowel disease and oestrogen deficiency are known to be possible risk 
factors but, in fact, IBD did not precede the development of colon cancer in the reported 
cases. Oestrogen receptors are found in colonic mucosa and epidemiological studies in 
postmenopausal women have found a reduced risk o f colonic malignancy in those treated 
with HRT (113). The effect of growth hormone on colonic cancer in TS is unknown. A 
recent report showed an increased incidence of colorectal cancer in children treated with 
human pituitary growth hormone treatment before 1985, but it is not clear whether any of 
these patients had TS (114). It should be noted that, except for a small number of patients 
(115,116), use of growth hormone in TS became commonplace only in the late 1980’s 
when synthetic growth hormone had replaced the human form. It may be some years 
before a definite answer to this question is available.
Women with TS are at increased risk of multiple melanocytic naevi, although these do not 
appear to be related to sun exposure and do not have an increased risk of malignant 
transformation (117). Excision is therefore recommended only for those naevi which 
cause irritation with clothing or if there is concern about malignant transformation, and 
women should be counselled about the increased risk, albeit anecdotal, of keloid scar 
formation in TS.
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1.2. Cardiovascular Risk in Turner Syndrome
Cardiovascular complications are the main cause of increased mortality in Turner 
Syndrome (TS), in which life expectancy may be reduced by up to 13 years (4), with a 
ten-fold increased risk o f mortality from circulatory disease (6). Cardiovascular disease 
(CVD) in TS may be both congenital and acquired (4-6).
1.2.1. Structural Heart Disease
1.2.1.1. Congenital Heart Disease
Congenital heart disease is estimated to occur in 22-40% of patients with TS (118-121). It 
is most common in those with karyotype monosomy X and least common with 
isochromosome Xq, suggesting that the long arm of the X chromosome may harbour 
genes which influence cardiac development (118-120,122). A maternally derived 
monosomic X chromosome in TS may be associated with more frequent congenital heart 
defects compared to a paternally derived X, suggesting an effect from an imprinted gene 
on cardiac development (17). Both coarctation and bicuspid aortic valve have been 
shown to be associated with developmental central lymphoedema (characterised by 
webbing of the neck), independent o f karyotype (123).
Bicuspid Aortic Valve
The congenital cardiac anomalies are predominantly left-sided, and bicuspid aortic valve 
(BAV) is the most common, occurring in 12-38% of TS patients (118,119,124-128). An 
association has been reported in TS between BAV and the ring X chromosome karyotype 
in one series (121), although this has not been confirmed by others. BAV may occur in 
isolation (which is more usual) or in association with other cardiac abnormalities 
(approximately 30% (119)). This differs from BAV in the general population, where the 
overall prevalence is just 0.24% in females and 0.75% in males, association with other 
cardiac abnormalities occurring in 70% of cases (129,130).
The prevalence of BAV in TS patients with aortic root dilatation on echocardiography has 
been quoted at 25-50% (126,128) (the prevalence of BAV in patients with aortic root 
dilatation in the general population is approximately 20% (131)). An association with
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coarctation of the aorta has also been demonstrated in TS, with BAV occurring in 19/49 
patients with coarctation in one study (124), whilst patients with a BAV were shown to 
have a relative risk for coarctation of 2.6 in another (119). Calcification of the BAV, 
which occurs with age, may cause functional impairment with either aortic stenosis or 
regurgitation. There is also a putative risk of infective endocarditis, although there are no 
reports in the literature o f this having occurred in patients with TS.
Coarctation of the aorta
Coarctation of the aorta has been reported to occur in 6-12% of women with TS 
(125,132), compared to a prevalence of 0.03% in the general population (133,134). 
Coarctation in TS is frequently associated with webbing of the neck and with severe 
lymphoedema in monosomy X aborted foetuses (123,135,136). This has prompted the 
suggestion that in TS it is caused by abnormal lymphatic flow which compresses the 
ascending aorta and alters intracardiac blood flow. Coarctation is an important cause of 
hypertension in TS. When identified clinically, coarctation is usually surgically corrected 
in childhood, but screening takes place in only a minority of girls.
1.2.1.2. Aortic dilatation and dissection
Aortic dilatation and dissection are more prevalent in TS than had previously been 
recognised (128). The prevalence o f aortic dilatation has been reported as between 8 and 
42% (126,128,137). Risk factors for aortic root dilatation include hypertension, aortic 
valve pathology and other cardiac malformations which have been reported in 90% of 
patients (128,137).
Aortic root dilatation itself is an important risk factor for aortic dissection, and the 
heightened awareness of this catastrophic complication in recent years has prompted 
greater attention to predisposing factors. In a survey of death certification, 3 out of 156 
patients died from aortic dissection, and a fourth from aortic rupture with coarctation (4), 
whilst the deaths of 8% of women in another mortality study were attributed to aortic 
aneurysm (6). 50% of those with aortic dilatation and/or dissection were under the age of 
21 years in a recent literature review (128), and dissection has been catastrophic in four 
pregnant women with TS (138-140). This is a particularly worrying finding in an era of
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increasing demand for assisted reproduction. Indeed, a recent study has estimated that the 
mortality rate for TS women achieving pregnancy through ovum donation may be as high 
as 2% from aortic dissection or rupture (141).
Atherosclerosis is a well documented risk factor for aortic dissection in the general 
population (142,143), although a mesenchymal defect may be more important in TS 
(128). There have been at least 44 case reports of aortic dissection, with histology 
available in 26 cases: 65% of these had evidence of cystic medial necrosis (118,124,144). 
This prompts an analogy to Marfan syndrome, which therefore provides a valuable 
paradigm by which to study the risk o f aortic dissection in TS. In Marfan’s, abnormal 
microfibrils are thought to alter load-bearing by the aorta and predispose to aortic 
dilatation by degeneration in the elastic laminae. Previous studies have shown that the 
aorta in Marfan syndrome has abnormal elastic properties causing it to be stiff with 
reduced compliance (145-147). Other risk factors for aortic dissection in TS include 
coarctation (as in Noonan syndrome, another condition in which webbing of the neck may 
result from foetal lymphatic obstruction (135,148)), BAV and hypertension 
(126,128,137). BAV and hypertension are known associations of aortic dissection in the 
general population. The prevalence of BAV in one series of patients with aortic 
dissection under the age o f 40 years was 9% (149).
1.2.2. Atherosclerosis
Ischaemic heart disease is thought to be twice as common in adults with TS as in the 
general population (5). Women with TS have a high prevalence of risk factors for 
atherosclerosis in addition to hypertension, including both insulin dependent (IDDM) and 
non-insulin dependent diabetes mellitus (NIDDM), insulin resistance, obesity and 
dyslipidaemia which will be considered below. Oestrogen deficiency and 
supplementation are also thought to contribute and these will be considered in Section
1.2.3.
1.2.2.1 Hypertension
Hypertension is three times more common in TS (5), occurring in up to 21% of girls and 
50% of women (3,87,128,150). A blunted circadian rhythm has been demonstrated in the
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blood pressure o f even normotensive girls who may lose their nocturnal ‘dip’ (150). 
Hypertension may be secondary to renal disease or coarctation in only 20% of patients 
(7). Small vessel renovascular disease has been proposed as a possible explanation (3), 
given the elevated renin activity which may be found before oestrogen therapy is 
instituted (150). Reduced arterial compliance and obesity are other potential contributors 
(34,35,151). Karyotype does not appear to influence the prevalence o f hypertension, 
which may be underestimated without the use of age-related normal ranges (3,151,152). 
Hypertension is exacerbated by ethinyl oestradiol but not by natural oestrogens or growth 
hormone (35,153).
1.2.2.2 Glucose Homoeostasis
Diabetes mellitus has been reported as the underlying cause o f death in 25% o f TS 
patients (154). IDDM is nearly 12 times more common than in the general population (5), 
although an excess of islet cell antibodies has not been documented (155,156). The 
prevalence o f NIDDM in TS is increased more than four-fold (5), and the prevalence of 
impaired glucose tolerance has been quoted at 10-78% (33,157-161). It has also been 
reported to occur at a younger age than in the general population, and a karyotype effect 
has been noted, with normal glucose tolerance predominating in patients with mosaicism 
(160).
An analysis of the literature with regard to glucose homoeostasis in TS (and indeed in the 
general population) is not straightforward because of the varying methodologies used in 
different studies. Some use oral or intravenous glucose tolerance tests (OGTT/ IVGTT) 
or a glucose infusion test to derive absolute values, or calculate area under the curve for 
insulin and glucose (33,157-162); others use insulin tolerance tests (162,163) or 
euglycaemic clamps (164-166). Furthermore, calculations to derive values for glucose 
oxidation (eg by indirect calorimetry) or non-oxidative glucose disposal (storage) are then 
of varying complexity, and the results and conclusions drawn are therefore not necessarily 
comparable, and indeed sometimes contradictory. Lastly, the degree of oestrogen 
deficiency in different study groups has been variable.
An additional problem which applies to many studies in TS patients is the difficulty of 
finding a suitable comparison group. With regard to glucose homoeostasis, body mass
2 9
Chapter 1
index (BMI) matching is frequently attempted, but most studies do not achieve this 
(33,164). It should also be noted that women with TS have a higher waist-hip ratio for a 
given BMI (167), and this has been taken to mean greater central obesity. Some studies 
compare only TS patients not treated with oestrogen replacement to normal controls (33), 
others have sought to match for oestrogen deficiency by comparing to women with 46XX 
premature ovarian failure (157,161).
Thus there are studies which demonstrate increased stimulated insulin concentrations 
during OGTT, IVGTT or glucose infusion in TS (33,157,159,163), decreased insulin 
concentrations (160,162,165), increased first phase insulin response (157) and decreased 
first phase insulin response (33,159,161-163). Reduced response to insulin secretagogues 
has also suggested insulin deficiency (168). Several studies have found increased glucose 
concentrations during OGTT or IVGTT analysis (33,160,169), but normal results have 
also been reported (162). There are studies which show no difference in fasting insulin 
and glucose concentrations in TS compared to normal controls (33,162,164) or raised 
fasting insulin concentrations (166), whilst a study comparing TS to women with 
premature ovarian failure found both decreased fasting insulin and glucose concentrations 
in TS (161). Euglycaemic clamp studies have suggested that the defect may be one of 
glucose storage (164), or perhaps even a muscle receptor defect (166). There have also 
been conflicting reports regarding the relationship between greater BMI and impaired 
glucose metabolism in TS, with some groups finding an association (159), while others do 
not (164).
There are few reports in the literature of pancreatic histology from TS patients, but one 
study found definite hyperplasia o f the islets of Langerhans with signs of decreased 
activity of the p-cells in an elderly woman with TS, whilst there was also a tendency to 
hyperplasia in a neonate (162).
Some previous work has suggested an increased incidence of diabetes amongst the 
relatives of patients with TS (168,170,171) but this has not been corroborated by other 
studies (157,162).
It is interesting that, as early as 35 years ago, it was suggested that the pathogenesis of 
diabetes in TS may be distinct from type 2 diabetes mellitus (157). Various mechanisms
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for the defects in glucose homoeostasis have been invoked, ranging from an insulin 
secretory defect to true insulin resistance and a more specific glucose storage defect (as 
distinct from a problem of glucose oxidation). The latter has also been demonstrated in 
other insulin-resistant states: not only in type 2 diabetics (172,173) and in the early pre­
diabetic state (174), but also in first degree relatives of type 2 diabetics (175), and in 
insulin resistant subjects with normal glucose tolerance (176). This glucose storage defect 
may be partly due to decreased glycogen synthesis (177-179).
To conclude from this literature review, if two of the most recent, and perhaps most 
carefully matched studies are to be believed (33,161), untreated women with TS do 
appear to have impaired first phase insulin secretion and insulin resistance. Fasting 
glucose and insulin concentrations are neither consistently higher or lower than in 
controls. Neither of these studies examined the relationship between oestrogen-treated 
women with TS and either normal or 46,XX premature ovarian failure controls.
The effects of oestrogen treatment on glucose homoeostasis in TS have already been 
alluded to, and will be considered further below. It should be noted, however, that growth 
hormone and oxandrolone, the other hormones widely used in paediatric practice in the 
treatment o f TS to maximise growth, also influence glucose metabolism. Growth 
hormone therapy has been shown to cause hyperinsulinaemia although not glucose 
intolerance (180,181), and it is reported that the effects are reversed after 6-12 months 
(182). Oxandrolone may further exacerbate hyperinsulinaemia (183), and in fact, 44% of 
girls taking either oxandrolone alone or in combination with growth hormone have been 
found to have abnormal glucose tolerance tests (184).
1.2.2.3. Obesity
Obesity is widespread in TS. In young adult populations, the BMI has been reported to 
average at 25-27kg/m2, significantly higher than in age-matched control groups (33,151), 
and fat free mass is also reduced (33). Although the relationship between BMI and 
glucose homoeostasis in TS has yet to be clarified, obesity undoubtedly contributes to the 
cardiovascular risk in these women. Obesity has been found to be associated with serum 
triglyceride and cholesterol concentrations (151,185), and also systolic and diastolic blood
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pressure (151). The weight problem in TS may be partly attributable to reduced physical 
fitness (33).
The obesity in TS appears to be predominantly central, with an increased waist-hip ratio, 
and a reduced fat free mass has been demonstrated on bioelectrical impedance measures
(33). Given that the relationship between obesity and glucose homoeostasis does not 
directly mirror that in the general population, further investigation o f the nature of the 
obesity in TS would appear warranted. The present study therefore set out to clarify body 
fat distribution in TS using bioelectrical impedance and whole body MRI.
1.2.2.4 Dyslipidaemia
Dyslipidaemia in TS has been documented in girls from the age of 11 years and has been 
reported to be independent of age, karyotype or BMI (185). The prevalence of 
hypercholesterolaemia has been reported to be 50% in a young adult TS population (186), 
although in this study a significant proportion of women were hypothyroid, and the effect 
of BMI on the results was not investigated. There have been reports of higher 
concentrations of total cholesterol, LDL and HDL subtractions in paediatric and adult 
series (185,186), but these are not universal findings (33,37,151,187). 
Hypertriglyceridaemia, related to obesity, has also been noted (151).
Growth hormone therapy has been shown to lower total and LDL cholesterol, and 
increase HDL cholesterol (180,188), but this does not appear to be a sustained effect on 
cessation of treatment (182). The effect of oestrogen will be discussed further below.
1.2.3 Cardiovascular Risk and Oestrogen
Women with TS may have a potentially increased cardiovascular risk as a result of both 
oestrogen deficiency in the untreated state, and oestrogen therapy in the oestrogen-replete 
state. This section will consider the possible risks from both. Data regarding oestrogen 
treatment in young women are scant and the validity of extrapolation of data from the 
studies in postmenopausal women, where the bulk of the evidence lies, is unknown.
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Premenopausal women in the general population are relatively protected from 
cardiovascular disease, and even after menopause, women have a lower cardiovascular 
risk than men with similar other cardiovascular risk factors (189). This gave rise to the 
theory that female sex steroids were protective from a cardiovascular risk point of view, a 
hypothesis which was supported by observational epidemiological studies (190-193) and 
even angiographic studies (194,195). Until relatively recently, therefore, the effect of 
exogenous oestrogen in postmenopausal women was thought to be neutral at worst, but 
probably beneficial, despite evidence to the contrary from the Framingham study nearly 
20 years ago (196,197).
Over the last few years, more studies have been published suggesting that oestrogen 
replacement in postmenopausal women confers no cardiovascular benefit and may even 
increase risk with regard to both primary and secondary prevention of cardiovascular 
disease (198-204). The deleterious effect of HRT on cardiovascular disease appears to be 
more marked in the 60-69 years age-group than in 50-59 year-olds (205). One 
explanation for this paradox is that oestrogen may slow atherogenesis in young women 
while a prothrombotic effect predominates in the older postmenopausal age-group.
1.2.3.1 Oestrogen Deficiency
There are very few data on cardiovascular disease in women with premature ovarian 
failure, but one study has shown that there is an increased cardiovascular mortality which 
is thought to be due to oestrogen deficiency (206). This is supported by data from studies 
in hypopituitarism, which have shown increased cardiovascular mortality in women 
(207,208), and particularly in those with gonadotrophin deficiency (209). The mortality 
data reflecting increased incidence o f cardiovascular disease in TS stem from a time when 
oestrogen replacement in adults was less widespread, and it may be that current cardiac 
risks are substantially reduced. Nevertheless, it should be noted that up to 24% of adults 
with TS default from oestrogen replacement therapy (210).
1.2.3.2. Oestrogen replacement therapy -  general considerations
As indicated above, the overwhelming majority of studies on the effects of exogenous 
oestrogen in oestrogen-deficient women have been carried out in middle-aged
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postmenopausal women, who are thought to be a very different category from young 
women with premature or primary ovarian failure. The use of exogenous oestrogens must 
be considered in terms of their various effects, which include symptom control for 
oestrogen deficiency, and effects on the cardiovascular system, breast and other cancers, 
primary or secondary prevention of osteoporosis, haemostasis and metabolism, liver and 
cognition. Since the subject of this study is cardiovascular disease, this will be the main 
focus of discussion, but brief consideration of the impact of HRT on other systems is 
warranted to illustrate the overall balance of risk and benefit.
There have been several studies in post-menopausal women showing that the use of HRT 
increases the risk of breast cancer and is unsafe, even for short periods, in women with a 
previous history o f breast cancer (204,211,212). The WHI but not HERS studies 
demonstrated an absolute risk reduction of colorectal cancer with use of HRT (204,213). 
The impact of HRT on osteoporosis in postmenopausal women is still disputed, however, 
with evidence that its effects are either beneficial (204) or neutral (213). It is no longer 
recommended as first line treatment for osteoporosis as any fracture protection appears to 
be short-lived on cessation of treatment (214). Further important points from the large 
prospective studies are that HRT increased the rates of venous thromboembolism (215) 
and biliary tract surgery (204,213). Thus the overall consensus must be that, whilst HRT 
is certainly beneficial in terms o f reducing symptoms of oestrogen deficiency in 
postmenopausal women (216), its use is not indicated for primary or secondary prevention 
of other conditions, and this also includes cardiovascular disease (see above).
It is interesting, however, that although the large prospective studies with hard clinical 
endpoints have failed to support the use of oestrogen replacement for cardiovascular 
disease prevention, there have been many studies suggesting benefit on surrogate markers 
o f cardiovascular disease. These will be considered in further detail below.
1.2.3.3 Oestrogen, Lipids and Metabolism
The literature on the effects of oestrogen replacement on lipids and metabolism in 
postmenopausal women is vast. It has been documented that oestrogen replacement 
induces a more favourable plasma lipid profile, with reduced total cholesterol and low 
density lipoprotein (LDL) concentrations and increased high density lipoprotein (HDL)
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concentrations (198,202,217-219). The effect of oestrogen replacement is complex, 
however, and has been shown to vary according to the type of regimen used -  whether 
conjugated equine oestrogen, 17-p oestradiol or oestradiol valerate, with or without 
progesterone, and whether oral or non-oral (eg transdermal, implants).
There is no absolute consensus in the literature as to which is better, although oral 
regimens, which exert greater effects on the liver through the first pass mechanism, are 
generally considered to result in greater changes in plasma lipoproteins, and may 
therefore result in increased HDL (both HDL-2 and HDL-3 subtractions (220)) and 
apolipoprotein A concentrations, and decreased lipoprotein (a) and apolipoprotein B 
concentrations, but also greater plasma triglyceride concentrations (219,221-223). Whilst 
LDL concentrations may be lower with oral oestrogen replacement, the particle size may 
also be smaller than with transdermal oestrogen, hence making the particles more 
susceptible to oxidation (224). Interpretation of these studies must nevertheless be 
cautious in view of the fact that oral and transdermal oestrogen groups were frequently 
studied on different progestogen regimens and may therefore not be directly comparable 
(218,222,225).
Whilst HRT has thus been shown to improve lipid profiles in postmenopausal women, 
this effect has not been demonstrated in short-term studies of oestrogen replacement in TS 
(33,35).
With regard to insulin sensitivity and glucose homoestasis, there have been a number of 
studies assessing the effects of oestrogen in healthy women, and also a few in TS. Oral 
contraceptive therapy in young normal women can result in relative insulin resistance, 
which may be due to a combination of oestrogen-induced insulin resistance and 
progestogen-associated changes in insulin half-life (226).
In postmenopausal women both endogenous and exogenous oestrogen may be associated 
with insulin resistance (227,228). The effect of the latter again appears to be associated 
with route of delivery, with oral oestrogen more likely to induce a deterioration in glucose 
tolerance than transdermal, possibly resulting from increased hepatic insulin uptake 
without a compensatory increase in first-phase pancreatic insulin secretion. There have 
been some studies suggesting that HRT reduces insulin resistance (229-231), even in
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women with type 2 diabetes mellitus (232,233), but overall the picture remains unclear 
(234-236). A paradox has been noted between a reduction in fasting plasma glucose but 
impaired glucose tolerance in women taking oestrogen (237). This may be due to an 
inhibitory effect of oestrogen on the action and secretion of glucagon and a stimulatory 
effect on glucocorticoid activity, with the reduced fasting insulin concentrations then 
being attributable to reduced gluconeogenesis resulting from glucagon antagonism (238). 
Insulin resistance has been reported to be greater during the combined oestrogen- 
progesterone phase of a cyclical preparation than the oestrogen-only phase (228). Higher 
doses of oestrogen and progestogens may attenuate any beneficial effect on insulin 
sensitivity (230,239,240).
Studies in TS women thus far have also not shown entirely consistent results. In the study 
by Elsheikh et al., fasting glucose and insulin were reduced after three months of 
treatment with oestradiol valerate and levonorgestrel (35). In the study by Gravholt et al., 
women were treated with 17(3-oestradiol via both oral and transdermal routes, using 
norethisterone as a progestogen. This regimen resulted in an increased area under the 
curve for glucose on oral glucose tolerance testing, but lower fasting serum insulin and 
acute plasma glucose response on intravenous glucose tolerance testing (33). The authors 
raised the question as to whether it was the norethisterone which had deleterious effects 
on glucose metabolism in the latter study.
It has been noted that oestrogen replacement therapy may affect body fat distribution, and 
this may contribute to the effect on insulin sensitivity. Visceral adipose tissue was found 
to be reduced in studies of postmenopausal women on HRT (241-244). This has also 
been demonstrated in TS. Elsheikh and Conway reported that oestrogen reduced waist- 
hip ratio without a change in body mass index (35), whilst Gravholt et al. found an 
increased proportion o f total fat free mass after oestrogen therapy (33).
A further aspect o f oestrogen therapy which must be considered is its effect on circulating 
concentrations of sex hormone binding globulin (SHBG). An association has been 
reported between insulin resistance and low concentrations of SHBG in both men and 
women (245-247), and in women (but not men) low levels of SHBG have been shown to 
predict the development of type 2 diabetes (248). Oral oestrogen therapy in particular is 
known to increase SHBG concentrations (225).
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Leptin, which reflects adiposity, should also be considered at this point. Gender 
differences, with concentrations o f leptin being higher in women, have been documented, 
(249), and also minor variations through the menstrual cycle in rats (250). Some in vitro 
studies suggested that leptin concentrations are influenced by short-term oestrogen 
administration (251,252), but this has not been substantiated by others (250). In vivo 
studies in postmenopausal women have shown that, although leptin concentrations do 
increase after the menopause (253), this effect is not independent of fat mass and insulin 
concentrations (254-256). Oestrogen administration may, however, prevent the increase 
in fat mass and thereby maintain premenopausal leptin concentrations (257).
1.2.3.4 Oestrogen, Inflammation and Haemostasis
Atherosclerosis, thrombosis and inflammation are linked through a number of complex 
molecular pathways (258,259). Numerous inflammation-sensitive factors have been 
found to predict increased cardiovascular risk, and of these, high sensitivity C-reactive 
protein (hs-CRP) has been found to be the strongest predictor (260), although recent work 
suggests it may not be quite as useful as previously thought (261). Other markers of the 
inflammatory cascade which predict future risk of plaque rupture include cellular 
adhesion molecules such as E-selectin and P-selectin, interleukin-6 (IL-6), tumour 
necrosis factor-a (TNF-a) and soluble intercellular adhesion molecule-1 (ICAM-1) (262). 
Factors more specific to the coagulation cascade include prothrombin, (a risk factor for 
venous thrombosis), von Willibrand factor (vWF) and coagulation factor VIIIc, and 
plasminogen and plasminogen activator inhibitor-1 (PAI-1) which participate in 
fibrinolysis. Fibrinogen and P-selectin are involved in both thrombosis and inflammation 
(263,264).
The effects of oestrogen replacement therapy on these factors have been assessed as a 
means of testing surrogate markers for cardiovascular risk. Once again, the evidence has 
been somewhat divergent. CRP has been shown to increase rapidly with oral oestrogen 
therapy (263,265-267). It has been suggested that this may explain the adverse early 
effects of oestrogen therapy (266). By contrast, oestrogen induced a more favourable 
cardiovascular risk profile with increases in plasminogen (263) and increases in E-selectin 
(266,268). With regard to different routes of oestrogen, the transdermal route does not 
cause the same increase in CRP (269). Overall, the effects of oral oestrogen on 
inflammation and haemostasis appear to be more marked than with transdermal oestrogen
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-  several studies have demonstrated an increase in fibrinolytic activity coupled with 
potentially antiatherogenic changes in lipids, but this is counterbalanced by a trend 
towards coagulation activation and hypercoagulability (268,270).
1.2.3.5 Oestrogen and Vascular Physiology
In addition to the effects on lipids, metabolism and markers o f inflammation and 
haemostasis mentioned above, oestrogen has also been shown to exert effects directly on 
vascular physiology and the endothelium. There are oestrogen receptors on the walls of 
both endothelial and smooth muscle cells (271-274).
Arterial endothelial dysfunction, particularly the reduction in bioavailability of 
endothelium-derived nitric oxide, is a key early event in atherogenesis, and may occur 
long before the appearance of structural atherosclerotic changes (275,276). Nitric oxide is 
thought to function as an endogenous antiatherogenic molecule by maintaining low 
arterial tone at rest, inhibiting leucocyte-endothelial interactions, attenuating platelet 
aggregation and inhibiting smooth muscle proliferation (277). The testing of endothelial 
nitric oxide release therefore provides important information about normal arterial 
physiology, and has been shown to be an independent predictor of coronary artery disease 
(278-281).
Endothelium-dependent flow-mediated dilatation (FMD) can be non-invasively measured 
at the brachial artery by ultrasound techniques. It has been shown to vary during the 
menstrual cycles o f normal women. One study found FMD to be higher during the 
follicular and luteal phases when serum oestrogen concentrations are higher, and lower 
during the menstrual phase (282), whilst another group has shown the nadir to be in the 
early luteal phase (283). The difference in FMD between men and women at the age of 
35 years but not at the age of 55 years (when women were assumed to be 
postmenopausal) suggests that differences between the sexes are at least partly 
attributable to sex steroid differences (284). Both oral and transdermal oestrogen therapy 
improve endothelium-dependent FMD in postmenopausal women (285-289), although the 
effect is more convincing with oral oestrogen (290). The improvement may be evident 
within one month of commencement in postmenopausal women (288), and has also been 
shown in young women with premature ovarian failure after six months of oestrogen
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therapy (291). Vaginal micronised progesterone does not appear to attenuate the 
beneficial effect of oestrogen (287), but oral progesterone therapy may do so (292). With 
regard to assessing FMD in women with TS, it is of interest to note that FMD has been 
found to be negatively correlated with vessel size in both men and women, but the effect 
may be more marked in women (284,293).
Another method of assessing progression to atherosclerosis is through ultrasound 
measurement of the thickness of the arterial intima-media complex, particularly in the 
carotid artery. The normal intimal thickness consists of a single layer o f endothelial cells 
over a thin layer of subendothelial connective tissue, but for the purposes of ultrasound 
measurement, the tunica media is also included (294). The spectrum of atherosclerotic 
lesions from the fatty streak to the fibrous plaque and finally the complicated lesion can 
be seen to increase intima media thickness (IMT) and changes in IMT may thus precede 
the development o f localised atherosclerotic plaques. This measure can provide 
predictive information on future vascular risk. A study in middle-aged men has shown 
that for each 0.1mm increase in common carotid IMT, the risk of anterior myocardial 
infarction was increased by 11% (294).
Oestrogen has been shown to exert effects on IMT. An interventional study in healthy 
postmenopausal women found a reduction in EMT of 0.0017mm (295). A study in 
postmenopausal women with elevated LDL cholesterol has shown a reduction in IMT in 
those taking oestrogen replacement compared to those who were not after three years, 
although this effect was not independent of the effect of a statin (296). The benefit of 
oestrogen has also been demonstrated in a cross-sectional study o f postmenopausal 
women with and without diabetes (297).
Another independent predictor o f cardiovascular events is increased elastic artery 
stiffness. This can also be assessed non-invasively by ultrasound. Pulse wave velocity 
(PWV) refers to the speed of a pulse wave travelling along a conduit vessel such as the 
carotid or radial arteries and is related mainly to structural factors such as increased 
collagen and medial smooth muscle (298). Augmentation index (AIx), which is derived 
from pulse wave analysis, is calculated as the difference between the second reflected 
peak and the first systolic peak as a percentage of pulse pressure (299)(see Figure 1.1.). 
AIx reflects structural factors, but also dynamic factors such as endogenous
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vasoconstrictor tone and endothelium-derived nitric oxide (298). Greater values of both 
PWV and AIx indicate stiffer arteries or reduced compliance.
Figure 1.1. Augmentation Index is calculated as the difference between the second 
reflected peak and the first systolic peak as a percentage of pulse pressure (AP/PP) 
(299)
Second peak-
APFirst peak
PP
PWV is an independent marker o f cardiovascular risk (300,301) and is associated with 
other cardiovascular risk factors such as blood pressure, insulin resistance, central obesity, 
greater carotid EMT (302) and coronary plaques (303). Data on the prognostic value of 
AIx are still emerging (304,305) and it has been suggested to have greater predictive 
power than PWV (306).
With regard to the effect of oestrogen on markers of arterial stiffness, a recent study has 
shown elastic artery stiffness to be less in younger premenopausal women compared to 
men, but greater in older postmenopausal women than men of a similar age (307). 
Augmentation index was found to be reduced in a cross-sectional study comparing 
postmenopausal women on and off HRT, despite no difference in their blood pressures 
(308). A study of PWV at different time points through the menstrual cycle of healthy 
premenopausal women found no variation, however (283), and another cross-sectional 
study of postmenopausal users and non-users of hormone replacement therapy found no 
difference in either PWV or AIx (309). It should be noted that augmentation index may 
also be influenced by both heart rate and body height (299,310).
4 0
Chapter 1
Oestrogen administration also results in an acute increase in peripheral blood flow in 
postmenopausal women, with reduced peripheral vascular resistance, possibly due to a 
direct relaxing effect on vascular myocytes or endothelium-dependent relaxation (311).
Thus far there have been very few studies of vascular physiology/ endothelial function in 
TS. Elsheikh et a l showed that augmentation index was significantly lower in women 
with TS taking oestrogen therapy than those not taking oestrogen; this effect was seen 
within three months and was independent of changes in blood pressure or serum lipids 
(35). Chan et al. showed in a venous plethysmography study that the vasodilator response 
to bradykinin on forearm blood flow was significantly reduced within six weeks of 
stopping oestrogen replacement in women with TS, and improved within six weeks of 
recommencement. The effect was endothelial, since GTN responses were unchanged
(34). There have been no longer-term studies or studies with hard clinical endpoints in 
TS.
In this study we aimed to assess various markers of vascular physiology/ endothelial 
function both in our cross-sectional study of women with TS compared to normal control 
women, and also in our oestrogen dose-ranging study comparing women with TS and 
women with primary amenorrhoea (PA), karyotype 46,XX.
1.2.4 Cardiovascular Imaging in Turner Syndrome
Optimal screening tools for the assessment of cardiovascular anomalies in women with 
TS have yet to be determined. Transthoracic echocardiography is commonly used, but 
images are frequently poor due to chest wall anomalies. Furthermore, aortic root diameter 
(ARdm) on echocardiography is recognised to correlate with body size which has a major 
impact in women with TS who have a mean height deficit o f about 20 cm (87). 
Adjustment for body surface area (BSA) appears most relevant to normal children and 
young adults in whom growth contributes to variability (312-314), whereas in older age- 
groups, adjustment for height, weight and age may be more relevant (314-316). There 
have been various recommendations on how best to correct for stature in subjects with 
TS. Traditionally, criteria used to define aortic root dilatation (ARD) on 
echocardiography have been derived by correcting individual measurements or aortic 
diameter for body surface area (BSA) using the Geigy correction tables (317). Because of
41
Chapter 1
their short stature, however, this correction method may result in women with TS actually 
being compared to children in normal population tables, potentially leading to an 
overestimate of the prevalence o f ARD in TS. This study aims to explore the effect of 
different strategies to account for the effect of short stature in TS on echocardiographic 
measurements.
Magnetic resonance imaging (MRI) can detect degrees of dilatation and coarctation which 
are not apparent on echocardiography (125). Previous work has suggested use of the 
ascending to descending aortic ratio (Asc:Desc ratio) as a measure of aortic root 
dilatation, a ratio of greater than 1.5 being considered abnormal in children on autopsy 
(318), normal adults on CT (319) and TS children on MRI (137). This means of ‘intra­
subject’ correction for size, which circumvents one problem of using echocardiography in 
which correction for body size is more crude, is itself prone to error if anomalies occur in 
the descending aorta.
Another aspect of echocardiography surveillance which requires clarification is the 
frequency of interval scanning. Current guidelines for the management of adults with TS 
recommend 3-5 yearly echocardiography for monitoring of the aortic root, but this advice 
is not based on any clear evidence (7,320,321).
1.3. Aims of this Research Project
This research project aimed to characterise the cardiovascular risk in women with TS with 
regard to congenital and acquired disease. The setting for the studies undertaken was the 
Middlesex Hospital Adult Turner Syndrome Clinic which is one of the largest such clinics 
in the world, serving a population drawn from all over England. At commencement of the 
research project, the clinic population totalled 254 women, and this has since risen to 384 
women. Approximately 60% of these patients are referred from the local paediatric 
clinic, and a further 40% are from primary care. This large clinic population has made it 
possible to assess various aspects of cardiovascular risk both cross-sectionally and 
longitudinally within the constraints posed by the distances at which some patients lived 
from the clinic.
4 2
Chapter 1
1.3.1 Echocardiography and Magnetic Resonance Imaging of the Aorta
In the Middlesex Hospital Adult TS clinic it became evident that protocols for cardiac 
screening in paediatric practice vary considerably and moreover, that some anomalies 
such as aortic root dilatation are likely to progress through adulthood. This research 
project aimed to compare measurements of aortic dimensions assessed by transthoracic 
echocardiography and by MRI in an adult TS population with controls, and to explore 
their relationships with clinical parameters. A further aim was to define the distribution 
of aortic dimensions found in an asymptomatic adult TS population as a reference source 
for future risk intervention studies.
A longitudinal study aimed to gain information about the rate of progression of aortic root 
dilatation on echocardiography in women with TS in order to verify whether the current 
interval guidelines o f 3-5 years are appropriate.
1.3.2. Cross-sectional Vascular Physiology Study
The precise mechanisms of the increased cardiovascular risk in TS are unclear. We 
hypothesised that women with TS have a fundamental arterial wall defect which may 
extend beyond the arch of the aorta and which may be related to genetic factors or 
oestrogen deficiency. In order to characterise the vasculopathy of TS this study assessed 
arterial structure (carotid and brachial artery dimensions and carotid artery intima media 
thickness), arterial stiffness (pulse wave velocity and augmentation index) and endothelial 
function (flow-mediated dilatation) in a cross-sectional cohort of women with TS. The 
TS women were compared to normal controls and to karyotypically normal women of 
normal stature with 46,XX primary amenorrhoea. This was to permit comparisons to 
women with a similar history of oestrogen deficiency but without the genetic 
abnormalities inherent in TS.
1.3.3. Cross-sectional Metabolic Study
Most of the studies assessing risk of diabetes and cardiovascular risk in TS have been 
small. This research project approached the issue from a different angle, by screening a 
large TS population for anthropometric and metabolic markers of cardiovascular disease.
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The aim was again to compare not only to normal controls, but also to women with 46XX 
premature ovarian failure (322), a subgroup of whom also had primary amenorrhoea.
Subgroups of this larger cross-sectional cohort were recruited to participate in more 
detailed analyses o f body composition using bioelectrical impedance and MRI scanning 
for fat content.
1.3.4. Longitudinal oestrogen dose-ranging study
It has been suggested that women with TS are relatively resistant to the actions of 
oestrogen and benefit from higher doses with regard to bone markers and liver function 
(37) and uterine development (323). The hypothesis of this part of the project was that 
higher doses of oestrogen may be beneficial to markers of cardiovascular risk and 
metabolism. In order to assess the relative oestrogen resistance of women with TS, they 
were once again compared to women with 46,XX primary amenorrhoea (PA), who are 
similarly oestrogen deficient but have a normal karyotype.
4 4
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Chapter 2 
General Methods
2.1. Patient Characteristics
All subjects with TS were recruited from the Middlesex Hospital Adult TS clinic. This 
clinic comprised a total of 254 women with TS, including women who had previously 
attended the Middlesex Hospital paediatric endocrine clinic, as well as new referrals. 
Figure 2.1 demonstrates the age o f diagnosis in this clinic population. The women, from 
all over the country, annually attend a monthly morning clinic, with travelling distances of 
up to 300 miles. For this reason, every effort was made to combine as many aspects of 
the study as possible with a clinic visit, although some patients were willing to attend for 
further visits to complete other parts of the study. All aspects of the study were 
coordinated and organised by a single investigator (JEO). Women were sent a patient 
information sheet approximately two weeks before the date of their clinic appointment. 
This was followed up with a telephone call, and a further discussion on the day of their 
clinic visit before obtaining written informed consent from participants. The study was 
approved by the UCL Hospitals Ethics Committee.
Figure 2.1. Age at diagnosis of 254 patients attending the Adult Turner Clinic at 
the Middlesex Hospital
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173 unselected women in the Middlesex Adult TS clinic were included in the overall 
cross-sectional study (karyotype distribution illustrated in Table 2.1. and Appendix 1), 
and subpopulations o f this cohort took part in various aspects of it (see Figure 2.2.). 
Every attempt was made to study women during the oestrogen-only phase of their 
hormone replacement in order to standardise the analysis. This was relevant for the cross- 
sectional vascular physiology study (Chapter 5), the cross-sectional metabolic study 
(Chapter 6) and the longitudinal oestrogen study (Chapter 8), since phase in the cycle 
would not be expected to have an impact on the other imaging studies. This will be 
discussed in each o f the relevant methods sections.
Clinical history and case notes were reviewed for previous medical history and surgery, 
particularly cardiac. History of oestrogen replacement, previous growth hormone and 
oxandrolone administration was recorded, and current medications, especially the use of 
antihypertensives, were noted. Oestrogen-deficient years were defined as the cumulative 
years after the age of 11 during which oestrogen-deficient subjects were not treated with 
oestrogen. Subjects were asked about their history of smoking and exercise. (These data 
are quoted in each individual chapter; Table 1, Appendix 1 shows a summary of these 
patient characteristics in each subpopulation.)
Table 2.1. Karyotype distribution of total study population
Karyotype % of TS women, 
n=173
Monosomy X (45,X) 50
Isochromosome X 22
Partial X deletion 3
Ring X 8
Any Y fragment 6
Mosaic 45,X/46,XX 8
Complex 3
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Figure 2.2. Distribution of the sample population. The relevant chapter discussing 
each section of the study is shown in parentheses.
Turner Syndrome ! 254 women 
in TS clinic
Total study population
1173 women included in study
Metabolic assessments
125 women
Cross-sectional 
metabolic study (6)
117 non-diabetic women
Normal Controls
Echocardiography (3)
36 women
Vascular physiology assessments (5)
25 women
Fat distribution study (7)
6 women underwent bioelectical impedance 
testing and whole body MRI scanning
46,XX Oestrogen Deficient Controls 
(Primary Amenorrhoea/ 
Premature Ovarian Failure)
Cross-sectional metabolic study (6)
31 women
Vascular physiology study (5) and oestrogen dose-ranging study (8)
11 women with primary amenorrhoea
MRI aorta (3)
20 women
Total OD controls
31 women
Serial echo study (4)
33 women
Oestrogen dose- 
ranging study (8)
14 women
Vascular physiology 
assessments (5)
93 women
Total healthy normal controls
 36 healthy women_____
Exclusions from metabolic study
 6 women taking OCP_____
Cross-sectional Metabolic study (6)
30 women
Echo vs MRI study (3)
128 women included 
in cardiovascular screening
Fat distribution study (7)
6 non-diabetic women underwent 
bioelectical impedance testing 
and whole body MRI scanning
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Clinical parameters recorded included anthropometric assessments such as height, weight, 
waist and hip measurements. Height was measured to the nearest 1 cm (Harpenden 
stadiometer, Holtain, Crosswell, Crymmych, Pembs., UK). Weight was measured in 
normal clothing, after removal of shoes and jacket or coat, using a digital weighing 
machine, to the nearest 0.1 kg (Tanita BWB-620, Marsden, London, UK). Height and 
weight measurements were used to calculate body mass index (BMI) (weight (kg)/ height 
(m) ) and body surface area (BSA) (square root of [(height in centimetres x weight in 
kilograms) / 3600]) using the Mosteller formula (324).
Waist circumference (cm) was measured at the narrowest part of the torso and hip 
circumference (cm) was measured in a horizontal plane at the level of the maximal 
circumference of the buttocks. Waist and hip were measured with a plastic tape in 
triplicate and the mean recorded. The waist:hip ratio (WHR) was calculated from these 
measurements.
Recumbent blood pressure was recorded when subjects had rested for at least 15 minutes 
at the right and left brachial arteries, and the left dorsalis pedis artery using an automated 
sphygmomanometer (Dinamap, Critikon, Tampa, Florida, USA). Five readings were 
taken at each site and mean systolic and diastolic blood pressure calculated. A large cuff 
was used for obese individuals.
Normal Controls
TS women were compared to 36 normal control women of similar age who were recruited 
from amongst the departmental and hospital staff. The stature of this control group at 
mean 1.60m was notably shorter than the population mean of 1.66m in order to lessen the 
impact of height adjustment. Again subpopulations of this cohort took part in different 
aspects of the study (Figure 2.2.). All normal control women were studied in the 
follicular phase of their menstrual cycle.
Oestrogen-deficient Controls
TS women were also compared to a second control group which comprised 31 
karyotypically normal (46,XX) amenorrhoeic women of normal stature. 11 of these 
women had 46,XX primary amenorrhoea (PA), nine with gonadal dysgenesis and two 
with hypogonadotrophic hypogonadism, and these took part in the cross-sectional
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vascular physiology study and the longitudinal oestrogen dose-ranging study. The other 
women in this group of 31 women all had premature ovarian failure (POF) and where the 
whole group is referred to, they will be described, for convenience, as oestrogen deficient 
(OD). All 46,XX PA women were studied in the oestrogen-only phase of their hormone 
replacement therapy; every attempt was made to study the other women with OD, many 
of whom also had long travelling distances, in the same phase (see further discussion in 
Section 2.7.).
2.2. Blood sampling
Subjects were asked to fast over night (12 hours) prior to blood sampling. Serum (taken 
in plain tubes containing granules to assist clot retraction) and plasma (tubes containing 
lithium-heparin anticoagulant) were collected for measurement of renal, liver, bone and 
lipid profiles, insulin concentrations and thyroid function. In the case of the women 
participating in the oestrogen dose-ranging study, serum gonadotrophins (follicle 
stimulating hormone, FSH, and luteinising hormone, LH) were also measured. Samples 
for glucose measurement were collected in fluoride tubes. EDTA samples were taken for 
full blood count and renin measurement and lithium heparin samples were collected for 
karyotype analysis. All samples were immediately stored on ice before being processed 
in the laboratory. The homoeostasis model insulin resistance index (HOMA-R) was 
calculated as the product of fasting insulin and glucose concentrations divided by 22.5.
Further samples were taken for storage of serum and plasma, the latter collected in both 
citrated and pre-chilled EDTA tubes. These were immediately stored on ice and 
centrifuged at 2,000 x g  at 2°C for 7.5 minutes within one hour of collection. They were 
then stored at -80°C.
2.3 Assays
Renal function (urea, electrolytes and creatinine), liver function (alkaline phosphatase, 
alanine transferase, gamma glutamyl transferase, albumin, bilirubin), calcium and 
phosphate concentrations were measured on a Roche Modular Autoanalyser, as was 
plasma glucose (using glucose oxidase reagent). Total cholesterol, high density 
cholesterol and triglyceride concentrations were determined enzymatically (LDL was
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estimated as described by Friedewald et <?/.(325)) and serum insulin, gonadotrophins, 
oestradiol and testosterone were measured by electrochemiluminescence immunoassay 
(Roche Modular Autoanalyser, Modular Analytics E l70). Plasma renin activity was 
measured by radioimmunoassay (RENCTK, DiaSorin, Italy). Full blood count and 
fibrinogen were measured on an automated analyser.
C-reactive protein was determined with an in-house enzyme immunoassay using rabbit 
antihuman antibodies (X0293) from Dako Diagnostics (Ely, Cambs., UK), validated 
against the UK Reference Preparation, with an assay range of 0.15-0.48 mg/1 and intra- 
and inter-assay correlations of coefficient of <10% as previously described (326).
Interleukin-6 (11-6) was measured by high sensitivity two-site ELISA (R&D Systems). 
This is a quantitative sandwich enzyme immunoassay technique utilising a monoclonal 
antibody specific for 11-6. The inter- and intra-assay coefficients of variation (CV) were 
<10%. The minimum detectable dose of IL-6 was 0.09 pg/ml. This method has 
previously been described (327).
Leptin was measured in serum using a well-validated in-house radioimmunoassay, with 
an antihuman rabbit monoclonal antibody and I125-labelled leptin. The assay was 
sensitive to 0.1pg/l with inter- and intra-assay CVs <10% as previously described (328).
2.4. Method for Echocardiography and Magnetic Resonance Imaging (MRI) of the 
Aorta -  Cross-sectional Study
128 women in the TS clinic were offered transthoracic echocardiography and MRI of the 
aorta, and successful images were obtained in 107 women using both modalities. These 
women were compared to 36 normal control women of similar age, all of whom 
completed echocardiography whilst 20 had MRI of the aorta (see Figure 2.2).
M-mode and two-dimensional echocardiography was completed in 120/128 (94%) 
women with TS (Acuson ‘Aspen’ echocardiography machine, Acuson, Mountain View, 
CA, USA). Echocardiography data were technically inadequate in 8/128 (6%) women. 
Measurements of aortic root diameter (ARdm) at the level of the annulus, estimates of left
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ventricular mass and the presence of BAV were recorded. Other abnormalities visualised 
on echocardiography were also noted.
Axial and sagittal oblique MR images of the aorta, as well as cine and phase contrast 
sequences were obtained (Siemens Magnetom plus 1.5T scanner, Siemens, New York, 
NY, USA) in 115/128 (89.8%) women with TS. 13/128 women (10.2%) were unable to 
tolerate MRI. Ascending (AAdm) and descending (DAdm) aortic diameters were 
measured at the level of the bifurcation of the pulmonary artery with calipers on hard 
copy images and corrected for the appropriate scale. The presence of ARD on MRI was 
defined as a ratio (Asc:Desc ratio) of >1.5 (137,318,319). The presence and degree of 
coarctation and flow disturbance at the classical aortic coarctation site immediately distal 
to the origin of the left subclavian artery (ligamentum arteriosum site) was noted. Other 
morphological abnormalities of the aorta were also recorded.
2.5. Method for Interval Assessment of Aortic Dilatation using Echocardiography
An initial pilot study for this project was commenced in 1997, and these women were 
rescanned as part of the current project to determine the rate of change of aortic 
dimensions, having also been included in the cross-sectional echocardiography study (see 
Figure 2.2). Interval echocardiography was performed in 43 TS women, but owing to 
technical difficulties, only 33 women (mean ± SD age 29.1 ± 6.6 years, height 1.47 ± 0.08 
m.) had two successful scans permitting measurement of the aortic root with a time 
interval of 3.8 ±1 . 4  years. The presence or absence of a bicuspid aortic valve was 
recorded. In order to reflect routine clinical practice, echocardiograms were performed as 
a standard request from the services at the Middlesex Hospital by duty 
echocardiographers.
29 women in this cohort also underwent Magnetic Resonance Imaging of the aorta around 
the time of their second echocardiogram and the presence of coarctation site abnormalities 
in particular was noted.
2.6. Method for Vascular Physiology Assessments -  Cross-sectional study
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Vascular physiology assessments for the cross-sectional analysis were performed in 93 
women with TS, 25 normal controls and 11 women with 46,XX PA. As previously 
mentioned, every attempt was made to assess women in the oestrogen-only phase of their 
hormone replacement. This was not always possible because of the fact that women often 
had to travel long distances to attend. 55 women were studied in the oestrogen-only phase 
of their hormone replacement therapy, 19 in the oestrogen and progesterone phase, 10 in 
the pill-free week, 7 on a continuous combined preparation and cycle phase was unknown 
in 2 women. All normal and 46,XXPA controls were studied in the follicular and 
oestrogen-only phases respectively.
All measurements were performed in a warm, temperature-controlled room at the 
Vascular Physiology Laboratory at Great Ormond Street. Antihypertensive medication 
was withheld for at least 24 hours. Subjects attended after a 12-hour overnight fast. On 
arrival they were allowed to rest for at least 15 minutes. The blood sample was then 
drawn and clinical parameters recorded as described above, including a baseline blood 
pressure and pulse. All vascular physiology measurements were performed by two 
experienced vascular technologists (AED and CS) and recorded on software. Tape- 
recorded images were analysed and computing of results performed by a single analyser 
(JEO).
Pulse Wave Velocity (PWV) and Augmentation Index (AIx)
Pulse wave velocity was determined with the subject supine, using a transcutaneous 
pressure tonometer (Sphygmocor system, ScanMed, Draycott, Gloucestershire, UK) to 
record the pressure pulse waveform consecutively at the carotid and femoral artery. The 
distance travelled by the pulse wave was measured over the body surface, and the pulse 
wave velocity (in metres/ second) was obtained from the mean time difference between 
the R-wave measured in a simultaneously recorded ECG and pressure wave in relation to 
the arterial path length.
Augmentation Index (AIx) was calculated using the radial pulse pressure waveform (see 
Figure 1.1.) to derive the central pressure waveform using a validated generalised transfer 
function. This was then corrected for heart rate.
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Intima Media Thickness (IMT)
Carotid IMT was measured in the far wall, 1cm below the common carotid bifurcation in 
plaque free segments using high resolution B-mode real-time ultrasound (Acuson XP10 
ultrasound system, Acuson, Mountain View, CA, USA) with a 5-10 MHz linear array 
transducer. The intima media thickness was defined by the lumen-intima and media- 
adventia interfaces. Ultrasound images were recorded on videotape and later masked 
interpretation of scans was performed. Carotid artery diameter was calculated from the 
end-diastolic distance between the lumen-intima interfaces measured in three sequential 
R-wave-triggered frames, whilst IMT was defined by the lumen-intima and media- 
adventitia interfaces. Three measurements were taken for both parameters on each side, 
and the mean of right and left taken as the overall average carotid artery diameter and 
IMT respectively.
Brachial artery diameter and Flow-mediated dilatation (FMD)
Brachial artery diameter and FMD were assessed after completion of PWV/ PWA and 
IMT measurements. Subjects had been supine for at least 20 minutes. Three monitoring 
ECG electrodes were attached to the chest. The brachial artery was imaged in 
longitudinal section 5-10 cms proximal to placement of a blood pressure cuff, just below 
the antecubital fossa. An Acuson XP10 ultrasound system was used with a 10-MHz 
linear-array transducer supported by stereotactic clamp. The image was magnified using 
a resolution box function and gated with the R-wave of the ECG. When the clearest B- 
mode image through the centre of the vessel was obtained with optimal contrast between 
the anterior and posterior vessel walls and the lumen of the vessel, the stereotactic clamp 
was fixed in place. A Doppler signal was recorded from the centre of the vessel with the 
range gate set at 1.5mm. Fine adjustments in the position of the transducer were made by 
means of micrometer screws attached to the base of the clamp to maintain image quality 
throughout the study. Sequential end-diastolic images of the artery were acquired every 3 
seconds throughout each study using data acquisition software (Brachial Tools, Medical 
Imaging Applications, Iowa, USA), and the diameter of a 1- to 2-cm segment was 
determined for each image using semiautomatic edge-detection algorithms. Blood flow at 
the vessel diameter measurement site was recorded continuously throughout the study 
using pulsed wave Doppler. Systemic blood pressure was measured in the contralateral 
arm at regular intervals throughout each study using an automated sphygmomanometer 
(Dinamap).
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Endothelium-Dependent (Flow-Mediated) Vasodilation
The baseline image and Doppler signal were recorded for 60 seconds, following which the 
blood pressure cuff was inflated to suprasystolic pressure (300mmHg) for 5 minutes. The 
cuff was then rapidly deflated and the artery imaged and Doppler signal recorded for 5 
minutes after cuff deflation. Brachial artery FMD was calculated as the maximum change 
in diameter from baseline, expressed as a percentage. It is accepted that errors are 
inherent in the flow velocity measures at a Doppler angle of 70 degrees in the centre of 
the vessel but relative changes are accurate.
Blood flow was expressed as reactive hyperaemia -  the ratio of change from baseline. 
The velocity time integral (VTI) in metres was determined at baseline, during cuff 
inflation, and at prespecified time points (at 5 and 15 seconds, and then every 15 seconds 
for the first 2 minutes of reactive hyperaemia).
Flow was calculated as:
VTI * HR * 7t r2 * cosO ml/minute 
where r = vessel radius and 0 = 70° (the angle of insonation of the blood vessel).
On cuff deflation the resultant reactive hyperaemia was calculated as the flow change 
from baseline, expressed as a percentage change in blood flow. This measurement was 
used to assess whether the studies between the different groups (in this case TS and 
control groups) were comparable.
Baseline vessel diameter (mm) was calculated as the mean of 20 measurements during the 
first minute of each study. Dilatation (maximal after reactive hyperaemia and mean of 1 
minute during steady-state conditions) was measured using the baseline average and the 
maximum of three measures averaged at peak, expressed as a percentage change from the 
baseline diameter.
Endothelium-independent (GTN mediated) dilatation
The effect of endothelium-independent stimulation was assessed by administration of a 
sublingual dose of 25pg glyceryl trinitrate (GTN). Although many studies have used 200- 
400pg doses of GTN, a 25pg dose gives a dilatation equivalent to the degree of FMD 
dilatation seen in healthy controls and was therefore used in this study. This small dose
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reduces the safety and ethical concerns regarding potential side effects from large doses of 
GTN.
As with assessment of FMD, the baseline image and Doppler signal were recorded for 60 
seconds. GTN was then administered sublingually, and the image and Doppler signal 
were recorded for a further 5 minutes. GTN-mediated brachial artery dilatation is 
calculated as the maximum change from baseline diameter, expressed as a percentage.
Blinded replicate measures for the FMD and GTN measurements were performed to 
assess reliability and found inter- and intra-observer correlation coefficients to be 0.96 
and 0.99 respectively.
2.7. Methods for Metabolic Assessments -  Cross-sectional study
117 women with TS and normal fasting serum glucose were compared to 30 normal 
control women of similar age who were taking no medication and had regular 
spontaneous menstrual cycles, and also to the 31 karyotypically normal, oestrogen-treated 
amenorrhoeic women, also of similar age. The latter group, which will be referred to as 
the 46,XX oestrogen deficient (OD) group, comprised 12 women with primary 
amenorrhoea (two of these having hypogonadotrophic hypogonadism), whilst the 
remainder had premature ovarian failure (POF). Eight women in the TS clinic with 
known diabetes mellitus were excluded from the study.
As previously mentioned, every attempt was made to study all women in the oestrogen- 
only hormone replacement phase or follicular phase as appropriate. Amongst the women 
with TS, 57 were studied in the oestrogen-only phase of their hormone replacement 
therapy, 23 in the oestrogen and progesterone phase, 10 in the pill-free week, 8 on a 
continuous combined preparation, and cycle phase was unknown in 19 women. Amongst 
the women with 46,XXOD, 26 were studied in the oestrogen-only phase of their hormone 
replacement therapy, 4 in the pill-free week and 1 on a continuous combined preparation. 
All normal controls were studied in the follicular phase of their menstrual cycles. 
Subjects attended after a 12-hour overnight fast. Clinical parameters and blood sampling 
were performed as previously described.
55
Chapter 2
2.8. Methods for Fat Distribution Study
Six non-diabetic oestrogen-treated women with TS were compared to six age-matched 
normal control women of similar BMI who were taking no medication and had regular 
spontaneous menstrual cycles (see Figure 2.2.). As previously, clinical history and case 
notes were reviewed, and clinical parameters recorded.
Subjects attended after a 12-hour overnight fast, although they were allowed to drink 
water until 3 hours before the test and a blood sample was taken as previously described.
Total body adipose tissue content
Rapid Ti weighted MR images (repetition time 36ms, echo time 14ms) were acquired as 
previously described (329). Subjects lay in the magnet in a prone position with arms 
straight above the head, and were moved through the magnet on a purpose-built platter. 
They were scanned from their fingertips to their toes by acquiring lOmm-thick transverse 
images with 30mm gaps between slices in the arms and legs, and 10mm gaps between 
slices in the trunk. Images were analysed for fat and non-fat components using 
SliceOmatic (Tomovision, Montreal, Quebec, Canada) (330). Total body adipose tissue, 
subcutaneous, total internal, subcutaneous abdominal and intra-abdominal adipose tissue 
volumes were measured (329). The coefficient of variation varies between different 
depots, but the data analysis method is generally highly reproducible: 3% for internal fat, 
5% for visceral fat, and less than 1% for total, subcutaneous and subcutaneous abdominal 
fat (331).
MRS o f the liver
lH MR spectra were acquired on a 1.5T Eclipse multinuclear system (Phillips Medical 
Systems, Cleveland, Ohio) using a flexible body coil. Spectra were obtained from the 
right lobe of the liver using a PRESS sequence (repetition time 1500ms, echo time 
135ms) without water saturation and with 128 signal averages. Transverse images of the 
liver were used to ensure accurate positioning of the 20x20x20mm voxel in the liver, 
avoiding blood vessels, the gall bladder and fatty tissue. Spectra were analysed as 
previously described, with intrahepatocellular lipids (IHCL) measured relative to liver 
water content after correcting for relative variations in Tl and T2 components (332). The 
coefficient of variation for repeated determinations of this measurement was 7% (332).
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MRS of muscle
Subjects were supine with the left leg immobilised in a 30cm diameter quadrature bird 
cage coil. !H MR spectra were obtained from the soleus and tibialis muscles with 
repetition time 1500ms, echo time 135 ms, 256 averages (333). Intramyocellular lipids 
(IMCL) were measured relative to the total muscle creatine signal after correcting for 
relative variations in T1 and T2 components. The coefficient of variation for repeated 
determinations of this measurement was 13.6 ± 3.5% (333).
Bioelectrical impedance for body fa t composition
Bioelectrical impedance was assessed in all women. This was measured from foot to foot 
using a Tanita BC-418MA body-fat analyser (Tanita Corp., Tokyo, Japan). Subjects 
stood on the metal sole plates of the machine without shoes, socks and heavy items of 
clothing. An allowance of 1kg was made for the weight of clothing. All measurements 
were made after asking subjects to urinate, and allowing a period of at least 10 minutes 
standing to minimise potential errors from acute shifts in fluid distribution. The machine 
provided a print-out of measured impedance and calculated body fat after entering the 
subjects’ sex, height and age. Standard prediction equations were used (334).
2.9. Methods for Longitudinal Oestrogen Dose-ranging Study
Fourteen women with TS from the original cross-sectional cohort were recruited (see 
Figure 2.2.), 13 of whom experienced primary amenorrhoea and one secondary 
amenorrhoea. They were compared to 11 women with 46,XX primary amenorrhoea (PA) 
of similar age; nine of the PA group had 46,XX gonadal dysgenesis, two had 
hypogonadotrophic hypogonadism. The latter two women were excluded from the 
analysis of gonadotrophin measurements, but their exclusion for all other analyses did not 
alter the results and data presented for all other parameters are therefore inclusive of these 
two women. All women taking part in the study were generally fit and well.
Clinical history and case notes were reviewed as previously discussed. All subjects 
entered the study recording good compliance with their routine oestrogen replacement. 
At each visit they were questioned about compliance with oestrogen therapy and 
intercurrent illness.
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All women sequentially received for three periods of twelve weeks (three 28-day cycles) 
each: oral 17-p oestradiol 1, 2 and 4mg daily in the form of Femoston 1/10, Femoston 
2/10 and two daily tablets of Femoston 2/10 respectively (Solvay Pharmaceuticals, 
Southampton, UK). The progestogen in these preparations is dydrogesterone lOmg, 
which was contained in the tablets taken from days 15-28 in each cycle.
All assessments were carried out in the oestrogen-only phase of oestrogen replacement 
during week 10 of each oestrogen dose (between days 8 and 14 of the third pack). As in 
the cross-sectional study, women attended after a 12-hour overnight fast; clinical 
parameters were recorded and blood samples were taken. Vascular physiology 
measurements were recorded according to the methods described above. These included 
pulse wave velocity and augmentation index to assess arterial stiffness, intima media 
thickness measurement to assess arterial structure, and flow-mediated dilatation to assess 
endothelial function. Notes on the position of the arm for FMD studies and ultrasound 
images of the brachial and carotid artery were recorded and matched to ensure 
consistency between sites of analysis for FMD and IMT on each of the three visits.
2.10. Power Calculations
The initial design of this study used aortic root dilatation as the primary outcome measure. 
Power calculations were performed to estimate the number of subjects required to provide 
meaningful outcomes in subgroup analysis. Further power calculations were then 
performed for other aspects of the study.
Power Calculations for Echocardiography and Magnetic Resonance Imaging (MRI) of  
the Aorta -  Cross-sectional study
Pilot data suggested that in a total of 100 subjects, the estimated sizes of subgroups were: 
50 with karyotype monosomy X, 25 with isochromosome X, 25 with oestrogen deficiency 
for more than five years, and 25 who had received growth hormone treatment. There 
were no data available which allowed us to predict a clinically significant difference in 
aortic root diameter in TS comparable to Marfan syndrome. 2mm differences in aortic 
root diameter on echocardiography between groups were therefore taken to be significant 
as this represents the change seen over two years in Marfan syndrome (335,336). A
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standard deviation of 4mm was used as determined by our pilot data in adult patients with 
TS. In order to detect a 2mm difference in aortic root diameter with 80% power, we 
calculated that 63 subjects would be required. To find differences in subgroups defined 
by 1:1 or 1:4 ratios, such as monosomy X or growth hormone users in childhood, a 
requirement of 126 subjects was calculated.
Power Calculations for Interval Assessment o f Aortic Dilatation using 
Echocardiography
Using power calculations based on pilot data of interval echocardiography in 10 TS 
subjects which were available from clinic prior to this study, the mean ± SD change in 
aortic root diameter over three years was 0.27 ± 0.29cm. With a significance of 0.05 and 
a power of 90%, it was estimated that 14 subjects would be required to detect a significant 
difference.
Power Calculation for Vascular Physiology Assessments (Intima-Media Thickness) -  
Cross-sectional study
Published data in the general population have shown that an increase in IMT in the 
common carotid artery correlates with an 11% increase in risk of myocardial infarction 
(294). Pilot data in 18 subjects with TS compared to controls showed a mean ± SD 
difference in IMT of 0.4 ± 0.4mm. We calculated that for a power of 90% and a 
significance level of 0.05, 22 subjects would be needed in subgroup analysis to detect a 
0.4mm difference in IMT. With a total population cohort of 93 patients, this would allow 
us to demonstrate differences in IMT in the larger subgroups such as karyotype 
(monosomy X in 50%) and childhood treatment with growth hormone (used in 
approximately 25% of women with TS), defined by 1:1 and 1:4 ratios respectively. 11 
women with 46,XX PA were recruited for illustration of the effect of oestrogen 
deficiency.
Power Calculations for Longitudinal Oestrogen Dose-ranging study
The power calculation for this study was based on published sources documenting IMT 
changes in response to oestrogen. A study in postmenopausal women showed that LMT is 
reduced by 0.012 ± 0.012 mm/year with oestrogen replacement therapy (296). A power 
calculation based on a difference of 0.012 mm, a standard deviation of 0.012 mm, a
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significance level of 0.05 and a power of 90% estimated a requirement of 13 subjects to 
determine a significant within-subject difference. We recruited 14 TS subjects and 11 
46,XX PA subjects.
2.11. Statistical Analysis
Statistical analysis was performed using SPSS Version 11.0 for Windows. Associations 
between variables were assessed using Pearson’s correlation coefficient and ANOVA or 
Student’s t-test for continuous variables with log transformation where appropriate and 
controlling for other variables as cofactors where indicated. Spearman’s correlation 
coefficient was used for non-parametric variables and categorical variables, with the x 
test also being used for the latter. Linear regression analysis (entry method) was 
performed to assess independent associations of continuous variables, and binary logistic 
regression analysis was used for categorical variables.
In Chapter 3, linear regressions and 95% prediction intervals in Figure 3.2 were plotted 
using SigmaPlot 8.0; the differences between these regression lines were assessed by 
comparing 95% confidence intervals.
Normally distributed data such as the differences in mean aortic root diameter with time 
in Chapter 4, were assessed using a paired Student’s t-test, whilst duration of oestrogen 
exposure in TS and 46,XX PA groups was compared by Mann Whitney U test (Chapters
5, 6 and 8).
It has been noted that in the vascular physiology and metabolic studies in chapters 5 and
6, the majority but not all TS and 46,XX OD women were studied in the oestrogen-only 
phase of cyclical hormone replacement therapy. All statistical analysis in both chapters 
was performed initially using the ‘oestrogen-only phase’ women and then on the entire 
cohort. Since the inclusion of the additional women did not significantly alter the results, 
but increased the power of the study, the results presented are all inclusive.
Additional specific points regarding statistical analysis in Chapter 6 were that Scheffe 
post-hoc analysis was used as appropriate and that all cross-sectional analyses were 
performed first using data from the entire OD cohort and again including only the twelve
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46,XX primary ameorrhoea women. Since there was no significant difference in the 
results, the findings for the total OD cohort are presented, since the greater number of 
subjects increased the statistical power of the comparisons. As the OD group differed 
from normal controls only with respect to triglycerides, these two groups were combined 
in Figure 6.1. for clarity of illustration. Interaction analysis was performed on univariate 
analysis of variance to assess the effect of TS status in regression equations.
In Chapter 8, to assess the effects of varying doses of oestrogen on the parameters tested, 
a repeated-measures ANOVA was used with log transformation as appropriate. The 
comparisons quoted throughout are of the lmg and 4mg doses of oestradiol.
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Chapter 3 
Echocardiography and Magnetic Resonance Imaging (MRI) 
of the Aorta -  Cross-sectional Study
3.1 Aims
The aim of this study was to compare measurements of aortic dimensions obtained by 
echocardiography and MRI in women from our clinic population compared to controls, 
and to explore their relationships with clinical parameters and their sources of error. A 
further aim was to define the distribution of aortic dimensions found in an asymptomatic 
TS population as a reference source for future risk intervention studies.
128 women with TS were included in this study. Echocardiographic images were 
obtained in 120 women, MRI images in 115 women and successful images using both 
techniques in 107 women. The women with TS were compared to 36 normal control 
women, all of whom underwent echocardiography, and 20 had MRI of the aorta.
3.2. Results
Comparison ofTS and control women -general, metabolic and cardiac findings
Women with TS were shorter, had greater BMI, systolic and diastolic blood pressures 
(BP) at the right and left brachial and left dorsalis pedis arteries, and were less likely to 
smoke or take exercise compared to controls (Tables 3.1. and 3.2.). There was no 
difference between TS and control women with regard to BP differences between the left 
and right brachial arteries, or the left brachial and left dorsalis pedis arteries (Table 3.2.). 
Diabetes mellitus was present in 7 women with TS and no controls. Plasma renin activity 
and triglyceride concentrations were greater in women with TS compared with controls.
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Table 3.1. Comparison of clinical characteristics in women with Turner Syndrome 
and controls
Clinical Characteristics Turner Syndrome 
(n=128)
Controls
(n=36)
p-value
Age, years8 31.1 ±8.5 33.5 ±7.3 0.124
Height, ma 1.47 ±0.07 1.60 ±0.06 <0.001
BMI, kg/m11* 27.1 ±5.6 23.6 ±3.1 0.001
BSA, m2a 1.50 ±0.18 1.62 ±0.14 <0.001
Right brachial 76 ±10 69 ± 9 <0.001
Diastolic Blood Pressure, mmHga
Right brachial 122 ± 14 114 ±10 0.002
Systolic Blood Pressure, mmHga
Total cholesterol, mmol/la 5.4 ± 1.0 5.2 ±0.9 0.326
HDL cholesterol, mmol/la 1.9 ±0.5 1.9 ±0.3 0.550
LDL cholesterol, mmol/la 3.0 ±0.8 2.9 ± 0.9 0.643
Triglycerides, mmol/la 1.1 ±0.6 0.8 ± 0.3 0.006
Plasma renin activity, nmol/h/lb 1.79 ±2.76 0.89 ± 2.38 0.001
Prevalence of Diabetes Mellitus, % Type 1 1.6 0 0.450
Type 2 3.9 0 0.228
Smoking History, % Never 84.6 52.8
Ex 6.7 36.1 <0.001d
Current 8.7 11.1
Proportion taking Exercise, % None 59.6 38.9
(Mild= 1 hour per week, Mild 26.0 16.7
Moderate= 2 hours per week, Moderate 10.6 11.1 <0.001d
Vigorous= 3 or more hours per week) Vigorous 3.8 33.3
Age at starting oestrogen, years' 14 (5-47)
Years of oestrogen deficiency' 3 (0-41)
Previous GH treatment, % 31
Age of starting GH, years' 11 (6-17)
Duration of GH treatment, years' 4.0 (0.3-9.0)
Karyotype distribution, %
Monosomy X 49.2
Isochromosome X 22.7
Partial X deletion 2.3
Ring X 10.2
Any Y fragment 6.3
Mosaic 45,X/ 46,XX 5.5
Complex 3.9
Key: amean± SD; bgeometric mean ± SD; 'median (range); dp-value refers to overall %2 test
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Table 3.2. Mean ± SD blood pressures and blood pressure differences at 
brachial and dorsalis pedis arteries in TS and normal control women
TS Normal
controls
p-value
Mean left brachial BP 105 ± 12 98 ± 9 0.003
Mean right brachial BP 106 ±12 99 ± 9 0.001
Mean left dorsalis pedis BP 127 ±15 116 ± 14 0.001
Mean left brachial -  mean right 
brachial systolic BP
-1.5 ±5.9 -0.8 ± 3.7 0.460
Mean left brachial -  mean left 
dorsalis pedis BP
-21.8 ± 13.3 -18.3 ±10.4 0.163
A normal echocardiogram was found in 63/120 (53%) women with TS and all controls. 
Abnormalities detected by echocardiography are shown in Table 3.3.
Table 3.3. Abnormalities detected by Echocardiography in the TS women
Cardiovascular abnormalities 
on Echocardiography
Frequency, % 
(n=120)
Congenital
Aortic Root Dilatation 16
Bicuspid Aortic Valve 18
Aortic Stenosis 10
BAV with AS 5
BAV without AS 13
Coarctation 2
Ventriculo-septal defect 1
Functional
Valve regurgitation
Aortic Regurgitation 18
Mitral Regurgitation 16
Pulmonary Regurgitation 2
Tricuspid Regurgitation 12
Ventricular/ atrial abnormalities
Left ventricular/ septal hypertrophy8 11
Left ventricular dysfunction1* 1
Dilated left atrium 2
Right ventricular hypertrophy 1
Dilated right heart 1
Other abnormalities
Aortic aneurysm and dissection 1
Key: AS-Aortic Stenosis; BAV=Bicuspid Aortic Valve; “Secondary to hypertension, AS 
or coarctation; bHistory of cardiac surgery
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A normal MRI (ie no coarctation, aortic root dilatation (ARD) or other dysmorphology) 
was found in 39/115 (34%) women with TS compared with 19/20 (95%) controls. 
Entirely normal appearances on both echo and MRI were found in 26/107 (24%) women 
with TS who underwent both studies. Representative MRI scans in Figure 3.1 show the 
two major patterns of aortic pathology -  a dilated aortic root and coarctation site 
narrowing.
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Figure 3.1 MR images of (a) a normal aorta, (b) aortic root dilatation 
(Ascending:Descending Aortic ratio marked by white arrows), (c) coarctation (white 
arrow indicates coarctation site), (d) severe aortic dilatation with dissection.
Figure 3.1a.
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Figure 3.1c.
Figure 3.1b.
Figure 3.1 d.
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The karyotype distribution of the women with TS is shown in Table 3.1. Women with 
monosomy X tended towards greater likelihood of a cardiovascular imaging abnormality 
on echo or MRI (i.e. bicuspid AV, other valve abnormalities, ARD, coarctation site 
abnormalities and other aortic dysmorphology) compared with other karyotypes 
(prevalence of monosomy X 52 vs 31%, p=0.054 for abnormal vs normal).
The individual with an incidental finding of aortic dissection on routine screening (Figure 
3.Id) was immediately referred for surgery. The inclusion of data from this individual 
was found to have no major influence on any of the findings when calculations were 
repeated after exclusion (data not shown). Inclusive data are therefore used throughout, 
except in Figure 3.2 where they were considered inappropriate.
Comparison o f TS and control women -  Aortic Dimensions
With regard to echocardiography, absolute measurements of ARdm were similar in TS 
compared to controls (Table 3.4), despite their slightly higher blood pressure. When 
controlling for differences in BSA and height between TS and controls, however, ARdm 
was significantly greater in TS, with height adjustment having the greatest effect (Table
3.4.).
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Table 3.4. Comparison of aortic measurements in women with Turner Syndrome 
and controls
All measurements in cm Turner
Syndrome
Controls p-value
Echocardiography*
Aortic root diameter (ARdm) 
ARdm adjusted for BSA 
ARdm adjusted for height
2.86 ± 0.46 
2.88 ± 0.04 
2.90 ± 0.04
2.761 0.22 
2.7010.07 
2.62 10.09
0.242
<0.001
0.010
MRI1’
Ascending Aortic diameter (AAdm) 
Descending Aortic diameter (DAdm) 
Ascending:Descending (Asc:Desc) ratio
2.8310.61
1.9710.27
1.4410.23
2.52 10.23 
1.8610.27 
1.4010.11
0.029
0.092
0.483
MRI Excluding coarctation site abnormalities0
AAdm
DAdm
Asc:Desc ratio
2.63 1 0.36
1.8710.18
1.4110.18
MRI Coarctation abnormalities onlyd
AAdm
DAdm
Asc:Desc ratio
3.1210.81e 
2.0610.30° 
1.51 ±0.22f
Key: Values quoted are mean ± SD; an=120 for TS, n=36 for controls; bn=115 for TS, 
n=20 for controls: cn=66; dn= 40; ep<0.001, and fp=0.019 for comparison to those without 
coarctation site abnormalities.
To apply height correction for ARdm we used the equation: Adjusted 
ARdm=ARdm+( 1.6-height)* 1.74 with 1.6 being the mean height of controls and 1.74 
being the slope of the regression line of ARdm and height in women with TS. Using this 
adjustment and applying the common criterion for ARD on echocardiography of 3.4cm 
(incidentally the upper limit of ARdm in our control group), 19/120 (16%) women 
qualified for ARD. Absolute measurements of ARdm were used to derive TS-specific 
reference ranges shown in Figure 3.2a.
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Figure 3.2. The distribution of (a) Absolute Aortic Root diameter (ARdm) on 
echocardiography and (b) Ascending Aortic diameter (AAdm) on MRI with age 
(subject with aortic dissection excluded).
Turner syndrome: filled circles and solid lines, Controls: open circles and dashed 
lines. Lines represent the linear regression plot with 95% prediction lines for the 
distribution.
Figure 3.2a.
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With regard to MRI, AAdm, but not DAdm or the Asc:Desc ratio, was significantly 
greater in women with TS than controls. The Asc:Desc ratio was not associated with 
either BSA or height. ARD (defined as Asc:Desc ratio >1.5) was found in 38/115 (33%) 
women with TS -  significantly more than the 16% for echocardiography (p<0.01) 
(Figure 3.3). Coarctation site abnormalities may be associated with pre- and post-stenotic 
dilatation, potentially confounding the Asc:Desc ratio (Figure 3.1c). This aspect was 
investigated in 106 women with TS, excluding the nine who had had previous coarctation 
surgery. Both AAdm and DAdm were significantly greater in 40 women with coarctation 
site abnormalities compared to 66 women with TS who had no coarctation but with only 
minor alteration to the Asc:Desc ratio (Table 3.4.). Individual ascending aortic diameters 
were used to derive a TS-specific normal distribution (Figure 3.2b).
Figure 3.3. Comparison of Height-Adjusted Aortic Root Diameter (ARdm) on 
Echocardiography and Aortic Root Dilatation by MRI criteria in 107 women with 
Turner Syndrome (dashed line marks aortic dilatation on MRI at Asc:Desc ratio 
>1.5; dash-dotted line marks the upper limit of ARdm in the control group)
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There was a positive correlation between ARdm on echocardiography and aortic 
dimensions on MRI (AAdm: r=0.502, p<0.001; DAdm: r=0.318, p=0.001; Asc:Desc ratio: 
r=0.323, p=0.001) although each modality identifies different subjects with ARD (Figure 
3.3).
Determinants o f aortic dilatation
Age and bicuspid aortic valve were the only two variables which had significant 
associations with aortic measurements. The strength of association between age and 
aortic dimensions was more pronounced in women with TS than in controls (Figure 3.2). 
Aortic dimensions were greater in those women with TS who had a BAV than those 
without (Table 3.5). There was also a positive association between ARdm and LV mass 
(r=0.317, p=0.004), which persisted when women with a BAV were excluded (r=0.286,
p=0.016).
Table 3.5. Association of aortic abnormalities with bicuspid AV in women with TS 
(mean ± SD)
Variable No Bicuspid AV Bicuspid AV p-value
Age, years 
ARdm on Echo, cm 
AAdm, on MRI, cm 
Asc:Desc ratio on MRI 
% Coarctation site abnormality 
%‘Occult coarctation’
31.0 ±8.4 
2.80 ±0.36 
2.71 ±0.40 
1.40 ±0.20 
34.1 
3.3
32.3 ±9.1 
3.12 ±0.71 
3.33 ± 1.02 
1.61 ±0.29 
58.8 
46.2
0.488
0.003
<0.001
<0.001
0.055
<0.001
TS and control women -  coarctation site abnormalities on MRI
Of the 106 women with no previous cardiac surgery, 40 (38%) had previously 
undiagnosed abnormalities at the classical coarctation site, compared with one of the 20 
control women (%2 p<0.001). The abnormalities in the TS women were defined as a 
visible flow disturbance on the jet vortex at this site in 24 of these 40 women (or 24/106; 
22.6%), and a visible narrowing of the aortic lumen in 23 women (23/106; 21.7%). In 8 
TS women (8/106; 7.5%), the impingement on the aortic lumen was at least 30% and flow 
disturbance was sufficiently great to warrant classification as ‘occult coarctation’ (Figure
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3.2c). One control (1/20; 5%) had a small notch at the coarctation site with no associated 
flow disturbance which was deemed to be haemodynamically insignificant.
Presence of a bicuspid AV was more likely both amongst women with any coarctation site 
abnormality (25 vs 11%, although not quite achieving statistical significance) and 
amongst those with ‘occult coarctation’ (75 vs 11%, p<0.001) compared to women 
without coarctation site abnormality respectively (Table 3.5.). There were no consistent 
differences between TS women with and without coarctation site abnormalities with 
regard to right and left or upper and lower body blood pressures.
3.4 Discussion
This study has demonstrated a high prevalence of occult aortic abnormalities in a cohort 
of adults with Turner Syndrome using both echocardiography and MRI, with only 25% of 
women having normal results on both imaging modalities. The two techniques are 
complementary in that they identify different aspects of aortic pathology, and technical 
problems may arise in either. It has been demonstrated that aortic dimensions assessed by 
echocardiography in women with TS can be simply adjusted for height deficit and while 
the Asc:Desc ratio on MRI avoids this problem, it in turn may be affected by anomalies in 
the descending aorta. Reference ranges have been produced for aortic root diameter on 
echocardiography and ascending aortic diameter on MRI for women with TS.
This study evaluated the cardiovascular system by both imaging modalities in adults with 
TS, allowing the relative merits of each to be characterised. The two modalities differ in 
the site of measurement of the aorta: Echocardiography usually measures the ARdm at the 
annulus, whilst AAdm on MRI is measured slightly distal, at the level of bifurcation of 
the pulmonary arteries. It is therefore, not surprising that the two imaging modalities 
identify different individuals qualifying for ARD (Figure 3.3). With long term follow up 
of this cohort it may be possible to determine which group has the greatest risk of 
dissection. In this regard it is notable that the effect of age on the aorta was a particular 
feature of the Turner women (Figure 3.2).
Amongst the few studies which have evaluated the use of cardiovascular MRI in TS, the 
prevalence of ARD on MRI has varied between 12.5% and 33.3% depending on the exact
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criteria used (125,132) compared with 33% in this study. Data from the control group 
used in the present study confirmed the CT-derived definition of Asc:Desc ratio >1.5 as a 
reliable criterion for ARD on MRI. The utility of this ratio is hampered by the fact that 
the DAdm is slightly increased in women with TS, eradicating a significant difference in 
the mean ratio when compared with controls. This would imply that the wall of the entire 
aorta might be defective in TS and the use of the ratio might be falsely reassuring. Also, 
coarctation site defects are associated with increases in both AAdm and DAdm -  
increases which may cancel each other out on calculation of the ratio. In women with any 
degree of coarctation, therefore, absolute values of ascending aortic diameter are likely to 
be better predictors of the risk of dissection.
MRI has not been advocated as the investigation of first choice for evaluation of the aorta 
in TS in view of its limited availability, greater cost, and the fact that a significant number 
of women with TS (10.2% in this study) are unable to tolerate the scan because of 
claustrophobia. MRI is of greatest advantage in the assessment of the coarctation site 
which is not always visible on echocardiography because of the shape of the chest wall in 
women with TS. There is clearly a spectrum of pathology at the coarctation site and there 
is no consensus as to what constitutes a ‘significant’ defect worthy of intervention. The 
finding in the present study of 8% of women with an ‘important’ occult coarctation agrees 
with similar studies quoting 6% (132) and 12% (125). The absence of consistent blood 
pressure differences accompanying the imaging abnormalities may be explained by the 
small number of subjects. The goal now will be to develop a strategy to define risk in 
terms of flow disturbance.
In conclusion, this study has shown that aortic imaging by echocardiography and MRI 
provides complementary information, but it is only with longitudinal study of this 
population that it will be possible to determine how each relates to future morbidity. 
Ideally all women with TS will have cardiovascular imaging by both techniques as a 
routine, and certainly echocardiography should be universal. Accepting that MRI may not 
be available for all women with TS, a practical way forward would be to target high risk 
subgroups such as those with a BAV, those pursuing ovum donation or those in whom 
clear echocardiographic imaging is unobtainable. Given the difficulties of correcting for 
short stature, this study has defined TS-specific reference ranges for absolute 
measurements of both aortic root diameter on echocardiography and ascending aortic
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diameter on MRI in the hope that they will aid future interpretation of these measurements 
and help define thresholds for risk management strategies.
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Chapter 4 
Interval Assessment of Aortic Root Dilatation 
using Echocardiography
4.1. Aims
Increasing age has been demonstrated as one of the primary determinants of aortic root 
diameter, both in TS (337) and in the general population (313,314,316). Current 
guidelines recommend that adults with TS should have 3- to 5-yearly echocardiography 
for monitoring of the aortic root, although there is currently no evidence on which to base 
this timing interval (7,26,320,338).
This study assessed echocardiographic aortic root dimensions longitudinally in order to 
determine the rate of change of aortic diameter in TS, and investigated whether any 
clinical associations might predict the rate of aortic dilatation. Successful sequential 
imaging was obtained in 33 women at a mean time interval of 3.8 ± 1.4 years.
4.2. Results
Patient Characteristics
Two women had undergone previous coarctation surgery. All women were taking 
oestrogen replacement throughout the study, but they varied in the number of cumulative 
years of previous oestrogen deficiency (median [range] 3 [0-22] years). Five women had 
previously received growth hormone treatment. Twenty-five women had never smoked 
and 18 did not take any exercise. Nine women were taking antihypertensive medication, 
and of these, three were commenced in the interval between scans. Twenty (61%) women 
had karyotype monosomy X.
Changes in ARdm and clinical parameters with time
Mean ± SD aortic root diameter in the cohort increased by 0.91 ±3 .0  mm between the 
first (ARdml) and second (ARdm2) scans (Table 4.1), which represented a change of 
0.33 ± 0.84mm (1.5 ± 3.3%) per year. Adjustment of ARdm2 values to represent ARdml 
+ difference after one year showed that there was a significant increase in diameter after
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one year (ARdml vs adjusted ARdm2: 28.5 ± 4.0 vs 28.8 ± 3.5 mm, p=0.030). To 
illustrate this, Figure 4.1 shows ARdm2 adjusted to a 3-year interval which approximates 
more closely to the actual mean time interval studied.
Table 4.1. Changes in clinical parameters at time of first and second 
echocardiograms (mean ± SD)
Patient Characteristics Echol Echo2
Aortic Root diameter (ARdm), mm 28.5 ±4.0 29.4 ±3.1
Systolic Blood Pressure, mmHg 128 ±18 123 ±15
Diastolic Blood Pressure, mmHg 78 ±12 80 ±11
Mean Blood Pressure, mmHg 95 ±10 94 ±9
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Figure 4.1. Changes of aortic root diameter at the time of the first echo with time, 
with the second value adjusted to a standard period of 3 years. Means are shown as 
bold dashes.
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In the interval between scans, blood pressure did not change significantly (Table 4.1), 
weight increased (55.5 ± 8.8 to 58.1 ± 12.1 kg, p=0.034), but there was no significant 
change in body surface area (1.50 ± 0.14 to 1.53 ± 0.18 m2, p=0.055).
Associations between the ARdm difference and clinical parameters
There was no association between absolute or percentage increase in ARdm with age, 
bicuspid AV (present in 12 women), coarctation site abnormalities, blood pressure, 
anthropometric parameters, previous growth hormone and oestrogen therapy, karyotype, 
smoking, exercise history or metabolic markers. ARdm increased in all three women who 
started antihypertensive therapy after their first echo.
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4.4. Discussion
This longitudinal study has demonstrated an overall increase in aortic root diameter of 
0.33 ± 0.84mm per year in women with TS. This rate of change is three-fold greater than 
that reported in a cross-sectional study of normal subjects of 0.1mm per year (314), but 
similar to that of 0.3-1.0 mm/year reported in a longitudinal study of subjects with 
bicuspid AV in the general population (339) These findings are consistent with the data 
from the previous cross-sectional part of this study (Chapter 3) which revealed age as one 
of the primary determinants of aortic root diameter (337).
This study was too small to identify a particular risk group for close monitoring. The 
absence of an association of bicuspid aortic valve with aortic diameter increment is 
interesting, since this was the other main predictor of aortic dilatation in the previous 
study (Chapter 3) (337).
Analysis of the individual data reveals that the pattern of change was variable with some 
women showing increases of over 11% per year, whilst in others there was an apparent 
decrease of 5.4% per year. This heterogeneity suggests that there may have been 
considerable inter- and perhaps also intra-observer error. Given the length of time 
between scans, and the fact that they were performed in a hospital setting, it was not 
possible to ensure a single operator, and this is likely to be representative of most clinical 
practice. It may be that the difficulties of echocardiography in women with TS increase 
the variability of measurements. In particular, chest wall anomalies limit the window of 
access to the aortic root.
An analogy has been made between TS and Marfan Syndrome (MS), prompted by the 
reports of cystic medial necrosis in 65% of TS cases of aortic dissection in which 
histology was available (118,124,144). The natural history of aortic dilatation in MS is 
reported to be more accelerated than in this TS study (2mm/year on average (336)), but 
there are several other similarities between TS and MS. In MS, too, aortic dilatation is 
related to age (340), and a longitudinal echocardiography study likewise found no 
relationship between the initial aortic diameter and the rate of dilatation (336).
In MS, it is recommended that patients with an aortic root diameter of 40-45 mm should 
have annual echocardiography, whilst those in whom it is >45mm should have
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individualised follow-up with a view to aortic surgery at an early stage (336). None of the 
TS women in this study had an aortic root >40 mm, but it is known that aortic root 
diameter is height-dependent, both in the general population (314) and in women with TS 
(337) Extrapolation of recommendations from MS may therefore require height- 
adjustment of ARdm values before application to TS. Furthermore, as in MS, the 
possibility of more sudden ‘non-linear’ aortic dilatation cannot be excluded (336), and 
this is supported by the multiple case reports of aortic dilatation and dissection in young 
women with TS (128). A comparison of echocardiography and MR imaging in MS has 
suggested asymmetry of the aortic root, which may be more obvious on MRI than 
echocardiography, as a possible cause of unexpected aortic dissection (341).
In conclusion, this study has shown that the rate of progression of aortic dilatation in TS is 
approximately three-fold greater than that reported in normal subjects, but less than in 
Marfan Syndrome. No predictive clinical features of aortic dilatation in TS have been 
identfied in this study, suggesting that all women should continue to be screened. An 
interval of 3-5 years would seem to be appropriate in women whose ARdm remains below 
36 mm, the maximum ARdm recorded in this study. More frequent scanning seems 
advisable over this threshold. At the present time echocardiography remains the mainstay 
of serial screening in view of its greater availability, but serial MRI screening may 
become more widespread in the future as this may circumvent the problems of operator 
error. MRI is certainly required in women whose echocardiographic window is poor. 
Further studies are required to assess the effects of antihypertensive medication, and 
particularly beta blockade (by analogy with Marfan Syndrome (342)) on deceleration of 
aortic dilatation in TS.
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Chapter 5 
Vascular Physiology Assessments -  Cross-sectional study
5.1. Aims
Although the aortic abnormalities of TS are well recognised as previously described 
(337,343), we hypothesized that women with TS have a fundamental arterial wall defect 
extending beyond the arch of the aorta. This may be related to genetic factors or 
oestrogen deficiency. The present study set out to characterize the vasculopathy of TS by 
assessing arterial structure (carotid and brachial artery diameter and carotid artery intima 
media thickness), arterial stiffness (pulse wave velocity and augmentation index) and 
endothelial function (flow-mediated dilatation). The arterial diameters in this study were 
compared to echocardiography and MRI assessments undertaken in the women with TS 
and normal controls as previously described. 93 women with TS were compared to 25 
normal controls and 11 women with 46,XX primary amenorrhoea (PA).
5.2. Results
General comparisons and observations o f clinical and metabolic factors
Women with TS were shorter and had greater body mass index, waist circumference, 
systolic and diastolic blood pressures, heart rate, serum CRP and IL-6 concentrations than 
women in the normal control and 46,XX PA groups (Table 5.1.). They smoked less (85% 
vs 60% vs 36% had never smoked in TS, normals and 46,XX PA groups respectively, 
p<0.001) and took less exercise (15% vs 48% vs 36% took regular moderate or vigorous 
exercise in the three groups respectively, p<0.001). Four women with TS had type 2 
diabetes mellitus.
All women with TS and 46,XX PA were on routine physiological oestrogen replacement 
and reported good compliance. TS women started oestrogen treatment at an earlier age 
(median [range] 14 [5-25] vs 17 [12-22] years, p=0.001) and had fewer years of oestrogen 
deficiency (3 [0-27] vs 6 [1-11] years, p=0.001) than the 46,XX PA women. In the TS 
group, proportions taking oral synthetic, oral natural and patch estrogens were 19.1%, 
71.9% and 9.0% respectively, with 100% of women in the 46,XX PA group taking oral 
natural oestrogens (%2 test p=0.127). 30.1% of TS women had previously been treated
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with growth hormone (GH), with a median [range] start age of 10 [5-17] years and 4.5 
[0.5-10] years’ duration of treatment. 48.4% of the women with TS had karyotype 
monosomy X.
Table 5.1. Comparison of clinical characteristics in women with Turner Syndrome 
(TS), normal controls and women with 46,XX primary amenorrhoea (PA).
Clinical Characteristics
TS
(n=93)
Normal
(n=25)
46,XX PA 
(n=ll) p-value
Age, years8 32.6 ± 8.2 33.316.9 30.21 8.4 0.556
Height, ma 1.4710.06 1.6110.05 1.6710.09 <0.001
BMI, kg/m" * 27.015.8 24.313.1 21.813.3 0.002
Waist, cm8 80.8112.8 74.5 16.9 74.616.7 0.026
Diastolic Blood Pressure, mmHg8 76110 6 7 1 6 6 3 1 6 <0.001
Systolic Blood Pressure, mmHg8 121114 11218 10818 <0.001
Heart rate, beats/minute8 75113 6 5 1 9 65113 0.001
Total cholesterol, mmol/18 5.411.0 5.011.0 5.010.9 0.088
LDL cholesterol, mmol/18 3.110.9 2 .811.0 2.5 1 0.8 0.104
HDL cholesterol, mmol/18 1.910.5 1.910.3 2.010.5 0.843
Triglycerides, mmol/18 1.010.4 0.8 10.2 0.910.3 0.034
Glucose, mmol/18 4.811.2 5.011.1 4.711.1 0.351
Insulin, mIU/lb 4.912.4 6.613.2 6.411.9 0.087
HOMA-Rb 1.010.5 1.510.7 1.310.4 0.070
C-reactive protein, mg/18 3.011.5 0.811.1 0.911.0 <0.001
Interleukin-6, pg/mlb 1.510.8 0.9 1 0.3 0.7 10.3 <0.001
Key: amean± SD; bgeometric mean ± SD; p-values refer to group differences on ANOVA
A bicuspid aortic valve (BAV) was identified in 17 (18%) women with TS, and six 
women were known to have significant aortic coarctation from the MRI study (Chapter 
3). Two women with TS had aortic stenosis (peak aortic valve gradients 31 and 42 
mmHg respectively), of whom one also had bicuspid aortic valve, and these subjects were 
excluded from the analyses of augmentation index. 20 women were taking
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antihypertensive medication (9 on atenolol, 5 on an angiotensin converting enzyme 
inhibitor, 4 on bendrofluazide, 1 on an angiotensin II receptor antagonist and 1 on a 
calcium channel antagonist). Both exclusion of the women with each category of 
complications individually, and of all TS women with any complication (n=32), did not 
alter the relationship between TS status and the vascular parameters studied except 
augmentation index as mentioned above. The data presented for TS throughout the study 
are therefore inclusive of all TS women unless otherwise stated.
Comparison o f the vascular phenotype in TS, 46JOC PA and normal controls 
Comparison o f arterial structure
Women with TS had greater absolute and height-adjusted carotid diameters than women 
in the normal control and 46,XX PA groups (Table 5.2). This relationship remained after 
adjusting for factors which were associated with carotid diameter in women with TS 
(Table 5.3.): height, waist and IMT (p<0.001). Group differences were also significant 
for absolute and height-adjusted brachial artery diameters. Relative differences in arterial 
diameters between women with TS compared to controls are shown in Figure 5.1.
IMT was greater in TS than in normal control women (p<0.001) but similar in the TS and 
46,XX PA groups (p=0.837) (Table 5.2). These group differences remained significant 
after adjustment for factors which were associated with IMT in women with TS (Table
5.3.): age, diastolic blood pressure and carotid artery diameter (p=0.002).
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Table 5.2. Comparison of absolute and height-adjusted measures of arterial 
structure and stiffness in women with Turner Syndrome (TS), normal controls and 
women with 46,XX primary amenorrhoea (PA). (Note IMT and PWV are not 
height-related variables.)
Absolute Values Height-adjusted Values
TS
(n=93)
Normal
(n=25)
46,XX 
GD 
(n=ll)
P-
valuea
TS
(n=93) (n=25)
46,XX 
GD 
(n=ll)
P-
valuea
Structure
Carotid Artery 
diameter, mm
5.71b 
±0.64
5.27
±0.34
5.22
±0.38 <0.001
5.85
±0.63
5.00
±0.65
4.74
±0.67 <0.001
Brachial Artery 
diameter, mm
3.29
±0.44
3.06
±0.36
2.97
±0.30 0.006
3.39
±0.46
2.87
±0.48
2.65
±0.49 <0.001
Carotid Intima Media 
Thickness (IMT), mm
0.61
±0.07
0.55
±0.06
0.60
±0.05 <0.001 - - - -
Stiffness
Pulse Wave Velocity 
(PWV), m/sec
6.57 
± 1.25
6.44
±0.90
5.82
±0.75 0.129 - - - -
Augmentation Index 
(AIx), %
21.7b 
± 12.2
10.1 
± 12.7
10.1 
± 10.8 <0.001
19.5 
± 13.9
14.8 
± 13.3
18.0 
± 14.9 0.379
Key: Values shown are mean ± SD; ap-values refer to group differences on ANOVA; 
bindicates the value which differs from the others on ANOVA with Scheffe post-hoc 
analysis, p<0.05
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Figure 5.1. Comparison of percentage differences in height-adjusted arterial 
diameters in women with TS compared to control values set at 100%. Solid black 
bars represent women with Turner Syndrome (TS), unshaded bars represent normal 
control women. (Vascular physiology and Echocardiography performed in all TS 
and control women, MRI performed in 76 women with TS and 20 normal controls.)
% difference 
between TS 
and normal 
control women
Aortic Root Ascending 
Aorta
Descending Carotid Arteiy Brachial Artery 
Aorta
Key: ap<0.05, bp<0.01 for the comparison between TS and controls.
Comparison o f arterial stiffness
Pulse wave velocity (PWV) was similar in all three groups of women. Augmentation 
index (AIx) was greater in women with TS than in the other two groups, but the 
difference between these groups was no longer significant after adjustment for height 
(Table 5.2).
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Table 5.3. Associations between clinical and metabolic variables and structural 
arterial factors (carotid artery diameter and IMT) in women with TS. Selected 
variables showing significant simple correlations were included in multiple
regression analysis and the resulting partial correlation coefficients are shown.
Clinical Characteristics
Carotid Artery diameter, 
correlation coefficients, r
Carotid Artery IMT, 
correlation coefficients, r
Simple Partial Simple Partial
Age, years 0.102 0.488c 0.427c
Height, m 0.340b 0.315 b -0.137
Weight, kg 0.281b -0.061
BMI, kg/m2 0.314c -0.001
Waist, cm 0.372c 0.236* 0.047
Diastolic Blood Pressure 0.004 0.370c 0.239*
Systolic Blood Pressure 0.118 0.325 b
Heart rate 0.003 0.018
Total cholesterol 0.228a 0.108 0.118
HOMA 0.067 0.027
C-reactive protein, mg/1 0.125 0.038
Interleukin-6, pg/ml 0.088 0.057
Oestrogen deficient years 0.058 0.132
Aortic Root diameter 0.189a 0.064 0.122
Carotid Artery IMT 0.2548 0.271b 1.000
Carotid Artery diameter 1.000 0.254* 0.221*
Brachial Artery diameter 0.269 b -0.066 0.079
Flow-mediated dilatation -0.211* -0.127 -0.128
Pulse Wave Velocity 0.170 0.127
Augmentation Index 0.114 0.413c 0.134
Key: a p<0.05; b<0.01; cp<0.001
Comparison o f brachial artery vasomotor function
FMD was similar in the three groups, with and without adjustment for the magnitude of 
the flow stimulus (Table 5.4.) and brachial artery diameter. Vasodilator responses to 
GTN were also similar.
85
Chapter 5
Table 5.4. Comparison of endothelial function measured at the brachial artery in 
women with Turner Syndrome (TS), normal controls and women with 46,XX 
primary amenorrhoea (PA)
TS
(n=93)
Normal
(n=25)
46,XX PA 
(n=ll) p-value
Absolute flow-mediated 
dilatation, mm 0.27 ±0.11 0.27 ±0.10 0.22 ± 0.07 0.344
% flow-mediated 
dilatation (FMD) 8.3 ±3.8 9.1 ±3.6 7.5 ±2.7 0.469
Absolute GTN-mediated 
dilatation, mm 0.33 ±0.14 0.32 ±0.12 0.33 ±0.11 0.979
% GTN-mediated 
dilatation 10.3 ±4.6 10.7 ±4.4 10.8 ±3.8 0.881
Baseline flow, ml/min 10.8 ±8.6 8.4 ±5.4 6.7 ±3.5 0.139
Max flow increase, ml/min 56.4 ± 26.5 66.6 ± 19.3 42.2 ± 11.0 0.033
Max flow increase, % 1174 ± 3150 1171 ±565 889 ± 400 0.946
Key: Values shown are mean ± SD; p-values refer to group differences on ANOVA.
Factors associated with the vascular phenotype in TS 
Factors associated with arterial structure
Height, waist circumference and IMT were independently associated with carotid artery 
diameter (Table 5.3.). Similar clinical associations were observed with the brachial artery 
diameter. Carotid and brachial artery diameters were associated with aortic root diameter 
(mean ± SD 2.8 ± 0.4 cm) (r=0.208 for carotid; r=0.228 for brachial; both p<0.05), and 
there was a weak correlation between carotid and brachial artery diameters which did not 
achieve significance (r=0.199, p=0.059).
Aortic root diameter was greater in the 17 women with BAV compared to those without 
(3.0 ± 0.4 vs 2.8 ± 0.4 cm, p=0.040), but carotid and brachial artery diameters were not 
influenced by BAV (carotid 5.6 ± 0.6 vs 5.7 ± 0.6 cm, p=0.416 and brachial 3.3 ± 0.3 vs 
3.3 ± 0.5 cm, p=0.882 in women with and without BAV respectively).
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Increasing age, diastolic blood pressure and carotid artery diameter were independently 
associated with increased IMT (Table 5.3.)- History of smoking, exercise, diabetes 
mellitus, previous growth hormone treatment, cumulative oestrogen-deficient years, 
karyotype and the presence of a bicuspid aortic valve, aortic stenosis and coarctation site 
abnormalities were not associated with carotid artery diameter or IMT. AIx was 
associated with IMT, but not after adjustment for age. Serum CRP and IL-6 
concentrations were not associated with IMT or arterial diameters.
Factors associated with arterial stiffness
PWV and AIx increased significantly with age (PWV r= 0.326, p=0.002; AIx r= 0.397; 
p<0.001) and both systolic and diastolic blood pressure (p<0.001). Neither PWV nor AIx 
were associated with waist circumference, lipids, smoking history, exercise, CRP, IL-6 or 
karyotype. Variation in the use of growth hormone in childhood and cumulative years of 
oestrogen deficiency were not associated with PWV or AIx after adjustment for age. 
PWV and AIx were similar in those with and those without bicuspid aortic valve.
Determinants o f Endothelial Function
FMD was independently associated with waist circumference (partial correlation 
coefficient r= -0.206, p=0.039), total cholesterol concentration (r= -0.215, p=0.032) and 
heart rate (r=0.303, p= 0.002). There was no association with CRP or IL-6 
concentrations.
5.4. Discussion
This study demonstrates the widespread structural vascular differences in women with TS 
characterized by enlargement of conduit arteries and increased carotid intimal thickening 
compared to normal controls. Of note, arterial enlargement appears to involve multiple 
vessels and is associated with increased intimal thickening. Although this suggests that 
common underlying mechanisms may be, at least in part, responsible, the similar increase 
in IMT without arterial dilatation that was observed in 46XXPA subjects supports a more 
selective contribution from oestrogen deficiency to the intimal hyperplasia seen in TS. It 
was also found that FMD was similar in TS, 46XXPA and normal control women, 
suggesting that conduit artery endothelial dysfunction does not contribute significantly to 
the large vessel abnormalities seen in young women with TS and early oestrogen 
deficiency.
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The occurrence of aortic dilatation in TS is well established as has been previously 
mentioned (126,128,137). It has been associated with the presence of bicuspid aortic 
valve, aortic coarctation and hypertension but its aetiology is poorly understood. In this 
study it was observed that although aortic root diameter was greater in women with TS 
who have bicuspid aortic valves, arterial dilatation is not restricted to these individuals 
and also occurs in other large conduit vessels, such as the carotid and brachial arteries, to 
a similar extent in those with and without bicuspid valves.
This study has demonstrated that carotid artery diameter is independently associated with 
TS status, height, waist circumference and carotid IMT. However, in contrast to women 
with TS and despite a greater degree of oestrogen deficiency, karyotypically normal 
women with primary amenorrhoea had normal carotid and brachial artery diameters, thus, 
suggesting that genetic factors rather than oestrogen deficiency have a greater influence 
on arterial dilatation in TS. The absence of an independent association between 
peripheral arterial diameter and bicuspid aortic valve, aortic stenosis or blood pressure, 
suggests an intrinsic abnormality of the arterial wall in TS. An analogy to the arterial 
dilatation seen in Marfan Syndrome has been postulated as previously mentioned 
(137,344). Indeed, cystic medial necrosis similar to that in Marfan Syndrome has been 
reported in 65% of TS case reports of aortic dissection, where histology was available 
(118,124,144).
The apparent relationship between generalized arterial dilatation and increased IMT, may, 
in part, be consistent with the ‘Glagov phenomenon’ (345) This refers to the outward 
remodelling and enlargement of atherosclerotic arteries as a consequence of complex 
inflammatory changes in the vascular wall that compensates for luminal occlusion in the 
earlier stages of disease development. For example, increased carotid artery diameter was 
independently associated with IMT as well as the presence of atherosclerotic plaques and 
increased blood pressure in a population based study of older subjects (346). Increased 
IMT is a marker of early carotid atherosclerosis and an independent predictor of an 
adverse cardiovascular prognosis in the general population (294) In the present study, 
IMT was greater in both TS and 46,XX PA groups compared to controls. However, the 
fact that carotid artery diameter was increased only in the TS group suggests that factors 
other than the ‘Glagov phenomenon’ were involved.
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In the general population, IMT has been shown to be associated with traditional risk 
factors for ischaemic heart disease, such as age, blood pressure, serum lipids, smoking, 
diabetes mellitus and BMI (294,347-349) and also CRP (350-353) In this study of 
younger women, in addition to age and blood pressure, the major influences on variation 
of IMT measurements were TS status and oestrogen deficiency. Although women with 
TS had raised blood pressure, CRP and IL-6 concentrations compared to the other two 
groups, these did not account for their greater IMT. Indeed, the similar increase in IMT 
seen in TS and 46,XX PA women implicates oestrogen deficiency as the key determinant 
of neointimal hyperplasia in these subjects. Furthermore, as CRP and IL-6 do not appear 
to be associated with IMT, it may be that factors in the arterial wall such as local 
inflammation, oedema, extracellular matrix and foam cells are contributing to intimal 
thickening (354), or that CRP and IL-6 are less direct markers of ischaemic risk than 
previously thought (261,355). The local factors alluded to may in turn be influenced by 
oestrogen therapy (356-359) CRP and IL-6 will be considered further in Chapter 6.
Oestrogen deficiency may, therefore, be an appropriate target for early intervention in 
both TS and 46,XX PA to reduce progression of intimal thickening, and ultimately 
clinical atherosclerotic disease. Although there is a precedence in the literature, with 
exogenous oestrogen reducing IMT in older postmenopausal women (295-297) this is not 
a universal finding (344,360,361). It has been suggested that the reason for this 
discrepancy is a lack of benefit in women with established coronary artery disease, or 
insufficient duration of oestrogen therapy (356).
The comparisons of measures of aortic stiffness in this study in TS, normal controls and 
women with 46,XX PA should be interpreted with caution. Although there was a trend 
towards greater arterial stiffness, as measured by PWV, this did not achieve statistical 
significance. It has previously been suggested that PWV may be underestimated in the 
general population when the abdominal aorta becomes more tortuous with age (298), 
which may be an important factor in women with TS who frequently have greater 
tortuosity of the descending aorta (362) and elongation of the transverse arch (343) AIx 
was greater in women with TS than the other two groups, suggestive of an increased 
contribution of wave reflection to central aortic systolic blood pressure and left ventricular 
afterload. However, AIx is influenced by both heart rate and body height and should 
therefore be corrected for both (299,310). Although the difference in AIx between TS and
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controls was lost by height-adjustment, there may, however, still be relevance for central 
aortic pathophysiology and increased cardiac loading, since neither the transfer function 
used, nor height-adjustment with regard to this measure, have yet been validated 
specifically in women with TS.
PWV is an independent marker of cardiovascular risk (300,301) and is associated with 
other cardiovascular risk factors such as blood pressure, insulin resistance, central obesity 
and greater carotid IMT in the general population (302). Data on the prognostic value of 
AIx are still emerging and some studies suggest that it may have even greater predictive 
power than PWV (305,306). Invasive studies would be required for accurate clinical 
validation of these measures in TS.
It has been shown that endothelium-dependent vasodilator function reflects underlying 
cardiovascular risk factor burden (363) and independently predicts cardiovascular 
prognosis (278,364) The present study found, however, that FMD was similar in women 
with TS compared to normal or 46,XX PA controls suggesting that endothelial 
dysfunction is not an important mediator of arterial disease in TS.
As previously mentioned, there have thus far been very few studies of arterial dynamics in 
TS. Two studies have explored the effects of exogenous oestrogen in women with TS. 
Both augmentation index (35) and the vasodilator response to bradykinin in a 
plethysmography study (34) have been shown to improve when oestrogen deficient 
women with TS are treated with oestrogen. The results of the present study are similar to 
those in a recent smaller study which focused on both children and women with TS (365). 
In general, our findings extend those of Baguet et al. by virtue of the increased power and 
homogeneous adult oestrogen-replete population in the present study. For instance, IMT 
and carotid diameter in TS compared to controls only achieved significance when 
corrected for height in the previous study -  an adjustment absolutely required in a 
paediatric population. The current study has demonstrated differences in IMT and carotid 
diameter without height correction. In addition the observation of arterial dilatation has 
been extended to include the brachial, and women with 46,XXPA have also been studied 
to control for the oestrogen deficiency of TS.
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In conclusion, women with TS have arterial dilatation not only involving the aorta, but 
also other major conduit arteries, which does not appear to be a consequence of oestrogen 
deficiency. IMT is also greater in TS than normal controls, and appears to be related to 
the increased arterial dilatation. This raises the possibility of a common pathway for these 
two processes, although oestrogen deficiency does appears to contribute to intimal 
thickening in TS. FMD was similar in all groups, excluding an important contribution 
from conduit arterial endothelial dysfunction. The findings in this study suggest that both 
genetic factors and oestrogen deficiency influence the vasculopathy of TS. These data 
suggest that blood pressure and oestrogen deficiency are likely to be the most appropriate 
modifiable therapeutic targets for cardiovascular risk reduction in TS, but interventional 
studies will now be required.
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Chapter 6 
Metabolic Assessments - Cross-sectional study
6.1. Aims
The increased prevalence of ischaemic heart disease and diabetes mellitus have already 
been discussed (Section 1.2.3.)- Obesity is also common in TS (33,151) and is associated 
with elevated serum triglyceride and cholesterol concentrations (151,185) which may 
contribute to the increased cardiovascular risk. The obesity in TS appears to be 
predominantly central, with an increased waist-hip ratio and a reduced fat free mass (33).
The associations between obesity and type 2 diabetes mellitus (366,367), as well as other 
features of the insulin resistance/ metabolic syndrome such as hypertension, 
hypertriglyceridaemia and low HDL concentrations are well established in the general 
population (368,369). Since central obesity, hypertension, dyslipidaemia and impaired 
glucose homoeostasis are common in TS (33,151), the aim of this study was to determine 
whether these are indeed features of ‘metabolic/ insulin resistance syndrome’ in TS. 
Relationships between markers of the metabolic syndrome and obesity were investigated, 
with particular reference to the adipokines IL-6 and leptin, and also C-reactive protein. 
117 TS women with normal fasting serum glucose were compared to 30 normal control 
women and 31 women with 46,XX oestrogen deficiency (OD) of similar age.
6.2. Results 
Subject characteristics
Table 6.1. compares clinical characteristics between the three groups of subjects. In 
addition, women with TS smoked less (84.5 vs 56.7 vs 51.6% non-smokers amongst TS, 
normals and 46,XX OD respectively, p<0.001) and were more sedentary (60.0 vs 43.3 vs 
48.4% took no exercise amongst TS, normals and 46,XX OD respectively, p=0.002). The 
prevalence of karyotype monosomy X was 49.6% in women with TS. 35.0% of TS 
women had received previous growth hormone therapy and 26.5% had previously been 
treated with oxandrolone. TS women started oestrogen therapy at a younger age than 
women with OD (median [range] 14 [5-34] vs 20 [12-38] years, p<0.001), but the overall 
years of oestrogen deficiency were similar (3 [0-22] vs 5 [0-16], p=0.164). In the TS
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group, proportions taking oral synthetic, oral natural and patch oestrogens were 20%, 69% 
and 11% respectively, with 13%, 80% and 7% respectively in the 46,XX POF group (%2 
test p=0.517). Twenty-two (18.8%) women with TS but none of the normal or 46,XX OD 
controls were taking antihypertensive medication.
Comparisons between TS, normal controls and women with 46,XX OD
Women with TS had greater BMI, waist-hip ratio, absolute waist circumference and blood 
pressure than women in the other two groups (Table 6.1.). Triglyceride concentrations in 
the TS group were similar to those in the 46,XX OD group and greater than in normal 
controls. The group differences in triglycerides were no longer significant when adjusted 
for waist circumference (p=0.071), but remained so when adjusted for BMI (p=0.030).
Fasting glucose and insulin concentrations and calculated HOMA-R score were lower in 
women with TS. CRP and IL-6 concentrations were greater and leptin concentrations 
lower in TS women than in both other groups (see Figure 6.1.). On interaction analysis, 
there was no difference in the relationship between waist and insulin, leptin, IL-6 or CRP 
in TS and control women (Figure 6.1.). TS status was associated with insulin, HOMA-R, 
CRP and leptin concentrations, independent of either waist circumference or BMI 
(p<0.001 for all). The group differences in IL-6 concentrations were not significant, 
however, after adjustment for these physical markers of obesity.
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Table 6.1. Characteristics and Results for women with Turner Syndrome (TS), 
Normal controls and 46,XX oestrogen deficient women (OD).
TS
(n=117)
Normals
(n=30)
46,XX OD 
(n=31) p-valuec
Clinical characteristics
Age, years* 31.4 ±8.3 33.5 ±6.5 33.0 ±7.0 0.306
Height, m“ 1.48 ± 0.06f 1.60 ±0.06 1.64 ±0.08 <0.001
Weight, kg“ 58.7 ± 14.4 60.9 ± 9.3 61.6 ± 10.5 0.450
BMI, kg/m2a 26.8 ± 5.8f 23.7 ±3.2 22.9 ±3.4 <0.001
Waist, cm* 79.9 ± 12.4e 73.5 ±6.9 74.7 ± 8.6 0.005
Waist-hip ratio* 0.84 ± 0.05f 0.76 ± 0.05 0.78 ± 0.04 <0.001
Systolic Blood Pressure, mmHg* 121 ± 14f 111 ± 9 113 ± 12 <0.001
Diastolic Blood Pressure, mmHg* 76 ± 10f 67 ±6 61 ±9 <0.001
Biochemical markers
Total cholesterol, mmol/1* 5.4 ±0.9 5.1 ± 1.0 5.0 ± 1.0 0.075
LDL cholesterol, mmol/1* 3.0 ±0.8 2.8 ±0.9 2.7 ±0.9 0.098
HDL cholesterol, mmol/1* 1.8 ±0.5 1.9 ±0.3 1.8 ±0.5 0.679
Triglycerides, mmol/l“ 1.1 ±0.6 0.8 ± 0.3d 1.1 ±0.6 0.024
Insulin, mIU/1 b 4.7 ± 2.3e 6.3 ± 3.0 6.9 ± 2.9 0.004
Glucose, mmol/l“ 4.6 ± 0.6f 5.0 ±0.4 5.0 ±0.4 <0.001
HOMA-Rb 1.0 ± 0.5e 1.4 ±0.7 1.5 ±0.7 0.001
Leptin, ng/ml b 10.2 ±6.3 14.4 ±7.6 14.8 ±8.1 0.048
C-Reactive Protein, mg/l* 2.9 ± 1.5f 0.8 ± 1.0 1.2 ±0.9 <0.001
Interleukin-6, pg/mlb 1.5 ± 0.7d 1.0 ±0.5 1.2 ±0.5 0.014
Key: “Mean or bgeometric mean ± SD. cp-values refer to group differences on ANOVA; 
d,e’findicate the value which differs from the others on ANOVA with Scheffe post-hoc 
analysis: dp<0.05; ep<0.01; fp<0.001
Analyses within the TS cohort
Anthropometric measures of obesity (weight, waist circumference and BMI) were 
strongly intercorrelated (r >0.800, p<0.001 for all) and were associated with biochemical 
markers of obesity. In comparison, waist-hip ratio was weakly associated with other 
markers of obesity (correlation with BMI r=0.243, p=0.010; weight r=0.228, p=0.016). 
Waist circumference was associated with height (i=0.263, p=0.005), BMI (r=0.855,
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p<0.001), total, LDL and HDL cholesterol (r=0.215, p=0.024; r=0.229, p=0.016; and r= -  
0.262, p=0.006 respectively). There were also associations between waist circumference 
and triglycerides (r=0.410, p<0.001), fasting insulin (r=0.494, p<0.001) and HOMA-R 
(r=0.491, p<0.001) but not fasting glucose (r=0.154, p=0.110). Serum leptin, CRP and 
IL-6 were all strongly correlated with waist circumference (r=0.556, 0.402 and 0.370 
respectively, p<0.001 for all) (see Figurel). In addition, leptin was strongly and CRP and 
IL-6 were weakly correlated with insulin concentrations (r=0.267, p=0.004; r=182, 
p=0.055; and r=0.185, p=0.051 respectively). The associations between waist and all 
three adipokines/ pro-inflammatory markers were independent of the association with 
insulin.
There was no significant association between measures of obesity and karyotype or 
previous history of growth hormone and oxandrolone therapy. There was no significant 
difference in any metabolic parameter between groups of women with either TS or POF 
taking different types of oestrogen replacement.
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Figure 6.1. Relationships between serum insulin (A), leptin (B), IL-6 (C) and CRP 
(D) and waist circumference in women with TS compared to normal and 46,XXOD 
controls. Trend lines have been added and logarithmic axes used where 
appropriate. Filled circles and solid lines represent TS, open circles and dashed lines 
represent normal and 46,XXOD controls combined.
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6.4. Discussion
This study compared metabolic markers of obesity and cardiovascular risk in oestrogen- 
replete adults with TS, 46,XXOD and normal controls, demonstrating that, whilst women 
with TS are more centrally obese than normal and 46,XXOD control women of similar
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age, the evidence for an insulin resistance/ metabolic syndrome based is unconvincing 
when based on fasting insulin measurements. In addition, there appears to be a 
discrepancy between the adipokines leptin and IL-6 in women with TS, with leptin 
concentrations being lower than expected for the degree of adiposity.
The present findings confirm increased central adiposity in women with TS (33,151). It 
was found that waist-hip ratio, which has been used as a marker of obesity and 
cardiovascular risk in the general population (370-372), appears to be a poor index of 
obesity in TS. This may be because hip development is less pronounced, and even slim 
women therefore have a relatively high waist-hip ratio. Waist circumference and BMI 
appear to be better markers of obesity and associated cardiovascular risk in TS, consistent 
with data from other populations (373) and current guidelines for risk assessment (369).
With regard to metabolic profiles, this study shows similarly elevated triglyceride 
concentrations in TS and 46,XXOD women compared to normal controls and suggests 
that this may be an effect of oestrogen therapy, as previously demonstrated in 
postmenopausal women (217). The similarity of HDL concentrations in the three groups 
may also be attributable to oestrogen therapy.
This study found women with TS to have lower fasting glucose and insulin concentrations 
than normal controls and women with 46,XXOD. A reduction of fasting insulin and 
glucose concentrations paradoxically associated with a deterioration in glucose tolerance 
has been described in TS (33) and postmenopausal women (237) treated with oestrogen. 
This phenomenon has been attributed to a glucagon-antagonistic and glucocorticoid- 
stimulatory effect of oestrogen (238). In addition, a lower incidence of diabetes mellitus 
has been described in postmenopausal women on oestrogen replacement compared to 
non-users (374). Since both the TS and 46,XXOD groups were oestrogen-treated, 
however, it is unlikely that the lower glucose and insulin concentrations in the TS women 
are attributable to oestrogen therapy.
The high prevalence of impaired glucose tolerance in women with TS (5,33) appears to be 
secondary to an insulin secretory defect (161) or a glucose storage defect (164). It should 
be noted that the use of diabetes terminology, in particular IDDM and NIDDM in earlier 
studies (33), may not necessarily be exactly equivalent to the currently used type 1 and
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type 2, hence complicating interpretation of earlier studies. As early as 35 years ago, 
however, it was suggested that the pathogenesis of diabetes in TS may be distinct from 
‘maturity-onset type’ diabetes mellitus (157), as mentioned previously. The absence of 
fasting hyperinsulinaemia, despite excess central obesity, is consistent with this (375). 
The role of the ‘metabolic syndrome’ therefore becomes questionable in TS.
This study reports raised CRP and IL-6 and reduced leptin concentrations in TS. These 
parameters were measured as indicators of body fat (376-379) and inflammatory markers 
of cardiovascular risk (260,380). CRP and IL-6 are predominantly associated with 
visceral fat (381-383), although the relationship is complex. Oral oestrogen therapy itself 
is known to increase CRP concentrations via an effect on the liver (384), but CRP 
concentrations have been shown to predict cardiovascular risk independent of oestrogen 
therapy (385). The effect of oral oestrogen on IL-6 concentrations is inconsistent 
(384,386-388).
Given the significantly higher CRP concentrations in TS women compared to both other 
groups, it is unlikely that they can be attributed to the effect of oestrogen, since the 
46,XXOD women were also oestrogen-treated. IL-6 concentrations were elevated in TS 
women compared to normal controls, but not compared to 46,XXOD women, so an 
oestrogen effect is difficult to determine and may contribute. Notably both CRP and IL-6 
were strongly correlated with waist circumference. Thus their elevated concentrations in 
the TS women are likely to be attributable to the increased central adiposity, although 
other factors may also contribute since they are non-specific inflammatory markers.
The concentration of leptin, which originates predominantly from subcutaneous fat 
(376,389) but is generally elevated in people of increased adiposity, was lower in women 
with TS than in the other two groups. A previous study did not demonstrate but inferred 
hypoleptinaemia in TS women compared to normal controls because of the greater 
percentage of body fat (167). It could be postulated that low leptin in TS results from 
reduced subcutaneous adiposity, and this prompted further investigation of fat distribution 
as discussed in Chapter 7. Another possible explanation is that the reduced leptin 
concentrations are related to low fasting insulin concentrations, since leptin production is 
regulated by chronic rather than acute insulin concentrations (390). The correlation 
between leptin and insulin in TS women in this study was not independent of the effect of
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waist size, however. Metabolic syndrome is typically, but not unequivocally, associated 
with increased leptin concentrations (391,392). A unifying hypothesis to explain the low 
insulin and leptin concentrations in the context of greater obesity would be that the insulin 
secretory defect is the primary abnormality, causing low leptin concentrations, which then 
results in inhibited satiety mechanisms (393,394).
In conclusion, women with TS have various physical and biochemical features suggestive 
of the metabolic/ insulin resistance syndrome, but the evidence that they are all 
interrelated in a true ‘metabolic syndrome’ is questionable. An excess prevalence of 
central obesity in TS is evident. Hypertriglyceridaemia in TS may be partly related to 
oestrogen therapy, although obesity probably contributes. The abnormalities of glucose 
homoeostasis do not follow the classical pattern associated with the metabolic syndrome 
and may result from a unique metabolic defect. The elevated CRP and IL-6 
concentrations are consistent with visceral adiposity, but the hyperleptinaemia often 
associated with the metabolic syndrome was not evident. Although these markers are 
undoubtedly related to obesity in TS, other factors such as oestrogen therapy, low fasting 
insulin, and perhaps other sources of pro-inflammatory cytokines appear to contribute. 
The features compatible with the metabolic syndrome in TS are not fully explained by the 
obesity, the history of oestrogen deficiency nor indeed current oestrogen therapy, and it 
may be that one or more TS-specific metabolic defects explain this apparent paradox.
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Chapter 7 
Fat Distribution Study
7.1. Aims
The high prevalence of obesity in TS (33,151) with a predominantly central distribution 
(33) has already been alluded to (Chapter 1, Section 1.2.2. and Chapter 6). This is in the 
context, however, of unexpectedly low circulating insulin concentrations (Chapter 6) 
(33,161).
Various techniques are available to assess obesity and fat distribution. These include 
anthropometric measures, magnetic resonance imaging (MRI) and bioelectrical 
impedance. MRI is being increasingly used to localise fat depots in different populations 
(329), whilst bioelectrical impedance has been shown to correlate well with other markers 
of obesity in the general population (334). On MRI the most sensitive markers of insulin 
resistance are abdominal adipose tissue, intrahepatocellular lipids and intramyocellular 
lipids in the soleus muscle (395,396).
The aim of this study was to characterise body fat content and distribution in six TS 
subjects and six normal control women by different physical and imaging techniques, and 
to compare these to biochemical markers of obesity in order to gain a greater 
understanding of the unusual metabolic profile of TS.
7.2. Results 
Subject characteristics
Table 7.1. compares clinical characteristics between the two groups of subjects. Women 
with TS were shorter and had greater systolic blood pressure and waist circumference. 
All but one woman in each group were non-smokers, and there was also no difference 
between the groups with regard to exercise taken (3 vs 4 women in TS and control groups 
respectively took no regular exercise). TS women had a median (range) oestrogen start 
age o f l4 ( l l-1 9 )  years, with 2 (0-8) cumulative years of oestrogen deficiency. 2 women 
had karyotype monosomy X, 2 had isochromosome X, one had ring X and one had a
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complex karyotype. Total cholesterol, CRP and 11-6 concentrations were greater in the TS 
women compared to the controls.
Table 7.1. Baseline characteristics in women with TS and normal controls.
Measurement
TS
(n=6)
Control
(n=6) P
Age, years8 34.9 ±8.2 34.7 ± 6.5 0.966
Height, ma 1.47 ±0.08 1.60 ±0.04 0.008
Systolic blood pressure, mmHga 123 ± 10 111 ± 6 0.038
Diastolic blood pressure, mmHga 76 ± 8 67 ± 6 0.056
Waist circumference, cm8 91.5 ± 10.7 75.8 ± 9.0 0.020
BMI, kg/m2* 30.0 ±5.3 25.7 ±4.5 0.168
Total cholesterol, mmol/la 6.0 ±0.9 4.6 ± 1.1 0.035
HDL cholesterol, mmol/la 1.9 ±0.6 1.8 ±0.4 0.867
LDL cholesterol, mmol/la 3.4 ± 1.0 2.4 ±0.9 0.094
Triglycerides, mmol/la 1.2 ±0.4 0.7 ±0.3 0.060
Fasting glucose, mmol/la 4.4 ± 0.2 5.0 ±0.4 0.015
Fasting insulin, mIU/1 b 5.4 ±2.8 6.2 ±3.3 0.772
Fasting HOMA-Rb 1.1 ±0.6 1.4 ±0.8 0.137
Leptin, ng/m lb 20.2 ± 9.8 21.7 ± 11.4 0.868
CRP, mg/l# 4.0 ±2.3 0.9 ±1.2 0.015
11-6, pg/mlb 2.3 ± 1.3 1.0 ±0.3 0.049
Bilirubin, pmol/lb 8.1 ±2.4 10.4 ±3.3 0.268
Alanine transferase, U/l 24.1 ±14.7 18.4 ±6.1 0.533
Alkaline phosphatase, U/lb 100.2 ± 39.2 59.6 ±5.5 0.031
Gamma glutamyl transferase, U/lb 70.6 ± 32.2 14.4 ±3.2 0.001
Key: Values shown are amean or geometric mean ± SD.
Comparisons between TS and control groups
With regard to absolute values for MRI and bioelectrical impedance, the only difference 
between the two groups was the excess of IHCL in the TS women (Table 7.2.). There 
was, however, a strong correlation between visceral adipose tissue and height (r=0.886,
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p=0.019), and height adjustment was therefore performed for all physical parameters of 
fat distribution. After correction for height differences, women with TS still had an 
excess of IHCL, but in addition they were shown to have greater ratios of total, visceral 
and internal (all non-subcutaneous, non-hepatic) fat to subcutaneous and subcutaneous 
abdominal fat, and a lower ratio of total to internal fat (the relationship between total and 
visceral fat did not quite achieve significance) (Figure 7.1., Table 7.2.). Height correction 
had no effect on the comparisons of bioelectrical impedance measures between the two 
groups.
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Figure 7.1. Representative T 1-weighted MR images from the abdomen (just below 
the umbilicus) of (a) a woman with TS (BMI 29.0 kg/m2) and (b) a normal control 
woman (BMI 30.6 kg/m2), demonstrating increased visceral adipose tissue in the 
woman with TS despite slightly lower BMI. Adipose tissue is shown in white.
Figure 7.1a.
Figure 7.1b.
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Table 7.2. Absolute and height-adjusted values of MRI and bioelectrical impedance
results in women with TS and normal controls
Measurement
Absolute values Height-adjusted values
TS
(n=6)
Control
(n=6)
p-value TS
(n=6)
Control
(n=6)
p-value
MRI data
Total Adipose Tissue (litres) 31.60
±8.93
28.35
±9.96
0.565 31.3 
± 13.5
28.7 
± 13.5
0.791
Subcutaneous Adipose Tissue (litres) 25.90
±8.11
23.60
±7.91
0.629 24.7 
± 10.8
24.8 
± 10.8
0.989
Subcutaneous Abdominal Adipose 
Tissue (litres)
8.39
±2.59
6.85
±3.28
0.388 7.9
±4.2
7.3
±4.2
0.837
Subcutaneous Peripheral Adipose 
Tissue (litres)
17.51
±5.69
16.75
±4.66
0.805 16.8
±7.4
17.5
±7.4
0.891
Internal Adipose Tissue3 (litres) 5.69 
± 1.56
4.75
±2.32
0.427 6.6
±2.6
3.9
±2.6
0.176
Visceral Adipose Tissue (litres) 2.77
±0.90
2.30 
± 1.44
0.515 3.3 
± 1.6
1.8 
± 1.6
0.191
Non-visceral Internal Adipose Tissue 
(litres)
2.92
±0.77
2.44
±0.91
0.353 3.2 
± 1.1
2.1 
± 1.1
0.194
Internal: Subcutaneous Adipose Tissue 
ratio
0.2
±0.06
0.2
±0.05
0.352 0.27
±0.06
0.15
±0.06
0.014
Visceral: Subcutaneous Abdominal 
Adipose Tissue ratio
0.3
±0.1
0.3
±0.1
0.914 0.4
±0.1
0.2
±0.1
0.030
Visceral: Subcutaneous Adipose 
Tissue ratio
0.11
±0.04
0.09
±0.04
0.404 0.14
±0.04
0.07
±0.04
0.045
Total Adipose: Subcutaneous Tissue 
ratio
1.2
±0.06
1.2
±0.05
0.352 1.3
±0.06
1.2
±0.06
0.014
Total: Subcutaneous Abdominal 
Adipose Tissue ratio
3.8
±0.4
4.5
±0.9
0.129 4.0 
± 1.0
4.3 
± 1.0
0.742
Total: Visceral Adipose Tissue ratio 12.0
±3.8
14.6
±5.8
0.375 8.9
±6.0
17.8
±6.0
0.062
Total: Internal Adipose Tissue ratio 5.7 
± 1.3
6.4 
± 1.4
0.372 4.6 
± 1.5
7.4 
± 1.5
0.024
Intramyocellular Lipids Soleus 11.04
±4.78
10.02
±6.20
0.755 14.9
±6.4
6.1
±6.4
0.081
Intramyocellular Lipids Tibialis 15.48 
± 14.67
9.31
±2.08
0.332 8.4 
± 12.3
16.4 
± 12.3
0.373
Intrahepatocellular Lipids 2.93 
± 1.50
0.42
±0.25
0.002 3.0 
± 1.5
0.4 
± 1.5
0.038
Bioelectrical Impedance data
Tanita total body fat (kg) 23.1
±7.6
22.7 
± 11.6
0.938 22.8 
± 14.0
23.1 
± 14.0
0.975
Tanita trunk fat (kg) 10.0
±3.8
10.1
±4.8
0.974 10.5
±6.2
9.7 
± 6.2
0.858
Tanita non-trunk fat (kg) 13.1
±4.0
12.6
±7.0
0.874 12.3
±8.1
13.4
±8.1
0.849
Tanita total body water (1) 29.9
±3.4
32.9
±2.2
0.100 31.2
±3.8
31.7
±3.8
0.849
Tanita % body fat 35.4
±5.9
31.0
±8.3
0.315 - - -
Tanita trunk % fat 29.4
±7.1
27.3
±9.3
0.668 - - -
Key: “Refers to all non-subcutaneous, non-hepatic fat. Values shown are mean ± SD
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Associations within TS and control groups
MRI and bioelectrical impedance
In TS women, there were strong correlations between bioelectrical impedance measures 
of total and trunk fat mass and MRI measures of total and subcutaneous AT on MRI 
(r>0.800, p<0.05 for all) (see Figure 1.2.). There was no association, however, between 
bioelectrical impedance trunk fat mass and MRI internal or visceral AT (Figure 7.3.).
In the control group there were strong associations both between bioelectrical impedance 
total and trunk fat mass and MRI total, subcutaneous, visceral and internal AT and also 
waist circumference (r>0.800, p<0.05 for all) (Figure 7.2.). In particular, and in contrast 
to the TS group, the relationship between bioelectrical impedance trunk fat mass and MRI 
visceral and internal AT was very strong in the control group (r>0.900, p<0.01) (Figure
7.3.), although there was no association with IHCL.
Figure 7.2. Comparison of total body fat measurements in TS and normal control 
women. Filled circles and solid line represent TS, open circles and dashed line 
represent controls.
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Figure 7.3. Comparison of trunk and visceral fat measurements in TS and normal 
control women. Filled circles and solid line represent TS, open circles and dashed 
line represent controls.
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Physical and biochemical markers o f adiposity
With regard to associations between MRI measures of adiposity and biochemical markers 
of obesity within the TS group, the only correlations were with triglyceride 
concentrations. These were positively correlated with visceral:subcutaneous abdominal 
AT ratio on MRI (r=0.928, p=0.008) and visceral: total AT ratio (r=0.841, p=0.036), but 
were negatively correlated with peripheral subcutaneous AT: total AT ratio (r= -0.928, 
p=0.008). No other parameter, physical or metabolic, had a significant association with 
MRI measurements, nor bioelectrical impedance measurements.
Within the control group, MRI visceral AT was strongly correlated with insulin, HOMA- 
R and CRP concentrations; bioelectrical impedance trunk mass was associated with 
insulin and HOMA-R (r>0.800, p<0.05 for all). There were no associations between 
soleus IMCL or IHCL and biochemical markers of obesity.
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Previous oestrogen, growth hormone and oxandrolone therapy in TS women
Within the TS cohort there was an association between both oestrogen start age and
cumulative years of oestrogen deficiency and IHCL (r=0.900, p=0.037 and r=0.928,
p=0.008 respectively) (Figure 7.4.). Previous history of growth hormone and oxandrolone
therapy or karyotype had no association with physical or biochemical markers of
adiposity.
Figure 7.4. The relationship between intrahepatocellular lipids (IHCL) on MR 
spectroscopy and oestrogen deficient years in women with TS.
IHCL
6
5
4
3
2
1
0
0 1 3 42 5 6 8 97
Oestrogen deficient years
7.3. Discussion
This study characterises the obesity of Turner Syndrome using both MRI and bioelectrical 
impedance techniques. Women with TS and controls had similar BMI, although women 
with TS had greater absolute waist circumference. This greater central obesity was 
confirmed on MRI by an excess of visceral and internal AT and intrahepatocellular lipids 
after adjustment for height.
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Bioelectical impedance measures of adiposity did not reflect the excess trunk mass in TS 
detected by MRI, even after height-adjustment, although there were good correlations 
with total and subcutaneous AT on MRI. This contrasted with the findings in the control 
group, in whom visceral and trunk measures of adiposity were well correlated between the 
two techniques. Our findings suggest that whilst bioelectrical impedance may be useful to 
gain an overall impression of total adiposity, fat localisation is poor in women with TS. 
MRI, however, which has been well validated in patient and control groups (329), is a 
useful method of assessing different fat depots in TS.
Women with TS not only had physical but also biochemical markers of excess adiposity 
with greater total cholesterol, CRP and 11-6 concentrations than controls. In the larger 
cross-sectional metabolic study (Chapter 6) a greater triglyceride concentration had also 
been demonstrated. The excess central adiposity in TS was associated with triglyceride 
concentrations. There is thus a discrepancy between the finding of increased visceral AT 
and intrahepatocellular lipids on MRI, two of the three measures most associated with 
insulin resistance (395) in the context of some elevated markers of obesity but an absence 
of hyperinsulinaemia. A possible explanation for this would be that the centrally 
distributed adipose tissue in TS is predominantly subcutaneous, but our findings have 
ruled this out. The excess visceral adipose tissue shown here infers an abnormality of 
adipose function/deposition, although the present study does not explain the mechanism. 
A further possibility is the existence of an insulin secretory defect in TS which has been 
previously suggested (33,161) and the findings in the present study are consistent with 
this.
Perhaps the most remarkable finding in this study was the association between oestrogen 
deficiency and intrahepatocellular lipids. Women with TS are known to have an 
increased prevalence of abnormal liver function (36,37), and it has been suggested that 
this may be related to oestrogen deficiency (37,74). It is possible that oestrogen 
deficiency in childhood years may affect adipose tissue lipolysis and/or alter adipocyte 
differentiation and function, which in turn would lead to increased liver fat content later in 
life (397). Accumulation of ectopic fat, especially in the muscle and liver has been 
implicated in the development of type II diabetes (398). Liver biopsies have revealed a 
variety of abnormalities including fatty infiltration, fibrosis and cirrhosis (7). It is 
therefore interesting to note the excess of intrahepatocellular lipids in women with TS
108
Chapter 7
compared to controls in this study, and the association with oestrogen deficiency, in the 
context of elevated liver enzymes in TS women. The sample size may have been too 
small to demonstrate a relationship between serum liver function biochemistry and 
hepatic fat (332).
In conclusion, this study has confirmed that the central obesity seen in women with TS on 
anthropometric measurements is reflected by excess total, internal and visceral adipose 
tissue on MRI, best demonstrated by adjustment for height. This fat distribution is 
associated with established biochemical markers of central adiposity but not 
hyperinsulinaemia. Intrahepatocellular lipids are elevated in TS and this is associated 
with history of oestrogen deficiency, which may explain the beneficial effect of oestrogen 
therapy on liver function. Bioelectrical impedance may be useful to estimate total body 
fat, but does not reliably localise fat depots in women with TS. Larger studies are now 
required to explore these relationships further.
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Chapter 8 
Longitudinal Oestrogen Dose-ranging Study
8.1 Aims
The increased cardiovascular risk in TS may be related either to genetic factors (resulting 
from the abnormal karyotype) or to oestrogen deficiency. The impact of oestrogen 
deficiency can be extrapolated from comparable other groups of women with early 
oestrogen deficiency, for instance, women with premature ovarian failure and 
hypopituitarism. The improvement of surrogate markers of cardiovascular risk with 
oestrogen therapy in postmenopausal women as previously discussed is in contrast to the 
greater cardiovascular morbidity (204), a paradox which remains unexplained at present.
It has been suggested that women with TS are relatively resistant to the actions of 
oestrogen and benefit from higher doses with regard to bone markers, liver function (37) 
and uterine development (323). The hypothesis of this study was that higher doses of 
oestrogen may be beneficial to markers of cardiovascular risk and metabolism in women 
with TS. In order to assess the oestrogen sensitivity of women with TS, 14 women with 
TS were compared to 11 women with 46,XX primary amenorrhoea (PA), who were 
similarly oestrogen deficient but with a normal karyotype. All women were sequentially 
treated with three months each of oral oestrogen replacement preparations containing 
lmg, 2mg and 4mg of 17p-oestradiol respectively.
8.2. Results
Comparisons o f women with TS and 46JOCPA (see Table 8.1.)
The two groups were of similar age but not height-matched (mean age ± SD 33.3 ±6.1 vs 
30.2 ± 8.6 years, p=0.306; height 1.48 ± 0.06 vs 1.67 ± 0.09 metres, p<0.001, in TS and 
46,XXPA women respectively). Women with TS smoked less (79% vs 36% had never 
smoked in TS and 46,XXPA groups respectively, p=0.032) but there was no difference 
with regard to exercise taken (64% vs 46% took no exercise, p=0.346). Women with TS 
started oestrogen replacement therapy at a younger age (median [range] years 15 [10-19] 
vs 17 [12-22], p=0.033) and had fewer cumulative years of oestrogen deficiency (3.5 [0-8] 
vs 6 [1-11] years, p=0.005) than women with 46,XXPA.
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Table 8.1. Comparison of characteristics on lmg oestradiol in women with TS and 
46,XXPA.
TS
(n=14)
46,XXPA
(n=ll) p-value
Anthropometric parameters
Systolic BP, mmHga 116 ± 9 106 ± 7 0.002
Diastolic BP, mmHga 73 ± 9 63 ± 4 0.008
Weight, kga 56.1 ± 10.9 60.8 ±11.8 0.290
BMI, kg/m"1" 25.7 ±4.4 21.8 ±3.4 0.023
Waist, cma 79.4 ±11.4 73.6 ± 7.4 0.157
Waist-hip ratio8 0.85 ± 0.05 0.78 ± 0.03 0.001
Lipids and Metabolism
Total cholesterol, mmol/la 5.6 ±0.9 4.9 ± 0.9 0.057
LDL cholesterol, mmol/la 3.2 ±0.8 2.6 ± 0.9 0.091
HDL cholesterol, mmol/la 1.9 ±0.4 1.8 ±0.5 0.690
Triglycerides, mmol/la 1.2 ±0.5 1.1 ±0.7 0.694
Glucose, mmol/la 4.7 ± 0.4 5.0 ±0.3 0.067
Insulin, mIU/lb 4.7 ± 2.4 7.6 ±2.6 0.058
HOMA-Rb 1.0 ±0.5 1.7 ±0.6 0.041
CRP, mg/la 1.9 ±0.8 1.1 ±0.8 0.012
Leptin, ng/mlb 15.8 ±9.9 11.6 ± 5.1 0.365
IL-6, pg/mlb 1.4 ±0.9 1.0 ±0.5 0.268
Sex Hormones
LH, IU/lb 17.8 ± 12.9 31.6 ±24.7 0.281
FSH, IU /r 36.0 ± 20.0 39.3 ± 26.3 0.610
Oestradiol, pmol/lb 204 ± 52 297 ± 65 0.028
Testosterone, nmol/lb 1.8 ±0.5 2.8 ±1.0 0.005
Liver Function
Gamma glutamyl transferase, U/lb 54.1 ±33.4 18.8 ±8.0 0.003
Alkaline phosphatase, U/lb 93.1 ±67.1 68.2 ± 18.1 0.024
Alanine transferase, U/lb 40.2 ±15.5 20.7 ±7.1 0.002
Bilirubin, pmol/lb 8.7 ±1.4 9.8 ±4.6 0.501
Albumin, g/la 46.1 ±2.5 47.2 ± 2.6 0.296
Urea, mmol/la 4.6 ±1.2 4.4 ± 0.7 0.609
Haematocrit, l/la 0.397 ±0.018 0.405 ± 0.036 0.342
Fibrinogen, g/la 2.58 ± 0.52 2.35 ± 0.45 0.260
Key: amean ± SD; bgeometric mean ± SD
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2/14 (14.3%) women with TS had previously received growth hormone treatment and 
28.6% had karyotype monosomy X. The remainder had a variety of TS karyotypes 
including 42.9% isochromosome X, 7.1% ring X, 14.3% any Y fragment and 7.1% 
mosaic 45,X/46,XX. None of the women in either group took antihypertensive 
medication.
Other group differences were assessed at the lmg oestradiol dose. Women with TS had 
greater BMI and waist-hip ratio than women in the 46,XXPA group. Lipid concentrations 
between the two groups were similar, as were insulin, leptin and 11-6 concentrations, 
whilst calculated HOMA-R was slightly lower and CRP concentrations somewhat higher 
in TS women than 46,XXPA women.
There were no significant differences in gonadotrophin concentrations between the two 
groups. The TS group had lower oestradiol and testosterone concentrations on lmg 
oestradiol.
Serum gamma glutamyl transferase (yGT), alanine transferase (ALT) and alkaline 
phosphatase (ALP) concentrations were all higher in TS than 46,XXPA women on lmg 
oestradiol. Fibrinogen concentration did not differ between the two groups.
Parameters of vascular physiology were similar between the two groups of women except 
for AIx which was higher in TS.
Oestrogen dose-ranging within TS and 46,XXPA groups (Tables 8.2. and 8.3.)
Anthropometric parameters
Increasing dose of oestrogen had no effect on blood pressure or weight over the period 
studied in either TS or 46,XXPA women.
Lipids and Metabolism
There was an increase in HDL cholesterol in both groups with increasing oestrogen dose, 
whilst insulin concentrations and calculated HOMA-R score were reduced in the women 
with 46,XXPA. Other metabolic markers were unaffected in both groups.
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Table 8.2. Variations in clinical, metabolic and hormonal parameters with
increasing doses of oestrogen in women with TS
Turner Syndrome 
(n=14)
Dose of oestradiol
p-valuelmg 2 mg 4mg
Anthropometric parameters
Systolic BP, mmHg a 116 ± 9 113 ± 7 114 ± 7 0.352
Diastolic BP, mmHg a 73 ± 9 71 ± 6 72 ± 8 0.598
Weight, kga 56.1 ± 10.9 56.1 ± 10.4 56.9 ± 11.6 0.218
Waist, cm a 79.4 ±11.4 79.3 ±11.6 78.4 ±12.3 0.297
Waist-hip ratio a 0.85 ± 0.05 0.85 ± 0.06 0.84 ± 0.06 0.174
Lipids and Metabolism
Total cholesterol, mmol/1a 5.6 ±0.9 5.8 ±0.7 5.8 ± 1.0 0.720
LDL cholesterol, mmol/1a 3.2 ±0.8 3.1 ±0.9 2.8 ±0.9 0.106
HDL cholesterol, mmol/1a 1.9 ±0.4 2.1 ±0.5 2.2 ± 0.2 0.003
Triglycerides, mmol/1a 1.2 ±0.5 1.3 ±0.4 1.6 ±0.6 0.070
Glucose, mmol/1a 4.7 ± 0.4 4.6 ± 0.3 4.5 ± 0.4 0.633
Insulin, mIU/1b 4.7 ± 2.4 6.2 ±2.9 5.2 ±2.8 0.187
HOMA-R b 1.0 ±0.5 1.3 ±0.6 1.0 ±0.6 0.814
CRP, mg/1 8 1.9 ±0.8 2.2 ± 0.6 3.7 ±5.6 0.279
Leptin, ng/m lb 15.8 ±9.9 15.6 ±9.6 13.4 ±9.4 0.413
IL-6, pg/m lb 1.4 ±0.9 1.2 ±0.7 1.5 ±0.9 0.933
Sex Hormones
LH, IU/1b 17.8 ±12.9 14.1 ±8.7 4.7 ±3.6 0.001
FSH, IU/1b 36.0 ± 20.0 23.6 ± 12.8 7.6 ±4.6 <0.001
Oestradiol, pmol/1b 204 ± 52 240 ± 96 398± 166 <0.001
Testosterone, nmol/1b 1.8 ±0.5 1.4 ±0.7 0.5 ±0.3 0.005
Liver Function
Gamma glutamyl transferase, U/lb 54.1 ±33.4 40.9 ± 26.5 33.8 ±20.9 0.002
Alkaline phosphatase, U/l 93.1 ±67.1 84.0 ± 26.6 86.9 ± 22.3 0.104
Alanine transferase, U/l b 40.2 ± 15.5 30.1 ± 11.6 27.1 ± 11.7 0.008
Bilirubin, pmol/1 b 8.7 ± 1.4 7.5 ± 1.7 7.0 ± 1.8 0.016
Albumin, g/1 8 46.1 ±2.5 45.3 ±2.7 43.3 ± 2.7 0.002
Urea, mmol/1 8 4.6 ± 1.2 4.3 ± 0.9 4.1 ±1.2 0.104
Haematocrit, 1/18 0.397 ±0.018 0.394 ± 0.020 0.382 ± 0.022 0.109
Fibrinogen, g/18 2.58 ±0.52 2.59 ± 0.49 2.93 ± 0.70 0.152
Key: amean ± SD; bgeometric mean ± SD
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Table 8.3. Variations in clinical, metabolic and hormonal parameters with
increasing doses of oestrogen in women with 46,XXPA
46,XXPA Dose of oestradiol
(n = ll) lmg 2mg 4mg p-value
Anthropometric parameters
Systolic BP, mmHg “ 106 ± 7 10818 10618 0.948
Diastolic BP, mmHg “ 63 ± 4 6 3 1 6 61 1 7 0.373
Weight, k g “ 60.8 ± 11.8 60.9110.7 61.1 111.7 0.421
Waist, cm “ 73.6 ± 7.4 74.6 1 6.7 73.1 17.3 0.422
Waist-hip ratio “ 0.78 ± 0.03 0.79 1 0.04 0.77 1 0.04 0.441
Lipids and Metabolism
Total cholesterol, mmol/1 “ 4.9±0.9 5 .010 .9 5.211.0 0.263
LDL cholesterol, mmol/1 * 2.6 ± 0.9 2.5 1 0.8 2.611 .0 0.919
HDL cholesterol, mmol/1 “ 1.810.5 2.010.5 2.2 10.5 0.001
Triglycerides, mmol/1 “ 1.110.7 1.010.4 1.210.7 0.824
Glucose, mmol/1 “ 5.010.3 4.7 1 0.3 4.610.8 0.130
Insulin, mIU/1b 7.612.6 6.411.8 5.1 12.3 0.031
HOMA-R b 1.710.6 1.310.4 1.010.5 0.030
CRP, mg/1 “ 1.1 10.8 0 .911 .0 1.511.5 0.279
Leptin, ng/mlb 11.615.1 13.716.6 13.717.8 0.401
IL-6, pg/m lb 1.010.5 0.7 1 0.3 1.010.5 0.957
Sex Hormones
LH, IU/lb 31.6124.7 19.21 15.2 9.017.1 <0.001
FSH, IU/1b 39.3 126.3 22.8 1 16.8 12.219.2 0.001
Oestradiol, pmol/1b 297 1 65 355 1 154 611 1311 0.007
Testosterone, nmol/1b 2.811 .0 2.810 .8 1.710.6 0.012
Liver Function
Gamma glutamyl transferase, U/lb 18.818.0 17.1 16.5 14.616.5 0.035
Alkaline phosphatase, U/l b 68.2118.1 66.1 118.8 66.5118.1 0.501
Alanine transferase, U/l b 20.717.1 20.8 1 9.4 19.116.5 0.386
Bilirubin, pmol/1 b 9.814.6 9 .314 .4 8.913.6 0.403
Albumin, g/1 “ 47.2 12.6 46.812.6 45.012.6 0.030
Urea, mmol/1 “ 4.41  0.7 4.2 1 0.9 4.41  0.6 0.934
Haematocrit, 1/1 “ 0.405 1 0.036 0.39010.024 0.3991 0.029 0.136
Fibrinogen, g/1 “ 2.35 1 0.45 2.09 1 0.49 2.401 0.68 0.828
Key: “mean ± SD; bgeometric mean ± SD
Sex hormone concentrations
In both groups, sex hormone concentrations reflected greater oestradiol concentrations 
and gonadotrophin suppression with increasing oestrogen dose (see Figure 8.1), and this 
was accompanied by a reduction in testosterone concentration.
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Figure 8.1. Serum Follicle Stimulating Hormone (FSH) in women with TS and 
46,XXPA at varying doses of oestradiol. Filled circles represent TS, open circles 
represent 46,XXPA (mean ± SE).
80 -I
70 
60
FSH, 50 
IU/I 40
30
20
10
0
1 2 4
Oestradiol dose, mg
Liver Function
Changes in liver function were more marked in the TS group (see Figure 8.2.). They 
showed a reduction in yGT and ALT concentrations, with concurrent decreases in 
bilirubin and albumin concentrations. In 46,XXPA women, there was a small significant 
reduction in yGT and albumin. Urea and haematocrit concentrations, recorded as 
additional markers of fluid status, did not alter in either group, and a similar pattern was 
seen for fibrinogen concentration.
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Figure 8.2. Serum Gamma Glutamyl Transferase (GT) in women with TS and 
46,XXPA at varying doses of oestradiol. Filled circles represent TS, open circles 
represent 46,XXPA (mean ± SE).
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Vascular physiology markers
IMT decreased with increasing oestrogen dose in both groups of women (Table 8.4., 
Figure 8.3.). FMD, PWV and AIx did not alter significantly, although in the 46,XXPA 
group there was a slight reduction in GTN-mediated vasodilatation with greater oestrogen 
dose. There was no difference in baseline brachial diameter, baseline flow or maximum 
flow increase in either TS or 46,XXPA group at the lmg and 4mg doses of oestradiol.
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Figure 8.3. Intima Media Thickness measurements in TS (black bars) and 46,XXPA 
women (white bars) with oestrogen deficiency at varying doses of oestradiol (mean ± 
SE). Dotted lines show reference range (mean ± SE) derived from 25 normal control 
women of similar age (Chapter 5).
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Table 8.4. Variations in vascular physiology markers during oestrogen dose-ranging 
study in women with TS and 46,XX PA (mean ± SD)
Turner Syndrome 
(n=14)
Dose of oestradiol
p-valuelmg 2mg 4mg
IMT, mm 0.63 ± 0.05 0.57 ± 0.06 0.56 ± 0.07 0.003
FMD % 7.50 ±3.55 8.69 ± 2.42 9.14 ±3.97 0.092
GTN % 11.31 ±5.10 9.84 ±3.53 10.80 ±4.54 0.645
PWV 6.3 ± 1.0 6.0 ±1.2 5.9 ±0.9 0.065
AIx 24.5 ± 8.8 23.5 ±11.3 23.1 ±9.9 0.401
46,XX PA 
(n = ll)
Dose of oestradiol
p-valuelmg 2mg 4mg
IMT, mm 0.63 ± 0.08 0.60 ± 0.05 0.57 ± 0.05 0.038
FMD % 8.44 ± 2.84 7.48 ± 2.73 8.95 ± 4.05 0.485
GTN % 11.83 ±3.30 10.84 ±3.81 8.84 ± 2.94 0.030
PWV 6.0 ±0.7 5.8 ±0.7 6.1 ±0.8 0.703
AIx 10.1 ± 10.4 10.1 ± 10.8 10.6 ± 11.8 0.792
8.4. Discussion
This study assessed the effects of varying doses of the same oral oestrogen preparation in 
young oestrogen-deficient women with TS and 46,XXPA. The most important findings 
are the reduction of intima media thickness in both groups, accompanied by an increase in 
HDL concentrations but with no increase in blood pressure or weight. There was also an 
improvement in liver function which was more marked in women with TS. There was 
thus no evidence for a greater degree of oestrogen resistance in women with TS compared 
to women with normal karyotype.
Vascular Physiology parameters
In the general population, a 0.1mm increase in IMT in the common carotid artery has 
been shown to be associated with an 11% increased risk of anterior myocardial infarction 
(294). The reductions of 0.07mm and 0.06mm in TS and 46,XXPA women respectively
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may therefore be important, particularly considering the absence of a change in blood 
pressure and the short duration of the study. A dose-dependent improvement has not 
previously been demonstrated in either postmenopausal or young oestrogen-deficient 
women. Previous work has shown that IMT improves in postmenopausal women 
receiving oestrogen therapy (295-297), but the reductions of 0.0017mm per year (295) 
and 0.012 mm per year (296) described are considerably less than the improvements seen 
over 6 months in this study. In the HERS sub-study, no difference in IMT was seen 
between oestrogen-treated and untreated women, although these subjects had established 
coronary artery disease (360). One explanation for this difference may be that the average 
age in the postmenopausal studies was around 60 years or more, compared with 32 years 
in the present study. Our results may therefore indicate that young women with oestrogen 
deficiency are more sensitive to oestrogen-mediated improvements of IMT than older 
women.
This finding supports the notion that the antiatherogenic effects of oestrogen in young 
women confer a net cardioprotective effect compared to the predominant prothrombotic 
effect of oestrogen in older women. With this in mind it is reassuring that no parallel 
increase in fibrinogen or blood pressure was found in this study. Furthermore, the 
reduction in IMT with increasing oestrogen dosing does not appear to be cytokine or 
inflammation-mediated as no change in IL-6 or CRP was found. Although the 
mechanism for such a dramatic reduction in IMT is unclear, our observations may, in part, 
be explained by increased responsiveness of vascular cells to the antiatherogenic effects 
of oestrogen in earlier developing atherosclerotic lesions compared to more established 
disease (356).
With regard to endothelial function, no major oestrogen-sensitive effects were noted. 
FMD, PWV and AIx showed no change with increasing oestrogen dose in the 46,XXPA 
group, in agreement with an FMD dose-ranging study in postmenopausal women (285). 
The trends towards an increase in FMD and a decrease in PWV in the TS women, 
although not significant in this small group, may be physiologically significant. One 
explanation may be that, whilst FMD is significantly greater in oestrogen-treated women 
compared to those who are oestrogen deficient as demonstrated in postmenopausal 
women (285,288), women with premature ovarian failure (291), and women with TS (34), 
the differences between oestrogen replete groups are less dramatic. It is possible that
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larger population samples and perhaps longer time intervals might strengthen these 
relationships.
Lipids, Metabolism and Blood Pressure
The increase in HDL cholesterol observed in this study is consistent with trends in 
previous studies in postmenopausal women (399). Markers of glucose homoeostasis did 
not change in the women with TS, but fasting insulin and calculated HOMA-R were 
reduced with increasing dose in 46,XXPA women. A reduction of fasting insulin and 
glucose concentrations paradoxically associated with a deterioration in glucose tolerance 
has been described in TS (33) and postmenopausal women (237) treated with oestrogen as 
previously discussed in Chapter 6. This phenomenon has been attributed to a glucagon- 
antagonistic and glucocorticoid-stimulatory effect of oestrogen (238). Although dynamic 
testing was not performed in our study, the absence of a deleterious effect of increasing 
oestrogen dose on fasting glucose and insulin concentrations in TS is reassuring.
The absence of an effect of increasing oestrogen dose on blood pressure or measures of 
obesity is consistent with previous studies in postmenopausal women which showed no 
significant difference either in oestrogen-treated women compared to controls (204), or in 
cross-over oestrogen studies (285), where the oestrogen is a form of hormone replacement 
therapy rather than the oral contraceptive pill. Although the duration of treatment in the 
present study was relatively short, the absence of a detrimental effect over a 6-month 
period is nevertheless encouraging.
Sex hormones
Women with TS and 46,XXPA showed similar responses to increasing dose of exogenous 
oestradiol with regard to increasing serum oestradiol and decreasing gonadotrophin 
concentrations, although TS women had significantly lower serum oestradiol 
concentrations than 46,XXPA women on lmg oestradiol. The changes in testosterone in 
both groups are interesting. A previous study has shown that untreated women with TS 
have reduced androstenedione and testosterone concentrations but normal DHEAS 
concentrations when compared to normal women, and it was suggested that these findings 
might indicate insufficient extraadrenal and extragonadal conversion of DHEAS to other 
androgens (400). This group also demonstrated that both free and total testosterone 
concentrations were reduced by the administration of oestrogen therapy. Our study has
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shown that total testosterone concentrations were lower in women with TS than those 
with 46,XXPA, but both were reduced with increasing doses of oestradiol. This may be 
related to an increase in SHBG or to an inhibitory effect of 17p-oestradiol on conversion 
of DHEAS by 3p-hydroxysteroid dehydrogenase (400).
Liver Function
The raised liver enzymes commonly found in women with TS are known to be suppressed 
by exogenous oestrogen (36,37). A lesser suppression of liver enzymes has been shown 
in normal postmenopausal women given a variety of oestrogen preparations (401). The 
use of oestrogen therapy in women with liver disease in the general population has 
traditionally been discouraged because of concerns about cholestasis, but this view was 
mainly derived from early data of the oral contraceptive pill using high doses of 
ethinyloestradiol (254). More recently, hormone replacement therapy using other forms 
of oestrogen such as oestradiol, especially by the transdermal route, have been found to be 
relatively safe, even in women with liver disease (402).
The significance of elevated liver enzymes in TS has been unclear and significant liver 
disease was thought to be rare (72). A recently published series has highlighed the 
possibility of severe liver disease, even requiring transplantation, developing in women 
with TS. In this study, it is interesting to note that the most severe architectural changes 
were noted particularly in women who had never received oestrogen therapy (74). Taken 
together, the present study and those of Guttman et al. (37) and Roulot et al. (74) are 
consistent in suggesting that exogenous oestrogen may be protective against progressive 
liver disease in women with TS.
Fibrinogen, which is also produced by the liver, is a useful marker of the haemostatic 
process which contributes to inflammation, being part of the final common pathway of the 
coagulation cascade, although the anticoagulant and fibrinolytic systems also come into 
play. Neither TS nor 46,XXPA women in this study demonstrated significant changes in 
the concentration of fibrinogen. Data from previous studies have shown inconsistent 
effects of exogenous oestrogen replacement on plasma fibrinogen (403-406). Whilst there 
are obviously other contributors to haemostasis and coagulation, it may be somewhat 
reassuring that, in the context of the other benefits observed with increasing dose of
121
Chapter 8
oestrogen, there was no evidence of an increased procoagulant state, at least with regard 
to fibrinogen.
In conclusion, this study has shown that women with TS and 46,XXPA are similarly 
sensitive to increasing dose of oral oestradiol therapy with regard to IMT, a marker of 
cardiovascular risk. This was in the absence of changes in other markers of 
cardiovascular risk, such as blood pressure, waist-hip ratio, glucose homoeostasis, 
adipokines, pro-inflammatory cytokines, and fibrinogen, albeit with a small increase in 
HDL cholesterol concentrations. Elevated liver enzymes are also sensitive to increasing 
dose of oestradiol, and demonstrate a dose-dependent improvement.
In the light of recent evidence in postmenopausal women (201,204,213), there has been a 
tendency to err on the side of caution and treat young and older oestrogen-deficient 
women with the minimum oestrogen dose tolerated. Some young women with TS or 
46,XXPA undoubtedly feel symptomatically better on higher doses of oestradiol, and it 
must be remembered that oestrogen therapy in these cases is replacing the natural pre­
menopausal oestrogen-replete state rather than extending years of oestrogen exposure 
beyond their ‘normal menopause’ in older women. This study suggests that greater 
dosage of oestradiol in young women, particularly those with TS, may be beneficial with 
regard to several organ systems.
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Chapter 9 
General Discussion, Conclusions and Future Directions
This is the first large study to characterise various aspects of the cardiovascular risk in 
adults with Turner Syndrome. These have included structural cardiovascular disease 
which may be both congenital and acquired, atherosclerosis, metabolic factors and 
obesity. The effects of the widely used treatments oestrogen and growth hormone have 
been assessed, both as they relate to historic use and more specifically in an oestrogen 
dose-ranging study. Furthermore, insights have been gained into liver disease in TS, both 
through its association with obesity and the effects of oestrogen.
Structural Cardiovascular Disease
It has been shown that both echocardiography and magnetic resonance imaging are 
required in order to effectively screen for aortic root dilatation, bicuspid aortic valve and 
coarctation, and that the two techniques provide complementary information. It has been 
demonstrated that height correction is a useful means of correcting for the short stature of 
TS, and reference ranges have been produced for both echocardiographic and MRI 
measurements of aortic root diameter in order to aid future interpretation. The 
longitudinal echocardiography study has confirmed that a screening interval of three to 
five years is probably appropriate, at least in TS women whose aortic root does not exceed 
3.6cm at the first scan. It is to be hoped that the cohort in this longitudinal study can 
continue to be followed for many years to come, so that these preliminary findings can be 
extended. Furthermore, a refined echocardiography protocol involving more detailed 
measurements of aortic dimensions at different levels of the ascending aorta, may be 
useful to gain greater understanding of the pattern of aortic dilatation in a follow-up 
series.
Although women with TS had raised blood pressures, the present study found no direct 
association between blood pressure and aortic diameters. Nevertheless, the obvious 
analogies with aortic dilatation in Marfan Syndrome (342,407) suggest that a prophylactic 
beta-adrenergic blockade blood pressure intervention trial would be useful in TS.
123
Chapter 9
The vascular physiology study has demonstrated that the dilatation previously noted in the 
aorta on echocardiography and MRI is also found in other conduit vessels, notably the 
common carotid and brachial arteries, suggesting that there may be a fundamental arterial 
wall defect throughout the vascular tree in TS. The absence of this dilatation in other 
young oestrogen deficient women with normal karyotype suggests that oestrogen 
deficiency is not the cause of this abnormality. Furthermore, the similarity of IMT but 
disparity of arterial diameters between the TS and 46,XXPA women suggests that a 
simple relationship resulting from arterial remodelling does not provide the explanation. 
The implications of this apparently generalised conduit artery dilatation now require 
clarification. The diameter of more distal arteries such as the retinal arteries could also be 
analysed to determine the degree to which arterial dilatation is a generalised phenomenon 
in TS. A study of arterial distensibility and resistance artery flow may help to explain the 
hypertension of TS in the context of such conduit artery dilatation.
The findings of this study show that important ‘occult’ coarctation is present in a 
significant number of TS women. It is not known, however, how these imaging findings 
relate to clinical risk. Since no significant associations were found between resting blood 
pressure and coarctation site abnormalities, an exercise blood pressure study would be 
useful to investigate this further. In addition, the use of imaging techniques can be refined 
to quantify the flow disturbance on both echocardiography (using Doppler techniques) 
and MRI (using flow quantification techniques).
Bicuspid aortic valve has been shown to be an important risk factor for both aortic root 
dilatation and coarctation site abnormalities. Clinicians attending to TS women should be 
made aware of this, and clinic protocols should highlight the need for particular attention 
in the surveillance of women with a bicuspid AV.
Atherosclerosis
Women with TS have been shown to have greater IMT than normal control women, but 
not compared to a similarly oestrogen-deficient young cohort of karyotypically normal 
women, indicating that this aspect of the vasculopathy of TS may be related to oestrogen 
deficiency. Greater strength is given to this hypothesis in that the intima-media 
thickening in both TS and 46,XX oestrogen-deficient women responds to increasing doses
124
Chapter 9
of oestrogen in a dose-dependent manner. It is, however, interesting to note that systemic 
markers of inflammation, which are elevated in women with TS, do not appear to have a 
significant relationship with IMT. In fact, CRP tended to rise with oestrogen use. This 
suggests that local oestrogen-sensitive factors in the arterial wall may contribute to intimal 
thickening, independent of systemic markers of inflammation. Investigation of other 
markers relevant to vascular risk which reflect activity and integrity of the extracellular 
matrix, such as matrix metalloproteinases and cellular adhesion molecules, in future 
studies may shed some light on this apparent paradox. The role of oestrogen will be 
considered further below.
Since blood pressure, another possible therapeutic target, has also been shown to be an 
independent positive association of IMT in women with TS, the need for a blood pressure 
intervention study in this population is further strengthened. Although intuition might 
dictate that aggressive antihypertensive treatment would be beneficial, it is difficult to 
justify what is likely to be lifelong therapy in such a young population without strong 
evidence.
It is interesting that flow-mediated dilatation, a marker of endothelial function, did not 
differ significantly between the TS, 46,XXPA and normal control women, nor indeed did 
it improve significantly in either TS or 46,XXPA women during the oestrogen dose- 
ranging study. Possible explanations may be that the differences between an oestrogen- 
deficient state and oestrogen repleteness are greater than those between different 
oestrogen-treated women, as also noted in postmenopausal women (285). A study of 
larger power may help to clarify these issues further, but the data presented here do not 
confirm FMD to be an important differentiating marker of cardiovascular risk in 
oestrogen-treated women.
Metabolic factors and Obesity
With regard to metabolic aspects of the cardiovascular risk in TS, this study has compared 
markers of obesity and cardiovascular risk in oestrogen-treated women with TS and 
46,XX and untreated normal controls. Furthermore, the obesity of TS has been 
characterised using MRI and bioelectrical impedance techniques. Women with TS have 
various features consistent with the insulin resistance/ metabolic syndrome. These
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include their central obesity, confirmed in this study to be an excess of visceral and 
intrahepatocellular adipose tissue, along with hypertriglyceridaemia, hypertension and 
elevated CRP and IL-6 concentrations. However, these occur in the context of low fasting 
serum insulin, glucose and leptin. This study has shown that the hypertriglyceridaemia 
but not the hypertension may be oestrogen-related, in view of the comparisons to 46,XX 
women similarly treated with oestrogen. The apparent features of the metabolic 
syndrome are, however, not fully explained by the obesity or oestrogen deficiency, nor 
indeed oestrogen treatment, and one or more TS-specific metabolic defects may explain 
this paradox.
The fat distribution study has shown that women with TS do have relatively, but not 
absolutely less subcutaneous adipose tissue than normal controls, thus not adequately 
explaining the lower leptin concentrations. An insulin secretory defect has been 
previously proposed, and this may explain the low leptin concentrations in TS, whilst the 
obesity in turn could be related to inhibited satiety mechanisms. The elevated CRP and 
IL-6 concentrations may be accounted for by the increased visceral obesity in TS which 
has been demonstrated in the MRI fat distribution study, and an abnormality of visceral 
adipose function or deposition could also account for the absence of hyperinsulinaemia, 
although the mechanism has yet to be elucidated. Assessment of other markers of adipose 
function may be useful, for instance, adiponectin which may help to clarify these 
relationships further (408,409). Adipose tissue biopsies would allow further 
characterisation of the distribution and possible dysregulation of adipokine production 
from visceral and subcutaneous fat depots through in vitro studies.
Given that this study has shown average fasting serum glucose to be low in TS women, 
but previous work has suggested an insulin secretory defect with glucose intolerance, this 
suggests that fasting glucose measurements are a poor screening tool for assessing glucose 
homoeostasis in TS. It should therefore be recommended that clinic protocols be 
amended so that all women undergo oral glucose tolerance testing as part of their 
cardiovascular risk surveillance.
Effects o f  Oestrogen Treatment
This study has assessed the effects of oestrogen therapy on aspects of cardiovascular risk
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in various ways. First, the history of cumulative years of oestrogen deficiency and 
oestrogen start age were recorded and correlated with parameters of cardiovascular risk 
being studied. Second, women with TS were compared to similarly oestrogen-treated 
women with 46,XXOD in cross-sectional studies to assess the influence of the oestrogen 
therapy in relation to normal controls, and to control for the oestrogen deficiency and 
replacement in order to elucidate the genetic influence. Finally, the effect of oestrogen 
was studied in the dose-ranging study of TS and 46,XXPA women.
History of oestrogen therapy appeared to have no demonstrable impact on present aortic, 
carotid or brachial artery diameter or on the rate of aortic dilatation. Similarly, no 
association was demonstrated between history of oestrogen deficiency and carotid artery 
IMT, or other indices of vascular physiology such as FMD and aortic stiffness. There was 
also no association between serum markers of obesity and oestrogen deficiency, but it is 
interesting to note that hepatocellular adipose tissue was greater with increased oestrogen 
deficient years. This is consistent with previous work which has suggested that abnormal 
liver function in TS may be related to oestrogen deficiency (37,74).
The comparisons of TS women with 46,XXOD women in chapters 5 and 6 show that the 
greater conduit vessel diameter noted in TS does not appear to be related to oestrogen 
deficiency or treatment, since the latter group were similarly oestrogen treated but more 
oestrogen deficient than TS women. IMT, however, was similar in the two groups of 
oestrogen deficient women and greater than in normal controls, thus suggesting that 
oestrogen is an important factor determining IMT. It is interesting that this relationship 
was not confirmed by an association between oestrogen-deficient years and IMT in the TS 
group, but this discrepancy may be explained by the fact that ‘cumulative oestrogen 
deficient years’ is only a calculated estimate of true oestrogen deficiency. No evidence of 
an oestrogen association with parameters of aortic stiffness was detected.
Neither obesity nor hypertension in TS can be accounted for by oestrogen therapy. 
Triglyceride concentrations were greater in both oestrogen treated groups than in normal 
controls, supporting a role for oestrogen therapy as suggested by previous work in 
postmenopausal women (217). Oestrogen did not appear to explain the low fasting 
glucose, insulin and leptin concentrations in TS, however, nor the increased CRP and IL-6 
concentrations.
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The longitudinal oestrogen dose-ranging study demonstrated that HDL cholesterol 
concentrations increased in a dose-dependent manner in both TS and 46,XXPA women, 
whilst blood pressure and weight remained unchanged. Sex hormones were increased 
with a concomitant reduction in gonadotrophins in both groups, and liver enzyme 
concentrations were reduced in both groups. The magnitude was, however, greater in TS 
women. The baseline comparison of liver function in the two groups suggests that, 
although oestrogen deficiency may contribute to abnormalities of liver function, other 
factors must also be involved to explain the discrepancy between similarly treated TS and 
46,XXPA women.
As already alluded to, perhaps the most important finding of the longitudinal oestrogen 
study was the dose-dependent improvement in IMT, with a suggestion that this can be 
almost normalised within six months of therapy. The fact that the magnitude of the 
reduction appeared to be greater than in previous work on postmenopausal women 
indicates that the scope for improvement, perhaps into the normal range, in young women 
with oestrogen deficiency may be greater than in postmenopausal women, in whom the 
atherosclerotic process may already have caused greater arterial wall damage. This study 
has not fully investigated possible prothrombotic effects of increasing oestrogen dose, but 
the absence of an increase in fibrinogen is reassuring. Future work should now focus on 
including a group of postmenopausal 46,XX women for direct comparison to the other 
groups, investigating the timescale of the oestrogen-replacement effect on IMT, and 
gaining further insight into the prothrombotic effects of oestrogen dose-ranging in young 
women. A greater understanding of the functional effects of reduced IMT may be gained 
by a study of arterial distensibility at increasing oestrogen doses. In the longer term, other 
aspects of risk and benefit at differing doses of oestrogen in young women should be 
addressed, including the risk of breast cancer.
Effects o f  Growth Hormone Treatment
This study has assessed the impact of previous growth hormone therapy on each 
parameter of cardiovascular risk studied. It is of interest that no aspect of arterial 
structure or function studied, nor indeed any metabolic parameter was found to be 
associated with previous growth hormone use. Clearly this was not an interventional
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study, but the findings are nevertheless important in that they do not indicate a role for 
future cardiovascular benefit in TS girls receiving the treatment, and also do not raise 
concerns about a negative longterm impact of growth hormone, particularly with regard to 
metabolic parameters.
Difficulties arising in this study
A theme throughout this study has been the difficulty of finding appropriate control 
groups. In order to control both for their genetic differences and the oestrogen deficiency, 
women with TS were compared to both normal women and to 46,XX oestrogen deficient 
women. The situation is more complex than this, however. Women with TS are of 
shorter stature, and also generally more obese than women of similar age in the normal 
population. Women with 46,XX oestrogen deficiency, by contrast, tend to be of greater 
stature than normal controls.
Finding a normal control group at the lower end of the normal range for stature, with 
women who were also of similar BMI and age, not on the oral contraceptive pill, and of 
similar smoking and exercise status, proved to be extremely difficult. It was accepted that 
it would not be possible to truly match for height. Adjustment for height appeared to be 
the most useful means of interpreting the data, particularly with respect to 
anthropomorphically dependent variables such as arterial diameters and analysis of body 
fat distribution.
Another methodological problem in this study was the fact that many of the subjects lived 
at considerable distance from the study centre. Thus, in the larger cross-sectional studies, 
despite considerable efforts of coordination, investigations could not always be uniformly 
timed at the optimal phase of the cycle, accounting for a certain degree of heterogeneity in 
cycle stage. Data were analysed both by applying strict cycle stage criteria, and also 
using the whole cohort in order to increase statistical power as described. Since there was 
no significant difference between the analyses in the cross-sectional studies, the inclusive 
data were used as indicated.
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Conclusion
In conclusion, the findings of this study should contribute to a greater understanding of 
cardiovascular risk factors in women with Turner Syndrome. The advantages and 
disadvantages of echocardiography and magenetic resonance imaging in the screening of 
structural heart disease have been discussed and TS-specific reference ranges for aortic 
diameters have been produced. The concept of a ‘vasculopathy’ in TS has been 
introduced with the finding that arterial dilatation is not confined to the heart, but also 
occurs in other vessels such as the brachial and carotid arteries. Metabolic insights have 
been gained, demonstrating that women with TS do have increased visceral adipose 
tissue, in spite of the fact that the full spectrum of features associated with the metabolic 
syndrome is not present. This lends further weight to the hypothesis that women with TS 
have specific metabolic defects which may account for this discrepancy. This study has 
gone some way towards elucidating the contributions of the genetic effect and the 
influence of oestrogen deficiency on the anomalies observed by the comparisons not only 
to normal control women, but also to oestrogen-deficient women of normal karyotype. 
Finally, a beneficial effect of increasing oestrogen dose has been demonstrated in women 
with TS and 46,XX oestrogen-deficient controls, both with respect to arterial IMT, and 
also liver dysfunction.
It is to be hoped that these advances will now be developed further and will translate into 
improved recognition and surveillance of problems specific to women with Turner 
Syndrome in the many newly emerging adult TS clinics.
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Appendix 1
Table 1. Distribution of patient characteristics in subpopulations of the total
cohort of women with Turner Syndrome
Total
cohort
(n=173)
Chapter
3
(n=128)
Chapter
4
(n=33)
Chapter
5
(n=93)
Chapter
6
(n=117)
Chapter
7
(n=6)
Chapter
8
(n=14)
Karyotype (%)
Monosomy X (45,X) 50 49 61 49 50 33 29
Isochromosome X 22 23 27 29 25 33 43
Partial X deletion 3 2 0 2 2 0 7
Ring X 8 10 6 9 8 2 0
Any Y fragment 6 6 3 4 6 0 14
Mosaic 45,X/46,XX 8 6 0 4 7 0 7
Complex 3 4 3 3 3 2 0
Oestrogen start age,
median (range) 14 14 14 14 14 15
years (5-47) (8-34) (5-25) (5-34) (H-19) (10-19)
Oestrogen-deficient
median (range) 3 3 3 3 2 3.5
years (0-41) (0-22) (0-27) (0-22) (0-8) (0-8)
%  treated with
Growth Hormone 31 15 30 35 0 14
Smoking history, %
Never smoked 85 76 85 85 83 79
Ex-smokers 7 10 5 5 0 7
Current smokers 8 14 10 10 17 14
Proportion taking 
Exercise, %
No exercise 60 55 58 60 50 64
Mild exercise 26 21 27 25 33 7
Moderate exercise 10 24 10 10 17 21
Vigorous exercise 4 0 5 5 0 7
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examinations, took blood samples, and prepared these samples in the laboratory for 
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samples. All other blood analysis was performed by the Biochemistry and 
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Vasculopathy in Turner Syndrome: Arterial Dilatation and Intimal Thickening without 
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Scientific Abstracts presented at International Meetings
1. J Ostberg, A Sahdev, J Brookes, GS Conway
Surveillance of the aorta in women with Turner’s Syndrome -  a comparison of 
Echocardiography and Magnetic Resonance Imaging
Poster presented at the British Endocrine Society Meeting, Birmingham, March 2000;
Abstract in Journal o f  Endocrinology Abstract Supplement Vol. 164, March 2000: P21
2. J Ostberg and GS Conway
A Comparison of Echocardiography and Magnetic Resonance Imaging of the Aorta in Women 
with Turner’s Syndrome
Oral Presentation and poster at the 5th International Turner Symposium, Naples, Italy, March 
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Abstract in Abstracts for the 5 International Turner Symposium, Naples, Italy, March 
2000: B1
3. JE Ostberg and GS Conway
Accelerated Aortic Root Dilatation in Turner Syndrome
Poster presented at the British Endocrine Society Meeting, Harrogate, April 2002;
Abstract in Endocrine Abstracts Vol. 3, 21st Joint Meeting of the BES, April 2002:
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4. JE Ostberg, J Brookes, and GS Conway
Optimisation of Aortic Imaging in Adults with Turner Syndrome
Poster presented at The Endocrine Society’s 84th Annual Meeting, San Francisco, USA, June 
2002;
Abstract in Program and Abstracts, ENDO 2002: P3-47
5. JE Ostberg, JAS Brookes, C McCarthy, GS Conway
Classification of the Spectrum of Aortic Dysmorphology in Adults with Turner 
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Oral Presentation at the British Endocrine Society Meeting, Glasgow, March 2003;
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Abstract in Program and Abstracts, ENDO 2003: P2-221
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November 2003 (short-listed for Clinical Oral Communication Prize);
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